



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/06, 5/10, 7/01, 7/02, 15/86	A1	(11) International Publication Number: WO 98/17783
		(43) International Publication Date: 30 April 1998 (30.04.98)

(21) International Application Number: PCT/US97/19541	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 23 October 1997 (23.10.97)	
(30) Priority Data: 08/735,609 23 October 1996 (23.10.96) US	
(71) Applicant: REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; 3003 South State Street, Ann Arbor, MI 48109-1280 (US).	
(72) Inventors: CHAMBERLAIN, Jeffrey, S.; 1209 Henry, Ann Arbor, MI 48104 (US). AMALFITANO, Andrea; 3305 Middle Brook Court, Durham, NC 27705 (US). HAUSER, Michael, A.; 13774 Sanford Road, Milan, MI 48160 (US). KUMAR-SINGH, Rajendra; Apartment 204, 219 S. Barrington Avenue, Los Angeles, CA 90049 (US). HARTIGAN-O'CONNOR, Dennis, J.; 1106 Maiden Lane Court #109, Ann Arbor, MI 48105 (US).	
(74) Agents: CARROLL, Peter, G. et al.; Medlen & Carroll, LLP, Suite 2200, 220 Montgomery Street, San Francisco, CA 94104 (US).	

(54) Title: IMPROVED ADENOVIRUS VECTORS

(57) Abstract

The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These "gutted" vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IMPROVED ADENOVIRUS VECTORS**FIELD OF THE INVENTION**

5 The invention relates to improved adenovirus vectors, and more specifically, adenovirus vectors useful for gene therapy.

BACKGROUND

Adenoviruses (Ad) are double-stranded DNA viruses. The genome of adenoviruses (~36 kb) is complex and contains over 50 open reading frames (ORFs). These ORFs are 10 overlapping and genes encoding one protein are often embedded within genes coding for other Ad proteins. Expression of Ad genes is divided into an early and a late phase. Early genes are those transcribed prior to replication of the genome while late genes are transcribed after replication. The early genes comprise E1a, E1b, E2a, E2b, E3 and E4. The E1a gene products are involved in transcriptional regulation; the E1b gene products are involved in the 15 shut-off of host cell functions and mRNA transport. E2a encodes the a DNA-binding protein (DBP); E2b encodes the viral DNA polymerase and preterminal protein (pTP). The E3 gene products are not essential for viral growth in cell culture. The E4 region encodes regulatory protein involved in transcriptional and post-transcriptional regulation of viral gene expression: a subset of the E4 proteins are essential for viral growth. The products of the late genes (e.g., 20 L1-5) are predominantly components of the virion as well as proteins involved in the assembly of virions. The VA genes produce VA RNAs which block the host cell from shutting down viral protein synthesis.

Adenoviruses or Ad vectors have been exploited for the delivery of foreign genes to 25 cells for a number of reasons including the fact that Ad vectors have been shown to be highly effective for the transfer of genes into a wide variety of tissues *in vivo* and the fact that Ad infects both dividing and non-dividing cells; a number of tissues which are targets for gene therapy comprise largely non-dividing cells.

The current generation of Ad vectors suffer from a number of limitations which 30 preclude their widespread clinical use including: 1) immune detection and elimination of cells infected with Ad vectors. 2) a limited carrying capacity (about 8.5 kb) for the insertion of foreign genes and regulatory elements, and 3) low-level expression of Ad genes in cells infected with recombinant Ad vectors (generally, the expression of Ad proteins is toxic to cells).

The latter problem was thought to be solved by using vectors containing deletions in the E1 region of the Ad genome (E1 gene products are required for viral gene expression and replication). However, even with such vectors, low-level expression of Ad genes is observed. It is now thought that most mammalian cells contain E1-like factors which can substitute for the missing Ad E1 proteins and permit expression of Ad genes remaining on the E1 deleted vectors.

What is needed is an approach that overcomes the problem of low level expression of Ad genes. Such an approach needs to ensure that adenovirus vectors are safe and non-immunogenic.

10

SUMMARY OF THE INVENTION

The present invention contemplates two approaches to improving adenovirus vectors. The first approach generally contemplates a recombinant plasmid, together with a helper adenovirus, in a packaging cell line. The helper adenovirus is rendered safe by utilization of *loxP* sequences. In the second approach, "damaged" adenoviruses are employed. While the "damaged" adenovirus is capable of self-propagation in a packaging cell line, it is not capable of expressing certain genes (e.g., the DNA polymerase gene and/or the adenovirus preterminal protein gene).

In one embodiment of the first approach, the present invention contemplates a recombinant plasmid, comprising in operable combination: a) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element; b) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone; c) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs; and d) a first gene of interest operably linked to said promoter element.

While it is not intended that the present invention be limited by the precise size of the plasmid, it is generally desirable that the recombinant plasmid have a total size of between 27 and 40 kilobase pairs. It is preferred that the total size of the DNA packaged into an EAM derived from these recombinant plasmids is about the length of the wild-type adenovirus genome (~36 kb). It is well known in the art that DNA representing about 105% of the wild-type length may be packaged into a viral particle; thus the EAM derived from recombinant plasmid may contain DNA whose length exceeds by ~105% the size of the wild-type genome.

The size of the recombinant plasmid may be adjusted using reporter genes and genes of interest having various sizes (including the use of different sizes of introns within these genes) as well as through the use of irrelevant or non-coding DNA fragment which act as "stuffer" fragments (e.g., portions of bacteriophage genomes).

5 In one embodiment of the recombinant plasmid, said 5' end of said packaging sequence is linked to said 3' end of said left ITR. In this embodiment, said first gene of interest is linked to said 3' end of said packaging sequence. It is not intended that the present invention be limited by the nature of the gene of interest; a variety of genes (including both cDNA and genomic forms) are contemplated; any gene having therapeutic value may be
10 inserted into the recombinant plasmids of the present invention. For example, the transfer of the adenosine deaminase (ADA) gene is useful for the treatment of ADA- patients; the transfer of the CFTR gene is useful for the treatment of cystic fibrosis. A wide variety of diseases are known to be due to a defect in a single gene. The plasmids, vectors and EAMs of the present invention are useful for the transfer of a non-mutated form of a gene which is
15 mutated in a patient thereby resulting in disease. The present invention is illustrated using recombinant plasmids capable of generating encapsidated adenovirus minichromosomes (EAMs) containing the dystrophin cDNA gene (the cDNA form of this gene is preferred due to the large size of this gene); the dystrophin gene is non-functional in muscular dystrophy (MD) patients. However, the present invention is not limited toward the use of the dystrophin
20 gene for treatment of MD; the use of the utrophin (also called the dystrophin related protein) gene is also contemplated for gene therapy for the treatment of MD [Tinsley *et al.* (1993) Curr. Opin. Genet. Dev. 3:484 and (1992) Nature 360:591]; the utrophin gene protein has been reported to be capable of functionally substituting for the dystrophin gene [Tinsley and Davies (1993) Neuromusc. Disord. 3:539]. As the utrophin gene product is expressed in the
25 muscle of muscular dystrophy patients, no immune response would be directed against the utrophin gene product expressed in cells of a host (including a human) containing the recombinant plasmids, Ad vectors or EAMs of the present invention. While the present invention is illustrated using plasmids containing the dystrophin gene, the plasmids, Ad vectors and EAMs of the present invention have broad application for the transfer of any gene
30 whose gene product is missing or altered in activity in cells.

Embodiments are contemplated wherein the recombinant plasmid further comprises a second gene of interest. In one embodiment, said second gene of interest is linked to said 3' end of said right ITR. In one embodiment, said second gene of interest is a reporter gene. A

variety of reporter genes are contemplated, including but not limited to *E. coli* β-galactosidase gene, the human placental alkaline phosphatase gene, the green fluorescent protein gene and the chloramphenicol acetyltransferase gene.

As mentioned above, the first approach also involves the use of a helper adenovirus in combination with the recombinant plasmid. In one embodiment, the present invention contemplates a helper adenovirus comprising i) first and a second *loxP* sequences, and ii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end. It is preferred that said first *loxP* sequence is linked to the 5' end of said packaging sequence and said second *loxP* sequence is linked to said 3' end of said packaging sequence. In one embodiment, the helper virus comprises at least one adenovirus gene coding region.

The present invention contemplates a mammalian cell line containing the above-described recombinant plasmid and the above-described helper virus. It is preferred that said cell line is a 293-derived cell line. Specifically, in one embodiment, the present invention contemplates a mammalian cell line, comprising: a) a recombinant plasmid, comprising, in operable combination: i) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element, ii) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone, iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs, and iv) a first gene of interest operably linked to said promoter element; and b) a helper adenovirus comprising i) first and a second *loxP* sequences, and ii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end. As noted previously, said helper can further comprise at least one adenovirus gene coding region.

Overall, the first approach allows for a method of producing an adenovirus minichromosome. In one embodiment, this method comprises: A) providing a mammalian cell line containing: a) a recombinant plasmid, comprising, in operable combination, i) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element, ii) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone, iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of the ITRs, and iv) a first gene of interest operably linked to said promoter element; and b) a helper adenovirus comprising i) first and a

second *loxP* sequences. ii) at least one adenovirus gene coding region, and iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end; and

B) growing said cell line under conditions such that said adenovirus gene coding region is expressed and said recombinant plasmid directs the production of at least one adenoviral minichromosome. It is desired that said adenovirus minichromosome is encapsidated.

In one embodiment, the present invention contemplates recovering said encapsidated adenovirus minichromosome and, in turn, purifying said recovered encapsidated adenovirus minichromosome. Thereafter, said purified encapsidated adenovirus minichromosome can be administered to a host (e.g., a mammal). Human therapy is thereby contemplated.

It is not intended that the present invention be limited by the nature of the administration of said minichromosomes. All types of administration are contemplated, including direct injection (intra-muscular, intravenous, subcutaneous, etc.), inhalation, etc.

As noted above, the present invention contemplates a second approaches to improving adenovirus vectors. In the second approach, "damaged" adenoviruses are employed. In one embodiment, the present invention contemplates a recombinant adenovirus comprising the adenovirus E2b region having a deletion, said adenovirus capable of self-propagation in a packaging cell line and said E2b region comprising the DNA polymerase gene and the adenovirus preterminal protein gene. In this embodiment, said deletion can be within the adenovirus DNA polymerase gene. Alternatively, said deletion is within the adenovirus preterminal protein gene. Finally, the present invention also contemplates embodiments wherein said deletion is within the adenovirus DNA polymerase and preterminal protein genes.

The present invention further provides cell lines capable of supporting the propagation of Ad virus containing deletions within the E2b region. In one embodiment the invention provides a mammalian cell line stably and constitutively expressing the adenovirus E1 gene products and the adenovirus DNA polymerase. In one embodiment, these cell lines comprise a recombinant adenovirus comprising a deletion within the E2b region, this E2b-deleted recombinant adenovirus being capable of self-propagation in the cell line. The present invention is not limited by the nature of the deletion within the E2b region. In one embodiment, the deletion is within the adenoviral DNA polymerase gene.

The present invention provides cells lines stably expressing E1 proteins and the adenoviral DNA polymerase, wherein the genome of the cell line contains a nucleotide sequence encoding adenovirus DNA polymerase operably linked to a heterologous promoter.

In a particularly preferred embodiment, the cell line is selected from the group consisting of the B-6, B-9, C-1, C-4, C-7, C-13, and C-14 cell lines.

The present invention further provides cell lines which further constitutively express the adenovirus preterminal protein (pTP) gene product (in addition to E1 proteins and DNA polymerase). In one embodiment, these pTP-expressing cell lines comprise a recombinant adenovirus comprising a deletion within the E2b region, the recombinant adenovirus being capable of self-propagation in the pTP-expressing cell line. In a preferred embodiment, the deletion within the E2b region comprises a deletion within the adenoviral preterminal protein gene. In another preferred embodiment, the deletion within the E2b region comprises a deletion within the adenoviral (Ad) DNA polymerase and preterminal protein genes.

In a preferred embodiment, the cell lines coexpressing pTP and Ad DNA polymerase, contain within their genome, a nucleotide sequence encoding adenovirus preterminal protein operably linked to a heterologous promoter. In the invention is not limited by the nature of the heterologous promoter chosen. The art knows well how to select a suitable heterologous promoter to achieve expression in the desired host cell (e.g., 293 cells or derivative thereof). In a particularly preferred embodiment, the pTP- and Ad polymerase-expressing cell line is selected from the group consisting of the C-1, C-4, C-7, C-13, and C-14 cell lines.

The present invention provides a method of producing infectious recombinant adenovirus particles containing an adenoviral genome containing a deletion within the E2b region, comprising: a) providing: i) a mammalian cell line stably and constitutively expressing the adenovirus E1 gene products and the adenovirus DNA polymerase; ii) a recombinant adenovirus comprising a deletion within the E2b region, the recombinant adenovirus being capable of self-propagation in said cell line; b) introducing the recombinant adenovirus into the cell line under conditions such that the recombinant adenovirus is propagated to form infectious recombinant adenovirus particles; and c) recovering the infectious recombinant adenovirus particles. In a preferred embodiment, the method further comprises d) purifying the recovered infectious recombinant adenovirus particles. In yet another preferred embodiment, the method further comprises e) administering the purified recombinant adenovirus particles to a host which is preferably a mammal and most preferably a human.

In another preferred embodiment the mammalian cell line employed in the above method further constitutively expresses the adenovirus preterminal protein.

The present invention further provides a recombinant plasmid capable of replicating in a bacterial host comprising adenoviral E2b sequences, the E2b sequences containing a deletion within the polymerase gene, the deletion resulting in reduced polymerase activity. The present invention is not limited by the specific deletion employed to reduce polymerase 5 activity. In a preferred embodiment, the deletion comprises a deletion of nucleotides 8772 to 9385 in SEQ ID NO:4. In one preferred embodiment, the recombinant plasmid has the designation pΔpol. In another preferred embodiment, the recombinant plasmid has the designation pBHG11Δpol.

The present invention also provides a recombinant plasmid capable of replicating in a 10 bacterial host comprising adenoviral E2b sequences, the E2b sequences containing a deletion within the preterminal protein gene, the deletion resulting in the inability to express functional preterminal protein without disruption of the VA RNA genes. The present invention is not limited by the specific deletion employed to render the pTP inactive: any deletion within the pTP coding region which does not disrupt the ability to express the Ad VA RNA genes may 15 be employed. In a preferred embodiment, the deletion comprises a deletion of nucleotides 10,705 to 11,134 in SEQ ID NO:4. In one preferred embodiment, the recombinant plasmid has the designation pΔpTP. In another preferred embodiment, the recombinant plasmid has the designation pBHG11ΔpTP.

In a preferred embodiment, the recombinant plasmid containing a deletion with the 20 pTP region further comprises a deletion within the polymerase gene, this deletion resulting in reduced (preferably absent) polymerase activity. The present invention is not limited by the specific deletion employed to inactivate the polymerase and pTP genes. In a preferred embodiment, the deletion comprises a deletion of nucleotides 8,773 to 9586 and 11,067 to 25 12,513 in SEQ ID NO:4. In one preferred embodiment, the recombinant plasmid has the designation pAXBΔpolΔpTPVARNA+t13. In another preferred embodiment, the recombinant plasmid has the designation pBHG11ΔpolΔpTPVARNA+t13.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A is a schematic representation of the Ad polymerase expression plasmid 30 pRSV-pol indicating that the Ad2 DNA polymerase sequences are under the transcriptional control of the RSV-LTR/promoter element and are flanked on the 3' end by the SV-40 small t intron and SV-40 polyadenylation addition site.

Figure 1B is a schematic representation of the expression plasmid pRSV-pTP indicating that the Ad2 preterminal protein sequences are under the transcriptional control of the RSV-LTR/promoter element and are flanked on the 3' end by the SV-40 small-t intron and SV-40 polyadenylation signals.

5 Figure 2 is an ethidium bromide-stained gel depicting the presence of Ad pol DNA sequences in genomic DNA from LP-293 cells and several hygromycin-resistant cell lines. The ~750 bp PCR products are indicated by the arrow.

10 Figure 3 is an autoradiograph depicting the results of a viral replication-complementation assay analyzing the functional activity of the Ad polymerase protein expressed by LP-293 cells and several hygromycin resistant cell lines. The 8.010 bp *Hind*III fragments analyzed by densitometry are indicated by an arrow.

15 Figure 4 is an autoradiograph indicating that cell lines B-6 and C-7 contained a smaller and a larger species of Ad polymerase mRNA while LP-293 derived RNA had no detectable hybridization signal. The location of the two species of Ad polymerase mRNA are indicated relative to the 28S and 18S ribosomal RNAs, and the aberrant transcript expressed by the B-9 cell line is indicated by an arrow.

20 Figure 5 is an autoradiograph showing which of the cell lines that received the preterminal protein expression plasmid indicated the presence of pRSV-pTP sequences (arrow labelled "pTP") and E1 sequences (arrow labelled "E1").

Figure 6 is an autoradiograph indicating in which of the cell lines transcription of preterminal protein is occurring (arrow labelled "~ 3kb").

Figure 7 is an autoradiograph indicating that the expression of the Ad-polymerase could overcome the replication defect of H5*sub*100 at non-permissive temperatures.

25 Figure 8 graphically depicts plaque titre for LP-293, B-6 and C-7 cell lines infected with wtAd5, H5ts36, or H5*sub*100, and the results demonstrate that the C-7 cell line can be used as a packaging cell line to allow the high level growth of E1, preterminal, and polymerase deleted Ad vectors.

30 Figure 9 is an autoradiograph showing that the recombinant pol⁻ virus is viable on pol-expressing 293 cells but not on 293 cells which demonstrates that recombinant Ad viruses containing the 612 bp deletion found within pΔpol lack the ability to express Ad polymerase.

Figure 10 is a schematic representation of the structure of pAd5βdys wherein the two inverted adenovirus origins of replication are represented by a left and right inverted terminal repeat (LITR/RITR). P1 and P2 represent location of probes used for Southern blot analysis.

Figure 11 graphically illustrates the total number of transducing adenovirus particles produced (output) per serial passage on 293 cells. total input virus of either the helper (hpAP) or Ad5 β dys, and the total number of cells used in each infection.

Figures 12A-B show Southern blot analyses of viral DNA from lysates 3, 6, 9 and 12, digested with the restriction enzymes *BssHII*, *NruI* and *EcoRV*. For the analyses, fragments from the C terminus of *mus musculus* dystrophin cDNA (A) or the N terminus of *E. coli* β -galactosidase (B) were labeled with dCTP³² and used as probes.

Figures 13A-B show the physical separation of Ad5 β dys from hpAP virions at the third (A) and final (B) stages of CsCl purification.

Figure 14 graphically depicts the level of contamination of Ad5 β dys EAMs by hpAP virions obtained from the final stage of CsCl purification as measured by β -galactosidase and alkaline phosphatase expression. The ratio of the two types of virions - Ad5 β dys EAMs (LacZ) or hpAP (AP) in each fraction is indicated in the lower graph.

Figures 15A-B are western blot (immunoblot) analyses of protein extracts from *mdx* myoblasts and myotubes demonstrating the expression of β -galactosidase (A) and dystrophin (B) in cells infected with Ad5 β dys EAMs.

Figures 16A-C depict immunofluorescence of dystrophin expression in wild type MM14 myotubes (A), uninfected *mdx* (B) and infected *mdx* myotubes (C).

Figure 17 is a schematic representation of the MCK/lacZ constructs tested to determine what portion of the ~ 3.3 kb DNA fragment containing the enhancer/promoter of the MCK gene is capable of directing high levels of expression of linked genes in muscle cells.

Figure 18 is a schematic representation of a GFP/ β -gal reporter construct suitable for assaying the expression of *Cre* recombinase in mammalian cells.

Figure 19 is a schematic representation of the recombination event between the *loxP* shuttle vector and the Ad5d β 7001 genome.

DEFINITIONS

To facilitate understanding of the invention, a number of terms are defined below.

The term "gene" refers to a DNA sequence that comprises control and coding sequences necessary for the production of a polypeptide or precursor thereof. The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired enzymatic activity is retained. The term "gene" encompasses both cDNA and genomic forms of a given gene.

The term "wild-type" refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the "normal" or "wild-type" form of the gene. In contrast, the term "modified" or "mutant" refers to a gene or gene product which displays modifications in sequence and/or functional properties (*i.e.*, altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.

The term "oligonucleotide" as used herein is defined as a molecule comprised of two or more deoxyribonucleotides or ribonucleotides, usually more than three (3), and typically more than ten (10) and up to one hundred (100) or more (although preferably between twenty and thirty). The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof.

As used herein, the term "regulatory element" refers to a genetic element which controls some aspect of the expression of nucleic acid sequences. For example, a promoter is a regulatory element which facilitates the initiation of transcription of an operably linked coding region. Other regulatory elements are splicing signals, polyadenylation signals, termination signals, *etc.* (defined *infra*).

Transcriptional control signals in eucaryotes comprise "promoter" and "enhancer" elements. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription [Maniatis, T. *et al.*, Science 236:1237 (1987)]. Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect and mammalian cells and viruses (analogous control elements, *i.e.*, promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest. Some eukaryotic promoters and enhancers have a broad host range while others are functional in a limited subset of cell types [for review see Voss, S.D. *et al.*, Trends Biochem. Sci., 11:287 (1986) and Maniatis, T. *et al.*, *supra* (1987)].

The term "recombinant DNA vector" as used herein refers to DNA sequences

containing a desired coding sequence and appropriate DNA sequences necessary for the expression of the operably linked coding sequence in a particular host organism (e.g.

mammal). DNA sequences necessary for expression in prokaryotes include a promoter, optionally an operator sequence, a ribosome binding site and possibly other sequences. Eukaryotic cells are known to utilize promoters, polyadenylation signals and enhancers.

5 The terms "in operable combination", "in operable order" and "operably linked" as used herein refer to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.

10 The term "genetic cassette" as used herein refers to a fragment or segment of DNA containing a particular grouping of genetic elements. The cassette can be removed and inserted into a vector or plasmid as a single unit. A plasmid backbone refers to a piece of DNA containing at least plasmid origin of replication and a selectable marker gene (e.g., an antibiotic resistance gene) which allows for selection of bacterial hosts containing the plasmid; the plasmid backbone may also include a polylinker region to facilitate the insertion of 15 genetic elements within the plasmid. When a particular plasmid is modified to contain non-plasmid elements (e.g., insertion of Ad sequences and/or a eukaryotic gene of interest linked to a promoter element), the plasmid sequences are referred to as the plasmid backbone.

20 Because mononucleotides are reacted to make oligonucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor in one direction via a phosphodiester linkage, an end of an oligonucleotide is referred to as the "5' end" if its 5' phosphate is not linked to the 3' oxygen of a mononucleotide pentose ring and as the "3' end" if its 3' oxygen is not linked to a 5' phosphate of a subsequent mononucleotide pentose ring. As used herein, a nucleic acid sequence, even if internal to a larger oligonucleotide, also may be said to have 5' and 3' ends.

25 When two different, non-overlapping oligonucleotides anneal to different regions of the same linear complementary nucleic acid sequence, and the 3' end of one oligonucleotide points towards the 5' end of the other, the former may be called the "upstream" oligonucleotide and the latter the "downstream" oligonucleotide.

30 The term "primer" refers to an oligonucleotide which is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. An oligonucleotide "primer" may occur naturally, as in a purified restriction digest or may be produced synthetically.

A primer is selected to be "substantially" complementary to a strand of specific sequence of the template. A primer must be sufficiently complementary to hybridize with a template strand for primer elongation to occur. A primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being substantially complementary to the strand. Non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the template to hybridize and thereby form a template primer complex for synthesis of the extension product of the primer.

"Hybridization" methods involve the annealing of a complementary sequence to the target nucleic acid (the sequence to be detected). The ability of two polymers of nucleic acid containing complementary sequences to find each other and anneal through base pairing interaction is a well-recognized phenomenon. The initial observations of the "hybridization" process by Marmur and Lane. *Proc. Natl. Acad. Sci. USA* 46:453 (1960) and Doty *et al.*. *Proc. Natl. Acad. Sci. USA* 46:461 (1960) have been followed by the refinement of this process into an essential tool of modern biology.

The complement of a nucleic acid sequence as used herein refers to an oligonucleotide which, when aligned with the nucleic acid sequence such that the 5' end of one sequence is paired with the 3' end of the other, is in "antiparallel association." Certain bases not commonly found in natural nucleic acids may be included in the nucleic acids of the present invention and include, for example, inosine and 7-deazaguanine. Complementarity need not be perfect; stable duplexes may contain mismatched base pairs or unmatched bases. Those skilled in the art of nucleic acid technology can determine duplex stability empirically considering a number of variables including, for example, the length of the oligonucleotide, base composition and sequence of the oligonucleotide, ionic strength and incidence of mismatched base pairs.

Stability of a nucleic acid duplex is measured by the melting temperature, or " T_m ." The T_m of a particular nucleic acid duplex under specified conditions is the temperature at which on average half of the base pairs have disassociated. The equation for calculating the T_m of nucleic acids is well known in the art.

The term "probe" as used herein refers to a labeled oligonucleotide which forms a duplex structure with a sequence in another nucleic acid, due to complementarity of at least one sequence in the probe with a sequence in the other nucleic acid.

The term "label" as used herein refers to any atom or molecule which can be used to provide a detectable (preferably quantifiable) signal, and which can be attached to a nucleic acid or protein. Labels may provide signals detectable by fluorescence, radioactivity, colorimetry, gravimetry, X-ray diffraction or absorption, magnetism, enzymatic activity, and the like.

5 The terms "nucleic acid substrate" and nucleic acid template" are used herein interchangeably and refer to a nucleic acid molecule which may comprise single- or double-stranded DNA or RNA.

10 "Oligonucleotide primers matching or complementary to a gene sequence" refers to oligonucleotide primers capable of facilitating the template-dependent synthesis of single or double-stranded nucleic acids. Oligonucleotide primers matching or complementary to a gene sequence may be used in PCRs, RT-PCRs and the like.

15 A "consensus gene sequence" refers to a gene sequence which is derived by comparison of two or more gene sequences and which describes the nucleotides most often present in a given segment of the genes; the consensus sequence is the canonical sequence.

20 The term "polymorphic locus" is a locus present in a population which shows variation between members of the population (*i.e.*, the most common allele has a frequency of less than 0.95). In contrast, a "monomorphic locus" is a genetic locus at little or no variations seen between members of the population (generally taken to be a locus at which the most common allele exceeds a frequency of 0.95 in the gene pool of the population).

The term "microorganism" as used herein means an organism too small to be observed with the unaided eye and includes, but is not limited to bacteria, viruses, protozoans, fungi, and ciliates.

25 The term "microbial gene sequences" refers to gene sequences derived from a microorganism.

The term "bacteria" refers to any bacterial species including eubacterial and archaebacterial species.

The term "virus" refers to obligate, ultramicroscopic, intracellular parasites incapable of autonomous replication (*i.e.*, replication requires the use of the host cell's machinery).

30 Adenoviruses, as noted above, are double-stranded DNA viruses. The left and right inverted terminal repeats (ITRs) are short elements located at the 5' and 3' termini of the linear Ad genome, respectively and are required for replication of the viral DNA. The left ITR is located between 1-130 bp in the Ad genome (also referred to as 0-0.5 mu). The right ITR is

located from ~3.7500 bp to the end of the genome (also referred to as 99.5-100 mu). The two ITRs are inverted repeats of each other. For clarity, the left ITR or 5' end is used define the 5' and 3' ends of the ITRs. The 5' end of the left ITR is located at the extreme 5' end of the linear adenoviral genome; picturing the left ITR (LITR) as an arrow extending from the 5' end of the genome, the tail of the 5' ITR is located at mu 0 and the head of the left ITR is located at ~ 0.5 mu (further the tail of the left ITR is referred to as the 5' end of the left ITR and the head of the left ITR is referred to as the 3' end of the left ITR). The tail of the right or 3' ITR is located at mu 100 and the head of the right ITR is located at ~ mu 99.5; the head of the right ITR is referred to as the 5' end of the right ITR and the tail of the right ITR is referred to as the 3' end of the right ITR (RITR). In the linear Ad genome, the ITRs face each other with the head of each ITR pointing inward toward the bulk of the genome. When arranged in a "tail to tail orientation" the tails of each ITR (which comprise the 5' end of the LITR and the 3' end of the RITR) are located in proximity to one another while the heads of each ITR are separated and face outward (see for example, the arrangement of the ITRs in the EAM shown in Figure 10 herein). The "adenovirus packaging sequence" refers to the Ψ sequence which comprises five (AI-AV) packaging signals and is required for encapsidation of the mature linear genome: the packaging signals are located from ~194 to 358 bp in the Ad genome (about 0.5-1.0 mu).

The phrase "at least one adenovirus gene coding region" refers to a nucleotide sequence containing more than one adenovirus gene coding gene. A "helper adenovirus" or "helper virus" refers to an adenovirus which is replication-competent in a particular host cell (the host may provide Ad gene products such as E1 proteins), this replication-competent virus is used to supply *in trans* functions (e.g., proteins) which are lacking in a second replication-incompetent virus: the first replication-competent virus is said to "help" the second replication-incompetent virus thereby permitting the propagation of the second viral genome in the cell containing the helper and second viruses.

The term "containing a deletion within the E2b region" refers to a deletion of at least one basepair (preferably more than one bp and preferably at least 100 and most preferably more than 300 bp) within the E2b region of the adenovirus genome. An E2b deletion is a deletion that prevents expression of at least one E2b gene product and encompasses deletions within exons encoding portions of E2b-specific proteins as well as deletions within promoter and leader sequences.

An "adenovirus minichromosome" refers to a linear molecule of DNA containing the Ad ITRs on each end which is generated from a plasmid containing the ITRs and one or more gene of interest. The term "encapsidated adenovirus minichromosome" or "EAM" refers to an adenovirus minichromosome which has been packaged or encapsidated into a viral particle:

5 plasmids containing the Ad ITRs and the packaging signal are shown herein to produce EAMs. When used herein, "recovering" encapsidated adenovirus minichromosomes refers to the collection of EAMs from a cell containing an EAM plasmid and a helper virus; this cell will direct the encapsidation of the minichromosome to produce EAMs. The EAMs may be recovered from these cells by lysis of the cell (*e.g.*, freeze-thawing) and pelleting of the cell debris to a cell extract as described in Example 1 (Ex. 1 describes the recovery of Ad virus from a cell, but the same technique is used to recover EAMs from a cell). "Purifying" such minichromosomes refers to the isolation of the recovered EAMs in a more concentrated form (relative to the cell lysate) on a density gradient as described in Example 7: purification of recovered EAMs permits the physical separation of the EAM from any helper virus (if present).

10

15

The term "transfection" as used herein refers to the introduction of foreign DNA into eukaryotic cells. Transfection may be accomplished by a variety of means known to the art including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and biolistics.

20 The term "stable transfection" or "stably transfected" refers to the introduction and integration of foreign DNA into the genome of the transfected cell. The term "stable transfectant" refers to a cell which has stably integrated foreign DNA into the genomic DNA.

As used herein, the term "gene of interest" refers to a gene inserted into a vector or 25 plasmid whose expression is desired in a host cell. Genes of interest include genes having therapeutic value as well as reporter genes. A variety of such genes are contemplated, including genes of interest encoding a protein which provides a therapeutic function (such as the dystrophin gene, which is capable of correcting the defect seen in the muscle of MD patients), the utrophin gene, the CFTR gene (capable of correcting the defect seen in cystic 30 fibrosis patients), etc..

The term "reporter gene" indicates a gene sequence that encodes a reporter molecule (including an enzyme). A "reporter molecule" is detectable in any detection system, including, but not limited to enzyme (*e.g.*, ELISA, as well as enzyme-based histochemical

assays), fluorescent, radioactive, and luminescent systems. In one embodiment, the present invention contemplates the *E. coli* β-galactosidase gene (available from Pharmacia Biotech, Piscataway, NJ), green fluorescent protein (GFP) (commercially available from Clontech, Palo Alto, CA), the human placental alkaline phosphatase gene, the chloramphenicol acetyltransferase (CAT) gene; other reporter genes are known to the art and may be employed.

As used herein, the terms "nucleic acid molecule encoding," "DNA sequence encoding," and "DNA encoding" refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.

DESCRIPTION OF THE INVENTION

The present invention provides improved adenovirus vectors for the delivery of recombinant genes to cells *in vitro* and *in vivo*. As noted above, the present invention contemplates two approaches to improving adenovirus vectors. The first approach generally contemplates a recombinant plasmid containing the minimal region of the Ad genome required for replication and packaging (*i.e.*, the left and right ITR and the packaging or Ψ sequence) along with one or more genes of interest; this recombinant plasmid is packaged into an encapsidated adenovirus minichromosome (EAM) when grown in parallel with an E1-deleted helper virus in a cell line expressing the E1 proteins (*e.g.*, 293 cells). The recombinant adenoviral minichromosome is preferentially packaged. To prevent the packaging of the helper virus, a helper virus containing *loxP* sequences flanking the Ψ sequence is employed in conjunction with 293 cells expressing *Cre* recombinase; *Cre-loxP* mediated recombination removes the packaging sequence from the helper genome thereby preventing packaging of the helper during the production of EAMs. In the second approach, "damaged" or "deleted" adenoviruses containing deletions within the E2b region are employed. While the "damaged" adenovirus is capable of self-propagation in a packaging cell line expressing the appropriate E2b protein(s), the E2b-deleted recombinant adenovirus are incapable of replicating and expressing late viral gene products outside of the packaging cell line.

In one embodiment, the self-propagating recombinant adenoviruses containing deletions in the E2b region of the adenovirus genome. In another embodiment, "gutted"

viruses are contemplated: these viruses lack all viral coding regions. In addition, packaging cell lines co-expressing E1 and E2b gene products are provided which allow the production of infectious recombinant virus containing deletions in the E1 and E2b regions without the use of helper virus.

5 The Description of the Invention is divided into the following sections: I. Self-Propagating Adenovirus Vectors; II. Packaging Cell Lines; and III. Encapsidated Adenoviral Minichromosomes.

I. Self-Propagating Adenovirus Vectors

10 Self-propagating adenovirus (Ad) vectors have been extensively utilized to deliver foreign genes to a great variety of cell types *in vitro* and *in vivo*. "Self-propagating viruses" are those which can be produced by transfection of a single piece of DNA (the recombinant viral genome) into a single packaging cell line to produce infectious virus; self-propagating viruses do not require the use of helper virus for propagation.

15 Existing Ad vectors have been shown to be problematic *in vivo*. This is due in part because current or first generation Ad vectors are deleted for only the early region 1 (E1) genes. These vectors are crippled in their ability to replicate normally without the trans-complementation of E1 functions provided by human 293 cells, a packaging cell line [ATCC CRL 1573; Graham *et al.* (1977) J. Gen. Virol. 36:59]. Unfortunately, with the use of high 20 titres of E1 deleted vectors, and the fact that there are E1-like factors present in many cell types, E1 deleted vectors can overcome the block to replication and express other viral gene products [Imperiale *et al.* (1984) Mol. Cell Biol. 4:867; Nevins (1981) Cell 26:213; and Gaynor and Berk (1983) Cell 33:683]. The expression of viral proteins in the infected target 25 cells elicits a swift host immune response, that is largely T-cell mediated [Yang and Wilson (1995) J. Immunol. 155:2564 and Yang *et al.* (1994) Proc. Natl. Acad. Sci. USA 91:4407]. The transduced cells are subsequently eliminated, along with the transferred foreign gene. In immuno-incompetent animals, Ad delivered genes can be expressed for periods of up to one year [Yang *et al.* (1994), *supra*; Vincent *et al.* (1993) Nature Genetics 5:130; and Yang *et al.* (1995) Proc. Natl. Acad. Sci. USA 92:7257].

30 Another shortcoming of first generation Ad vectors is that a single recombination event between the genome of an Ad vector and the integrated E1 sequences present in 293 cells can generate replication competent Ad (RCA), which can readily contaminate viral stocks.

In order to further cripple viral protein expression, and also to decrease the frequency of generating RCA, the present invention provides Ad vectors containing deletions in the E2b region. Propagation of these E2b-deleted Ad vectors requires cell lines which express the deleted E2b gene products. The present invention provides such packaging cell lines and for the first time demonstrates that the E2b gene products, DNA polymerase and preterminal protein, can be constitutively expressed in 293 cells along with the E1 gene products. With every gene that can be constitutively expressed in 293 cells comes the opportunity to generate new versions of Ad vectors deleted for the respective genes. This has immediate benefits; increased carrying capacity, since the combined coding sequences of the polymerase and preterminal proteins that can be theoretically deleted approaches 4.6 kb and a decreased incidence of RCA generation, since two or more independent recombination events would be required to generate RCA. Therefore, the novel E1, Ad polymerase and preterminal protein expressing cell lines of the present invention enable the propagation of Ad vectors with a carrying capacity approaching 13 kb, without the need for a contaminating helper virus [Mitani *et al.* (1995) Proc. Natl. Acad. Sci. USA 92:3854]. In addition, when genes critical to the viral life cycle are deleted (*e.g.*, the E2b genes), a further crippling of Ad to replicate and express other viral gene proteins occurs. This decreases immune recognition of virally infected cells, and allows for extended durations of foreign gene expression. The most important attribute of E1, polymerase, and preterminal protein deleted vectors, however, is their inability to express the respective proteins, as well as a predicted lack of expression of most of the viral structural proteins. For example, the major late promoter (MLP) of Ad is responsible for transcription of the late structural proteins L1 through L5 [Doerfler, *In Adenovirus DNA. The Viral Genome and Its Expression* (Martinus Nijhoff Publishing Boston, 1986)]. Though the MLP is minimally active prior to Ad genome replication, the rest of the late genes get transcribed and translated from the MLP only *after* viral genome replication has occurred [Thomas and Mathews (1980) Cell 22:523]. This cis-dependent activation of late gene transcription is a feature of DNA viruses in general, such as in the growth of polyoma and SV-40. The polymerase and preterminal proteins are *absolutely* required for Ad replication (unlike the E4 or protein IX proteins) and thus their deletion is extremely detrimental to Ad vector late gene expression.

II. Packaging Cell Lines Constitutively Expressing E2b Gene Products

The present invention addresses the limitations of current or first generation Ad vectors by isolating novel 293 cell lines coexpressing critical viral gene functions. The 5 present invention describes the isolation and characterization of 293 cell lines capable of constitutively expressing the Ad polymerase protein. In addition, the present invention describes the isolation of 293 cells which not only express the E1 and polymerase proteins, but also the Ad-preterminal protein. The isolation of cell lines coexpressing the E1, Ad 10 polymerase and preterminal proteins demonstrates that three genes critical to the life cycle of Ad can be constitutively coexpressed, without toxicity.

In order to delete critical genes from self-propagating Ad vectors, the proteins encoded by the targeted genes have to first be coexpressed in 293 cells along with the E1 proteins. Therefore, only those proteins which are non-toxic when coexpressed constitutively (or toxic proteins inducibly-expressed) can be utilized. Coexpression in 293 cells of the E1 and E4 15 genes has been demonstrated (utilizing inducible, not constitutive, promoters) [Yeh *et al.* (1996) J. Virol. 70:559; Wang *et al.* (1995) Gene Therapy 2:775; and Gorziglia *et al.* (1996) J. Virol. 70:4173]. The E1 and protein IX genes (a virion structural protein) have been coexpressed [Caravokyri and Leppard (1995) J. Virol. 69:6627], and coexpression of the E1, 20 E4, and protein IX genes has also been described [Krougliak and Graham (1995) Hum. Gene Ther. 6:1575].

The present invention provides for the first time, cell lines coexpressing E1 and E2b gene products. The E2b region encodes the viral replication proteins which are absolutely required for Ad genome replication [Doerfler, *supra* and Pronk *et al.* (1992) Chromosoma 102:S39-S45]. The present invention provides 293 cells which constitutively express the 140 kD Ad-polymerase. While other researchers have reported the isolation of 293 cells which 25 express the Ad-preterminal protein utilizing an inducible promoter [Schaack *et al.* (1995) J. Virol. 69:4079], the present invention is the first to demonstrate the high-level, constitutive coexpression of the E1, polymerase, and preterminal proteins in 293 cells, without toxicity. These novel cell lines permit the propagation of novel Ad vectors deleted for the E1, 30 polymerase, and preterminal proteins.

III. Encapsidated Adenoviral Minichromosomes

The present invention also provides encapsidated adenovirus minichromosome (EAM) consisting of an infectious encapsidated linear genome containing Ad origins of replication, packaging signal elements, a reporter gene (e.g., a β -galactosidase reporter gene cassette) and a gene of interest (e.g., a full length (14 kb) dystrophin cDNA regulated by a muscle specific enhancer/promoter). EAMs are generated by cotransfected 293 cells with supercoiled plasmid DNA (e.g., pAd5 β dys) containing an embedded inverted origin of replication (and the remaining above elements) together with linear DNA from E1-deleted virions expressing human placental alkaline phosphatase (hpAP) (a helper virus). All proteins necessary for the generation of EAMs are provided *in trans* from the hpAP virions and the two can be separated from each other on equilibrium CsCl gradients. These EAMs are useful for gene transfer to a variety of cell types both *in vitro* and *in vivo*.

Adenovirus-mediated gene transfer to muscle is a promising technology for gene therapy of Duchenne muscular dystrophy (DMD). However, currently available recombinant adenovirus vectors have several limitations, including a limited cloning capacity of ~8.5 kb, and the induction of a host immune response that leads to transient gene expression of 3 to 4 weeks in immunocompetent animals. Gene therapy for DMD could benefit from the development of adenoviral vectors with an increased cloning capacity to accommodate a full length (~14 kb) dystrophin cDNA. This increased capacity should also accommodate gene regulatory elements to achieve expression of transduced genes in a tissue-specific manner. Additional vector modifications that eliminate adenoviral genes, expression of which is associated with development of a host immune response, might greatly increase long term expression of virally delivered genes *in vivo*. The constructed encapsidated adenovirus minichromosomes of the present invention are capable of delivering up to 35 kb of non-viral exogenous DNA. These minichromosomes are derived from bacterial plasmids containing two fused inverted adenovirus origins of replication embedded in a circular genome, the adenovirus packaging signals, a β galactosidase reporter gene and a full length dystrophin cDNA regulated by a muscle specific enhancer/promoter. The encapsidated minichromosomes are propagated *in vitro* by *trans*-complementation with a replication defective (E1+E3 deleted) helper virus. These minichromosomes can be propagated to high titer ($>10^8/\text{ml}$) and purified on CsCl gradients due to their buoyancy difference relative to helper virus. These vectors are able to transduce myogenic cell cultures and express dystrophin in myotubes. These results

demonstrate that encapsidated adenovirus minichromosomes are useful for gene transfer to muscle and other tissues.

The present invention further provides methods for modifying the above-described EAM system to enable the generation of high titer stocks of EAMs with minimal helper virus 5 contamination. Preferably the EAM stocks contain helper virus representing less than 1%, preferably less than 0.1% and most preferably less than 0.01% (including 0.0%) of the final viral isolate.

The amount of helper virus present in the EAM preparations is reduced in two ways. The first is by selectively controlling the relative packaging efficiency of the helper virus 10 versus the EAM virus. The *Cre-loxP* excision method is employed to remove the packaging signals from the helper virus thereby preventing the packaging of the helper virus used to provide in trans viral proteins for the encapsidation of the recombinant adenovirus minichromosomes. The second approach to reducing or eliminating helper virus in EAM stocks is the use of improve physical methods for separating EAM from helper virus.

15

EXPERIMENTAL

The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

In the experimental disclosure which follows, the following abbreviations apply: M 20 (molar); mM (millimolar); μ M (micromolar); mol (moles); mmol (millimoles); μ mol (micromoles); nmol (nanomoles); mu or m.u. (map unit); g (gravity); gm (grams); mg (milligrams); μ g (micrograms); pg (picograms); L (liters); ml (milliliters); μ l (microliters); cm (centimeters); mm (millimeters); μ m (micrometers); nm (nanometers); hr (hour); min (minute); msec (millisecond); $^{\circ}$ C (degrees Centigrade); AMP (adenosine 5'-monophosphate); 25 cDNA (copy or complimentary DNA); DTT (dithiotheritol); ddH₂O (double distilled water); dNTP (deoxyribonucleotide triphosphate); rNTP (ribonucleotide triphosphate); ddNTP (dideoxyribonucleotide triphosphate); bp (base pair); kb (kilo base pair); TLC (thin layer chromatography); tRNA (transfer RNA); nt (nucleotide); VRC (vanadyl ribonucleoside complex); RNase (ribonuclease); DNase (deoxyribonuclease); poly A (polyriboadenylic acid); 30 PBS (phosphate buffered saline); OD (optical density); HEPES (N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]); HBS (HEPES buffered saline); SDS (sodium dodecyl sulfate); Tris-HCl (tris[Hydroxymethyl]aminomethane-hydrochloride); rpm (revolutions per minute); ligation buffer (50 mM Tris-HCl, 10 mM MgCl₂, 10 mM

WO 98/17783

dithiothreitol, 25 µg/ml bovine serum albumin, and 26 µM NAD⁺, and pH 7.8); EGTA (ethylene glycol-bis(β-aminoethyl ether) N, N, N', N'-tetraacetic acid); EDTA (ethylenediaminetetraacetic acid); ELISA (enzyme linked immunosorbant assay); LB (Luria-Bertani broth: 10 g tryptone, 5 g yeast extract, and 10 g NaCl per liter, pH adjusted to 7.5 with 1N NaOH); superbroth (12 g tryptone, 24 g yeast extract, 5 g glycerol, 3.8 g KH₂PO₄ and 12.5 g K₂HPO₄ per liter); DMEM (Dulbecco's modified Eagle's medium); ABI (Applied Biosystems Inc., Foster City, CA); Amersham (Amersham Corporation, Arlington Heights, IL); ATCC (American Type Culture Collection, Rockville, MD); Beckman (Beckman Instruments Inc., Fullerton CA); BM (Boehringer Mannheim Biochemicals, Indianapolis, IN); Bio-101 (Bio-101, Vista, CA); BioRad (BioRad, Richmond, CA); Brinkmann (Brinkmann Instruments Inc., Westbury, NY); BRL, Gibco BRL and Life Technologies (Bethesda Research Laboratories, Life Technologies Inc., Gaithersburg, MD); CRI (Collaborative Research Inc., Bedford, MA); Eastman Kodak (Eastman Kodak Co., Rochester, NY); Eppendorf (Eppendorf, Eppendorf North America, Inc., Madison, WI); Falcon (Becton Dickinson Labware, Lincoln Park, NJ); IBI (International Biotechnologies, Inc., New Haven, CT); ICN (ICN Biomedicals, Inc., Costa Mesa, CA); Invitrogen (Invitrogen, San Diego, CA); New Brunswick (New Brunswick Scientific Co. Inc., Edison, NJ); NEB (New England Biolabs Inc., Beverly, MA); NEN (Du Pont NEN Products, Boston, MA); Pharmacia (Pharmacia LKB Gaithersburg, MD); Promega (Promega Corporation, Madison, WI); Stratagene (Stratagene Cloning Systems, La Jolla, CA); UVP (UVP, Inc., San Gabriel, CA); USB (United States Biochemical Corp., Cleveland, OH); and Whatman (Whatman Lab. Products Inc., Clifton, NJ).

Unless otherwise indicated, all restriction enzymes and DNA modifying enzymes were obtained from New England Biolabs (NEB) and used according to the manufacturers directions.

25

EXAMPLE 1

Generation Of Packaging Cell Lines That Coexpress The Adenovirus E1 And DNA Polymerase Proteins

30 In this example, packaging cell lines coexpressing Ad E1 and polymerase proteins were described. These cell lines were shown to support the replication and growth of H5ts36, an Ad with a temperature-sensitive mutation of the Ad polymerase protein. These

polymerase-expressing packaging cell lines can be used to prepare Ad vectors deleted for the E1 and polymerase functions.

5 **a) Tissue Culture And Virus Growth**

LP-293 cells (Microbix Biosystems, Toronto) were grown and serially passaged as suggested by the supplier.

10 Plaque assays were performed in 60 mm dishes containing cell monolayers at ~ 90% confluence. The appropriate virus dilution in a 2% DMEM solution was dripped onto the cells, and the plates incubated at the appropriate temperature for one hour. The virus containing media was aspirated, the monolayer was overlaid with 10 mls of a pre-warmed EMEM agar overlay solution (0.8% Noble agar, 4% fetal calf serum, and antibiotics) and allowed to solidify. After the appropriate incubation time (usually 7 days for incubations at 38.5°C and 10-12 days for incubations at 32°C), five mls of the agar-containing solution containing 1.3% neutral red was overlaid onto the infected dishes and plaques were counted 15 the next day. An aliquot of the virus H5ts36 [Freimuth and Ginsberg (1986) Proc. Natl. Acad. Sci. USA 83:7816] was utilized to produce high titre stocks after infection of 293 cells at 32°C. H5ts36 is an Ad5-derived virus defective for viral replication at the nonpermissive temperature [Miller and Williams (1987) J. Virol. 61:3630].

20 The infected cells were harvested after the onset of extensive cytopathic effect, pelleted by centrifugation and resuspended in 10 mM Tris-Cl, pH 8.0. The lysate was freeze-thawed three times and centrifuged to remove the cell debris. The cleared lysate was applied to CsCl₂ step gradients (heavy CsCl at density of 1.45 g/ml, the light CsCl at density of 1.20 g/ml), ultracentrifuged, and purified using standard techniques [Graham and Prevec (1991) In *Methods in Molecular Biology, Vol 7: Gene Transfer and Expression Protocols*, Murray 25 (ed.), Humana Press, Clifton, NJ, pp. 109-128]. The concentration of plaque forming units (pfu) of this stock was determined at 32°C as described above. Virion DNA was extracted from the high titre stock by pronase digestion, phenol-chloroform extraction, and ethanol precipitation. The leakiness of this stock was found to be <1 in 2000 pfu at the non-permissive temperature, consistent with previous reports [Miller and Williams (1987), *supra*].

30

b) **Plasmids**

The expression plasmid pRSV-pol [Zhao and Padmanabhan (1988) Cell 55:1005] contains sequences encoding the Ad2 polymerase mRNA (including the start codon from the

WO 98/17783

exon at map unit 39) under the transcriptional control of the Rous Sarcoma Virus LTR/promoter element: the Ad2 DNA polymerase sequences are flanked on the 3' end by the SV-40 small t intron and SV-40 polyadenylation addition site (see Fig. 1A). Figure 1A provides a schematic representation of the Ad polymerase expression plasmid pRSV-pol. 5 pRSV-pol includes the initiator methionine and amino-terminal peptides encoded by the exon at m.u. 39 of the Ad genome. The location of the PCR primers p602a and p2158c, the two *Scal* 1 kb probes utilized for Northern analyses, the polymerase terminator codon, and the polyadenylation site of the IVa2 gene (at 11.2 m.u. of the Ad genome) are indicated.

10 The expression plasmid pRSV-pTP [Zhao and Padmanabhan (1988), *supra*] contains sequences encoding the Ad2 preterminal protein (including the amino terminal peptides encoded by the exon at map unit 39 of the Ad genome) under the transcriptional control of the Rous Sarcoma Virus LTR/promoter element; the pTP sequences are flanked on the 3' end by the SV-40 small-t intron and SV-40 polyadenylation signals (see Figure 1B for a schematic of pRSV-PTP). Figure 1B also shows the location of the *EcoRV* subfragment utilized as a 15 probe in the genomic DNA and cellular RNA evaluations, as well as the initiator methionine codon present from map unit 39 in the Ad5 genome. The locations of the H5in190 and H5sub100 insertions are shown relative to the preterminal protein open-reading frame. The following abbreviations are used in Figure 1: ORF, open reading frame; small-t, small tumor antigen, and m.u., map unit.

20 pCEP4 is a plasmid containing a hygromycin expression cassette (Invitrogen). pFG140 (Microbix Biosystems Inc. Toronto, Ontario) is a plasmid containing sequences derived from Ad5~~dl~~309 which contain a deletion/substitution in the E3 region [Jones and Shek (1979) Cell 17:683]. pFG140 is infectious in single transfections of 293 cells and is used as a control for transfection efficiency.

25

c) Transfection Of 293 Cells

LP-293 cells were cotransfected with *Bam*HI linearized pRSV-pol and *Bam*HI linearized pCEP4 at a molar ratio of 10:1 using a standard CaPO₄ precipitation method [Sambrook *et al.* (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press. Plainview, NY, pp.16.33-16.36]. In addition, 293 cells were cotransfected with or with 30 *Bam*HI linearized pRSV-pol, *Bam*HI linearized pRSV-pTP and pCEP using a molar ratio of 10:1 (non-selectable:selectable plasmids).

Forty-eight hours after transfection, the cells were passaged into media containing hygromycin at 100 µg/mL. Individual hygromycin resistant colonies were isolated and expanded.

5

d) Isolation Of Ad Polymerase Expressing 293 Cell Lines

Twenty hygromycin resistant cell lines were expanded and screened for the ability to express the Ad polymerase protein. Initially, the individual cell lines were assayed for the ability to support growth of the viral polymerase mutant H5ts36 using the plaque assay described in section a) above. It was speculated that constitutive expression of the wild type Ad polymerase protein in a clonal population of 293 cells should allow the growth of H5ts36 at 38.5°C. However, it was unclear if constitutive expression of the Ad polymerase would be toxic when coexpressed with the E1 proteins present in 293 cells. Similar toxicity problems have been observed with the Ad ssDBP, and the pTP [Klessig *et al.* (1984) Mol. Cell. Biol. 4:1354 and Schaack *et al.* (1995) J. Virol. 69:4079].

15

Of the twenty hygromycin resistant cell lines isolated, seven were able to support plaque formation with H5ts36 at the non-permissive temperature, unlike the parental LP-293 cells; these cell lines were named B-6, B-9, C-1, C-4, C-7, C-13 and C-14 (see Table 1) (the B-6 and B-9 cell lines received only the pRSV-pol and CEP4 plasmids; C-1, C-4, C-7, C-13 and C-14 cell lines received the pRSV-pol, pRSV-pTP and CEP4 plasmids). For the results shown in Table 1, dishes (60 mm) of near confluent cells of each cell line were infected with the same dilution of H5ts36 at the temperature indicated, overlaid with agar media, and stained for plaques as outlined in section a. Passage number refers to the number of serial passages after initial transfection with the plasmid pRSV-pol.

25

The cell line B-6 produced plaques one day earlier than the other Ad polymerase-expressing cell lines, which may reflect increased polymerase expression (see below). Cell line B-9 demonstrated an increased doubling time whereas each of the other cell lines displayed no growth disadvantages relative to the parental LP-293 cells. As shown in Table 1, even after multiple passages (in some instances up to four months of serial passaging) the cells were still capable of H5ts36 plaque formation at the non-permissive temperature, indicating that the RSV-LTR/promoter remained active for extended periods of time. However, the cell lines B-9 and C-13 displayed a decreased ability to plaque the virus at 32°C as well as at 38.5°C, suggesting that a global viral complementation defect had occurred in

these cell lines after extended passaging. The remaining cell lines screened at later passages demonstrated no such defect, even after 20 passages (e.g., cell line B-6, Table 1).

TABLE 1
Plaques Ability Of H5ts36 At The Non-Permissive Temperature Utilizing 293-Ad Polymerase Expressing Cell Lines

Cell Line	Passage Number	Number Of Plaques At:	
		32.0°C	38.5°C
293	-	>500	0
B-6	9	>500	>500
	20	>500	>500
B-9	5	>500	>500
	14	90	18
C-1	5	>500	>500
	13	>500	>500
C-4	5	>500	>500
	14	>500	>500
C-7	5	>500	>500
	14	>500	>500
C-13	5	>500	>500
	27	120	4
C-14	5	>500	>500
	27	>500	370

e) Genomic Analysis Of Ad Polymerase-Expressing Cell Lines

Genomic DNA from LP-293 cells and each of the seven cell lines able to complement H5ts36 at 38.5°C were analyzed by PCR for the presence of pRSV-pol derived sequences.

Genomic DNA from LP-293 cells and the hygromycin resistant cell lines were harvested using standard protocols (Sambrook *et al.*, *supra*) and 200 ng of DNA from each cell line was analyzed by PCR in a solution containing 2 ng/mL of primers p602a and p2158c, 10 mM Tris HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, and 0.001% gelatin. The forward primer, p602a [5'-TTCATTTATGTTCAAGGTC AGGG-3' (SEQ ID NO:2)] is located in the SV-40 polyadenylation sequence. The reverse primer p2158c [5'-TTACCGCCACACTCGCAGGG-3' (SEQ ID NO:3)] is Ad-sequence specific with the 5' nucleotide located at position 3394 of the Ad 5 genome [numbering according to Doerfler

(1986) *Adenovirus DNA. The Viral Genome and Its Expression.* Nijhoff. Boston. MA. pp. 1-95].

PCR was performed with a Perkin Elmer 9600 Thermocycler utilizing the following cycling parameters: initial denaturation at 94°C for 3 min. 3 cycles of denaturation at 94°C for 30 sec. annealing at 50°C for 30 sec. and extension at 72°C for 60 sec. followed by another 27 cycles with an increased annealing temperature at 56°C. with a final extension at 72°C for 10 minutes. PCR products were separated on a 1.0 % agarose gel and visualized with ethidium bromide staining (Figure 2). A 1 kb ladder (Gibco-BRL) was used as a size marker. and the plasmid pRSV-pol was used as a positive control. The ~750 bp PCR products are indicated by an arrow in Figure 2.

As shown in Figure 2, all cell lines capable of H5ts36 plaque formation at 38.5°C contained the Ad pol DNA sequences. whereas the LP-293 cells did not yield any amplification product with these primers. This result demonstrates that each of the selected cell lines stably co-integrated not only the hygromycin resistance plasmid pCEP4. but also pRSV-pol.

f) Complementation Of The Replication Defect Of H5ts36 By Ad Polymerase Expressing Cell Lines

The C to T transition at position 7623 of the H5ts36 genome alters the DNA binding affinity of the Ad polymerase protein. rendering it defective for viral replication at non-permissive temperatures [Chen *et al.* (1994) *Virology* 205:364; Miller and Williams (1987) *J. Virol.* 61:3630; and Wilkie *et al.* (1973) *Virology* 51:499]. To analyze the functional activity of the Ad polymerase protein expressed by each of the packaging cell lines. a viral replication-complementation assay was performed. LP-293 cells or the hygromycin resistant cell lines were seeded onto 60 mM dishes at densities of 2.5-3.0 x 10⁶ per dish. infected with H5ts36 at a multiplicity of infection (MOI) of 10. and incubated for 24 hours at 38.5°C. or 48 hours at 32°C. Total DNA was harvested from each plate. then 2 µg of each sample were digested with *Hind*III. separated on a 1.0% agarose gel. transferred to a nylon membrane. and hybridized with ³²P-labeled H5ts36 virion DNA. Densitometric analysis of the 8.010 bp *Hind*III fragment in each lane was performed on a phophoroimager (Molecular Dynamics) utilizing a gel image processing system (IP Lab Version 1.5. Sunnyvale. CA).

The resulting autoradiograph is shown in Figure 3. In Figure 3, the lane marked "Std." (standard) contains 1 µg of *Hind*III-digested H5ts36 virion DNA. The 8.010 bp *Hind*III fragments analyzed by densitometry are indicated by an arrow.

As shown in Figure 3, H5ts36 had a diminished ability to replicate in LP-293 cells at 5 the non-permissive temperature. In contrast, all seven of the previously selected cell lines were able to support replication of H5ts36 virion DNA at 38.5°C to levels approaching those occurring in LP-293 cells at 32°C.

A densitometric analysis of the amount of H5ts36 viral DNA replicated in each of the 10 cell lines at permissive and nonpermissive temperatures is presented in Table 2 below. For this assay, the relative amounts of the 8.010 bp *Hind*III fragment were compared. The 15 relative levels of H5ts36 virion DNA replication determined by densitometric analysis of the 8.010 bp *Hind*III fragment isolated from each of the cell line DNA samples. The surface area of the 8.010 bp fragment in 293 cells incubated at 38.5°C was designated as 1, and includes some replicated H5ts36 virion DNA. The numbers in each column represent the ratio between the densities of the 8.010 bp fragment isolated in the indicated cell line and the density of the same band present in LP-293 cells at 38.5°C.

As shown in Table 2, the levels of replication at the permissive temperature were all 20 within four-fold of each other, regardless of which cell line was analyzed, but at the non-permissive temperature LP-293 cells reveal the H5ts36 replication defect. The viral bands that were present in the LP-293 DNA sample at 38.5°C represented input virion DNA as well as low level replication of H5ts36 DNA, which is generated due to the leakiness of the ts mutation at the high MOI utilized in this experiment. The Ad polymerase-expressing cell lines were all found to be capable of augmenting

TABLE 2
Densitometric Analysis Of H5ts36 Replication

Cell Line	Ratios Of 8.010 bp <i>Hind</i> III Fragment Generated At:	
	32.0°C	38.5°C
LP-293	42.6	1.0
B-6	27.3	57.2
B-9	69.0	15.8
C-1	113.6	34.1
C-4	100.2	65.5
C-7	114.9	75.0
C-13	43.1	42.2
C-14	46.7	27.8

H5ts36 genome replication. Although one cell line (B-9) allowed H5ts36 replication to levels only 16 fold greater than LP-293 cells, this was the same cell line that was observed to 5 display poor growth properties. Each of the remaining Ad polymerase-expressing cell lines allowed substantially greater replication of H5ts36 at non-permissive temperatures, compared to LP-293 cells (Table 2). An enhancement of replication up to 75 fold above that of LP-293 cells was observed with the cell line C-7 at 38.5°C. A substantially more rapid onset of viral cytopathic effect in Ad polymerase-expressing cell lines was observed at either temperature. 10 These estimates of H5ts36 replication-complementation are conservative, since they have not been adjusted for the low level replication of H5ts36 at 38.5°C [Miller and Williams (1987), 15 *supra*]. The leakiness of the H5ts36 mutation could potentially be overcome with the use of a virus deleted for the Ad polymerase gene.

20 g) **RNA Analysis Of Ad Polymerase-Expressing Cell Lines**

Total RNA was extracted from each of the cell lines using the RNAzol method (Teltest, Inc., Friendswood, TX 77546; Chomczynski and Sacchi (1987) Anal. Biochem. 162:156]. Fifteen micrograms of RNA from each cell line was electrophoresed on a 0.8% agarose-formaldehyde gel, and transferred to a Nytran membrane (Schleicher & Schuell) by 25 blotting. The filter was UV crosslinked, and analyzed by probing with the two ³²P-labeled 1 kb *Scal* subfragments of Ad which span positions 6095-8105 of the Ad5 genome (see Figure 1A). These two *Scal* subfragments of the Ad genome are complimentary to the 5' end of the Ad polymerase mRNA. The resulting autoradiograph is shown in Figure 4. In Figure 4, the 30

WO 98/17783

location of the smaller and larger species of Ad polymerase mRNA are indicated relative to the 28S and 18S ribosomal RNAs. The aberrant transcript expressed by the B-9 cell line is indicated by an arrow.

The results shown in Figure 4 revealed that the RNA derived from cell lines B-6 and C-7 contained two species of RNA, estimated to be ~4800 and ~7000 nt in length, while LP-293 derived RNA had no detectable hybridization signal. The presence of two polymerase RNA species suggests that the polyadenylation signal of the Ad IVa2 gene (present in the Ad-pol construct, see Fig. 1A) is being utilized by the cell RNA processing machinery, in addition to the SV-40 polyadenylation signal. Similar analysis of RNA derived from the cell lines C-1, C-4, C-13, and C-14 also detected the same two transcripts as those detected in the RNA of cell lines B-6 and C-7, but at decreased levels, suggesting that even low levels of Ad polymerase mRNA expression can allow for the efficient replication of polymerase mutants such as H5ts36. The cell line B-6 expressed high levels of polymerase transcript and can plaque H5ts36 one day earlier than the other cell lines at 38.5°C, suggesting a causal relationship. It is interesting to note that the two polymerase transcripts are also detected in RNA isolated from cell line B-9, but substantial amounts of a larger RNA transcript (size > 10 kb) is also present (see Figure 4). The high level production of the aberrant message may be related to the increased doubling time previously noted in this cell line.

20 h) Transfetability Of Ad Polymerase-Expressing Cell Lines

The ability of Ad polymerase-expressing 293 cell lines to support production of H5ts36 virions after transfection with H5ts36 genome DNA was examined as follows. 293 cells as well as hygromycin resistant cell lines were grown to near confluence on 60 mm dishes and transfected with either 3 µg of purified H5ts36 virion DNA, or with 3.5 µg of the plasmid pFG140 (Microbix Biosystems), using the cationic lipid Lipofectamine (Gibco-BRL). Cells that received the H5ts36 virion DNA were incubated at 32°C for 14 days, or 38.5°C for 10 days. The pFG140 transfected cells were incubated at 37.5°C for 10 days. All plates were then stained with the neutral red agar overlay and plaques were counted the next day. The results are shown in Table 3.

TABLE 3
Transfection Efficiency Of Ad pol-Expressing Cell Lines

Cell line	Number Of Plaques At:	
	32.0°C	38.5°C
LP-293	>500	0
B-6	>500	>500
B-9	n.d.*	n.d.
C-1	n.d.	>500
C-4	n.d.	>500
C-7	n.d.	>500
10 C-13	n.d.	100
C-14	n.d.	>500

* n.d. = not determined.

15 The results shown in Table 3 demonstrated that transfection of H5ts36 DNA at the
 non-permissive temperature allows for ample plaque production in all of the Ad polymerase-expressing cell lines tested, unlike the parental LP-293 cells. Cell line C-13 was at passage
 number 29, and demonstrated a somewhat decreased ability to generate plaques at this
 extended passage number. These same cell lines are also capable of producing plaques when
 20 transfected with the plasmid pFG140, a plasmid capable of producing infectious, E1
 dependent Ad upon transfection of the parental 293 cells [Ghosh-Choudhury (1986) Gene
 50:161]. These observations suggest that the Ad polymerase expressing cell lines should be
 useful for the production of second generation Ad vectors deleted not only for the E1 genes,
 but also for the polymerase gene. As shown below in Examples 2 and 3, this is indeed the
 25 case.

EXAMPLE 2

Isolation And Characterization Of Packaging Cell Lines That Coexpress The Adenovirus E1, DNA Polymerase And Preterminal Proteins

30 In Example 1, packaging cell lines coexpressing Ad E1 and polymerase proteins were described. These cell lines were shown to support the replication and growth of H5ts36, an Ad with a temperature-sensitive mutation of the Ad polymerase protein. These polymerase-

expressing packaging cell lines can be used to prepare Ad vectors deleted for the E1 and polymerase functions. In this example, 293 cells cotransfected with both Ad polymerase and preterminal protein expression plasmids are characterized. Cell lines co-expressing the Ad E1, polymerase and preterminal proteins can be used to prepare Ad vectors deleted for the E1, polymerase and preterminal protein (pTP) functions.

5 **a) Tissue Culture And Virus Propagation**

The use of LP-293 cells (Microbix Biosystems Inc., Toronto), Ad-polymerase expressing cell lines, and plaque efficiency assays of Ad viruses was conducted as described 10 in Example 1. All cells were maintained in 10% fetal bovine serum supplemented DMEM media (GIBCO) in the presence of antibiotics. The virus H5*sub*100 [Freimuth and Ginsberg (1986) Proc. Natl. Acad. Sci. USA 83:7816] has a temperature sensitive (ts) mutation caused by a three base pair insertion within the amino terminus of the preterminal protein, in addition to a deletion of the E1 sequences (see Figure 1B). H5*sub*100 was propagated and titred at 15 32.0°C in LP-293 cells; the leakiness of this stock was less than 1 per 1000 plaque-forming units (pfu) at the nonpermissive temperature of 38.5°C. A lower titer cell lysate containing the virus H5*in*190 (which contains a 12 base-pair insertion within the carboxy-terminus of the preterminal protein as well as a deletion of the E1 region, see Figure 1B) was provided by Dr. P. Freimuth [Freimuth and Ginsberg (1986), *supra*]. The polymerase and preterminal protein 20 expressing cell lines were always maintained in media supplemented with hygromycin (Sigma) at 100 µg/mL.

25 **b) Isolation Of Ad Polymerase And Preterminal Protein
Expressing 293 Cells**

The C-1, C-4, C-7, C-13, and C-14 cell lines (Ex. 1), which had been cotransfected with pRSV-pol, pRSV-pTP and CEP4, were screened for presence of pTP sequences and for the ability to support the growth of H5*ts*36 (ts for the Ad-polymerase), H5*in*190, and H5*sub*100 using plaque assays as described in Example 1.

i) Analysis Of Genomic DNA And Cellular RNA

Cell lines that had received the preterminal protein expression plasmid were screen for the presence of pRSV-pTP sequences and E1 sequences. Total DNA was isolated from the LP-293, B-6 (transfected with pRSV-pol only) or C-7 (cotransfected with pRSV-pol and pRSV-pTP) cell lines. two micrograms (μ g) of each DNA was codigested with the restriction enzymes *Xba*I and *Bam*HI, electrophoretically separated in a 0.6% agarose gel, and transferred onto a nylon membrane. The membrane was UV crosslinked, probed with both a 1.8 kb *BlnI-Xba*I fragment (spans the E1 coding region) isolated from the plasmid pFG140, and a 1.8kb *EcoRV* subfragment of Ad serotype 5 (spans the preterminal protein coding sequences; see Fig. 1B), both of which were random-primer radiolabeled with 32 P to a specific activity greater than 3.0×10^8 cpm/ μ g. The membrane was subsequently exposed to X-ray film with enhancement by a fluorescent screen. The resulting autoradiograph is shown in Figure 5.

In Figure 5, the preterminal specific sequences migrated as an ~11.0 kb DNA fragment while the E1 containing band migrated as a 2.3 kb DNA fragment. No hybridization of either probe to DNA isolated from either the LP-293 or B-6 cell lines was observed. As shown in Figure 5, only the C-7 cell line genomic DNA had preterminal coding sequences, unlike the parental LP-293 cells, or the Ad-polymerase expressing B-6 cells. In addition, all cell lines had E1 specific sequences present at nearly equivalent amounts, demonstrating that the selection design has not caused the loss of the E1 sequences originally present in the LP-293 cells. The results presented in Example 1 demonstrated that both the B-6 and C-7 cell lines contain polymerase specific sequences within their genomes, unlike the parental LP-293 cells.

To confirm that transcription of preterminal protein was occurring, total RNA was isolated from each of the cell lines, transferred to nylon membranes, and probed to detect preterminal protein-specific mRNA transcripts as follows. Total cellular RNA was isolated from the respective cell lines and 15 μ g of total RNA from each cell line was transferred to nylon membranes. The membranes were probed with the 1.8 kb *EcoRV* radiolabeled subfragment of Ad5 (see Fig. 1B) complementary to the preterminal protein coding region. The resulting autoradiograph is shown in Figure 6.

As shown in Figure 6, a single mRNA of the expected size (~3 kb in length) is detected only in RNA derived from the C-7 cell line. No hybridization was detected in lanes containing RNA derived from the LP-293 or B-6 cell lines. In Example 1, it was demonstrated that the C-7 cell line also expresses high levels of the Ad polymerase mRNA.

Thus, the C-7 cell line constitutively expresses both the Ad polymerase and preterminal protein mRNAs along with E1 transcripts.

ii) Plaquing Efficiency Of pTP Mutants On pTP-
Expressing Cell Lines

The C-7 cell line was screened for the ability to transcomplement the growth of preterminal mutant viruses. The virus H5*in*190 (contains a 12 base pair insertion located within the carboxy-terminus of the preterminal protein) has been shown to have a severe growth and replication defect, producing less than 10 plaque-forming units per cell [Freimuth and Ginsberg (1986) Proc. Natl. Acad. Sci. USA 83:7816]. The results are summarized in Table 4 below. For the results shown in Table 4, LP-293, B-6, or C-7 cells were seeded at a density of $2.0-2.5 \times 10^6$ cells per plate. The cells were infected with limiting dilutions of lysates derived from the preterminal protein-mutant viruses H5*in*190 or H5*sub*100, incubated at 38.5°C, and plaques counted after six days. As shown in Table 4, only the C-7 cell line could allow efficient plaque formation of H5*in*190 at 38.5°C (the H5*in*190 lysate used to infect the cells was of a low titer, relative to the high titer H5*sub*100 stock), while both the B-6 and C-7 cell lines had nearly equivalent plaquing efficiencies when H5*sub*100 was utilized as the infecting virus.

TABLE 4

Plaques Efficiency Of Preterminal Protein-Mutant Viruses

Virus	Mutation Location	Plaque Titres (pfu/ml)		
		LP-293	B-6	C-7
H5in190	carboxy-terminus	<1 x 10 ²	<1 x 10 ²	1.4 x 10 ⁵
H5sub100	amino-terminus	<1 x 10 ⁴	9.0 x 10 ⁸	4.5 x 10 ⁸

As shown in Table 4, when equivalent dilutions of H5in190 were utilized, the plaque efficiency of the C-7 cell line was at least 100-fold greater than that of the B-6 or LP-293 cells. This result demonstrated that the C-7 cell line produces a functional preterminal protein, capable of trans-complementing the defect of the H5in190 derived preterminal protein.

30 The cell lines were next screened for the ability to trans-complement with the temperature-sensitive virus, H5*sub*100, at nonpermissive temperatures. H5*sub*100 has a codon insertion mutation within the amino-terminus of the preterminal protein, as well as an E1 deletion. The mutation is responsible both for a temperature sensitive growth defect, as well

as a replication defect [Freimuth and Ginsberg (1986), *supra* and Schaack *et al.* (1995) J. Virol. 69:4079]. The plaqueing efficiency of the cell line C-7 was found to be at least 1000 fold greater than that of the LP-293 cells (at non-permissive temperatures) (see Table 4). Interestingly, the cell line B-6 was also capable of producing large numbers of H5sub100 derived plaques at 38.5°C, even though it does not express any preterminal protein. This result suggested that the high level expression of the polymerase protein was allowing plaque formation of H5sub100 in the B-6 cell line. To examine this possibility, the nature of H5sub100 growth in the various cell lines was examined.

10 c) **Complementation Of The Replication And Growth Defects
Of H5sub100**

The cell lines B-6 and C-7 were shown to overcome the replication defect of H5ts36 (Ex. 1). Since the preterminal and polymerase proteins are known to physically interact with each other [Zhao and Padmanabhan (1988) Cell 55:1005], we investigated whether the 15 expression of the Ad-polymerase could overcome the replication defect of H5sub100 at non-permissive temperatures using the following replication-complementation assay.

LP-293, B-6, or C-7 cells were seeded onto 60 mM dishes at a density of 2×10^6 cells per dish and infected the next day with H5sub100 at a multiplicity of infection (MOI) of 0.25, and incubated at 38.5°C for 16 hours or 32.0°C for 40 hours. The cells from each infected 20 plate were then harvested and total DNA extracted as described in Example 1. Four micrograms of each DNA sample was digested with *Hind*III, electrophoresed through a 0.7% agarose gel, transferred to a nylon membrane, and probed with ^{32}P -labeled H5ts36 virion DNA. The resulting autoradiograph is shown in Figure 7. As seen in Figure 7, the 25 H5sub100 replication defect when grown in LP-293 cells at 38.5°C is seen; this defect is not present when the virus is grown at the same temperature in either B-6 or C-7 cells.

The results depicted in Figure 7 demonstrates that both cell lines B-6 and C-7 could trans-complement the replication defect of H5sub100. This result demonstrated that the 30 expression of the Ad polymerase in B-6 cells was able to overcome the preterminal protein-mediated replication defect of H5sub100. While not limiting the present invention to any particular mechanism, the ability of Ad polymerase to overcome the preterminal protein-mediated replication defect of H5sub100 may be due to a direct physical interaction of the polymerase with the amino-terminus of the H5sub100-derived preterminal protein.

In support of this hypothesis, it has also been demonstrated that the H5sub100 replication defect can be overcome when LP-293 cells were infected with a 100-fold greater amount of H5sub100. However, complementation of the H5sub100 replication defect is not sufficient to overcome the growth defect of H5sub100, since temperature shift-up experiments have demonstrated that the H5sub100 growth defect is not dependent upon viral replication [Schaack *et al.* (1995), *supra*]. Therefore, the overexpression of the Ad-polymerase must have allowed a very low level but detectable production of infectious H5sub100 particles in the B-6 cell line. The reduced growth of H5sub100 is therefore not due to a replication defect, but rather some other critical activity that the preterminal protein has a role in, such as augmentation of viral transcription by association with the nuclear matrix [Schaack and Shenk (1989) Curr. Top. Microbiol. Immunol. 144:185 and Hauser and Chamberlain (1996) J. Endo. 149:373]. This was confirmed by assessing the ability of the C-7 cell line to overcome the growth defect of H5sub100 utilizing one-step growth assays performed as follows.

Each of the cell lines (LP-293, B-6 and C-7) were seeded onto 60 mm dishes at 2.0 x 10⁶ cells/dish. The cell lines were infected at an MOI of 4 with each of the appropriate viruses (wtAd5, H5ts36, or H5sub100), and incubated at 38.5°C for 40 hours. The total amount of infectious virions produced in each 60 mm dish was released from the cell lysates by three cycles of freeze-thawing, and the titer was then determined by limiting dilution and plaque assay on B-6 cells at 38.5°C. The results are summarized in Figure 8.

The results shown in Figure 8, demonstrated that even though the B-6 cell line allowed normal replication and plaque formation of H5sub100 at 38.5°C (in fact, B-6 cells were utilized to determine the plaque titres depicted in Figure 8) they could not allow high level growth of H5sub100 and only produced titres of H5sub100 equivalent to that produced by the LP-293 cells. The C-7 cell line produced 100 fold more virus than the LP-293 or B-6 cells, see Figure 8. Encouragingly, the titre of H5sub100 produced by the C-7 cells approached titres produced by LP-293 cells infected with wild-type virus, Ad5. When the H5sub100 virions produced from infection of the C-7 cells were used to infect LP-293 cells at 38.5°C, all virus produced retained the *ts* mutation (*i.e.*, at least a 1000 fold drop in pfu was detected when LP-293 cells were respectively infected at 38.5°C vs. 32.0°C). This finding effectively rules out the theoretical possibility that the H5sub100 input virus genomes recombined with the preterminal protein sequences present in the C-7 cells.

In addition, the C-7 cell line allowed the high level growth of H5ts36, demonstrating that adequate amounts of the Ad-polymerase protein were also being expressed. The C-7 cell

line was capable of trans-complementing the growth of both H5ts36 and H5sub100 after 4 months of serial passaging, demonstrating that the coexpression of the E1, preterminal, and polymerase proteins was not toxic.

These results demonstrate that the constitutive expression of both the polymerase and preterminal proteins is not detrimental to normal virus production, which might have occurred if one or both of the proteins had to be expressed only during a narrow time period during the Ad life cycle. In summary, these results demonstrated that the C-7 cell line can be used as a packaging cell line to allow the high level growth of E1, preterminal, and polymerase deleted Ad vectors.

10

EXAMPLE 3

Production Of Adenovirus Vectors Deleted For E1 And Polymerase Functions

In order to produce an Ad vectors deleted for E1 and polymerase functions, a small, frame-shifting deletion was introduced into the Ad-pol gene contained within an E1-deleted Ad genome. The plasmid pBHG11 (Microbix) was used as the source of an E1-deleted Ad genome. pBHG11 contains a deletion of Ad5 sequences from bp 188 to bp 1339 (0.5-3.7 m.u.); this deletion removes the packaging signals as well as E1 sequences. pBHG11 also contains a large deletion within the E3 region (bp 27865 to bp 30995; 77.5-86.2 m.u.). The nucleotide sequence of pBHG11 is listed in SEQ ID NO:4 [for cross-correlation between the pBHG11 sequence and the Ad5 genome (SEQ ID NO:1), it is noted that nucleotide 8,773 in pBHG11 is equivalent to nucleotide 7,269 in Ad5].

pBHG11 was chosen to provide the Ad backbone because this plasmid contains a large deletion within the E3 region (77.5 to 86.2 m.u.) and therefore vectors derived from this plasmid permit the insertion of large pieces of foreign DNA. A large cloning capacity is important when the pol⁻ vectors is to be used to transfer a large gene such as the dystrophin gene (cDNA = 13.6 kb). However, the majority of genes are not this large and therefore other Ad backbones containing smaller deletions within the E3 region (e.g., pBHG10 which contains a deletion between 78.3 to 85.8 m.u.; Microbix) may be employed for the construction of pol⁻ vectors using the strategy outlined below.

WO 98/17783

a) **Construction Of A Plasmid Containing A Portion Of The Adenovirus Genome Containing The Polymerase Gene**

A fragment of the Ad genome containing the pol gene located on pBHG11 was subcloned to create pBSA-XB. Due to the large size of the Ad genome, this intermediate plasmid was constructed to facilitate the introduction of a deletion within the pol gene the pol deletion. pBSA-XB was constructed as follows. The polylinker region of pBluescript (Stratagene) was modified to include additional restriction enzyme recognition sites (the sequence of the modified polylinker is provided in SEQ ID NO:5; the remainder of pBluescript was not altered); the resulting plasmid was termed pBSX. pBHG11 was digested with *Xba*I and *Bam*HI and the 20.223 kb fragment containing the pol and pTP coding regions with *Xba*I and *Bam*HI to generate pBSA-XB.

b) **Construction Of pBHG11 Δ pol**

A deletion was introduced into the pol coding region contained within pBSA-XB in such a manner that other key viral elements were not disturbed (e.g., the major late promoter, the tripartite leader sequences, the pTP gene and other leader sequences critical for normal virus viability). The deletion of the pol sequences was carried out as follows. pBSA-XB was digested with *Bsp*EI and the ends were filled in using T4 DNA polymerase. The *Bsp*EI-digested. T4 polymerase filled DNA was then digested with *Bam*HI and the 8809 bp *Bam*HI/*Bsp*EI(filled) fragment was isolated as follows. The treated DNA was run on a 0.6% agarose gel (TAE buffer) and the 8809 bp fragment was excised from the gel and purified using a QIAEX Gel Extraction Kit according to the manufacturer's instructions (QIAGEN, Chatsworth, CA).

A second aliquot of pBSA-XB DNA was digested with *Bsp*HI and the ends were filled in with T4 DNA polymerase. The *Bsp*HI-digested. T4 polymerase filled DNA was then digested with *Bam*HI and the 13.679 bp *Bam*HI/*Bsp*HI(filled) fragment was isolated as described above.

The purified 8809 bp *Bam*HI/*Bsp*EI(filled) fragment and the purified 13.679 bp *Bam*HI/*Bsp*HI(filled) fragment were ligated to generate p Δ pol. p Δ pol contains a 612 bp deletion within the pol gene (bp 8772 to 9385; numbering relative to that of pBHG11) and lacks the 11.4 kb *Bam*HI fragment containing the right arm of the Ad genome found within pBHG11.

To provide the right arm of the Ad genome, pΔpol was digested with *Bam*HI followed by treatment with calf intestinal alkaline phosphatase. pBHG11 was digested with *Bam*HI and the 11.4 kb fragment was isolated and purified using a QIAEX Gel Extraction Kit as described above. The purified 11.4 kb *Bam*HI fragment was ligated to the 5 *Bam*HI/phosphatased pΔpol to generate pBHG11Δpol. Proper construction of pBHG11Δpol was confirmed restriction digestion (*Hind*III).

c) **Rescue And Propagation Of Ad5Δpol Virus**

The Ad genome contained within pBHG11Δpol lacks the packaging signals. 10 Therefore, in order to recover virus containing the 612 bp deletion within the pol gene from pBHG11Δpol, this plasmid must be cotransfected into packaging cells along with DNA that provides a source of the Ad packaging signals. The Ad packaging signals may be provided by wild-type or mutant Ad viral DNA or alternatively may be provided using a shuttle vector which contains the left-end Ad5 sequences including the packaging signals such as 15 pΔE1sp1A, pΔE1sp1B (Microbix) or pAdBglII (pAdBglII is a standard shuttle vector which contains 0-1 m.u. and 9-16 m.u. of the adenovirus genome).

To rescue virus, pBHG11Δpol was co-transfected with Ad5d^l7001 viral DNA . 20 Ad5d^l7001 contains a deletion in the E3 region; the E3 deletion contained within Ad5d^l7001 is smaller than the deletion contained within the Ad genome contained within pBHG11. It is not necessary that Ad5d^l7001 be used to recover virus; other adenoviruses, including wild-type adenoviruses, may be used to rescue of virus from pBHG11Δpol.

It has been reported that the generation of recombinant Ads is more efficient if Ad 25 DNA-terminal protein complex (TPC) is employed in conjunction with a plasmid containing the desired deletion [Miyake *et al.* (1996) Proc. Natl. Acad. Sci. USA 93:1320]. Accordingly, Ad5d^l7001-TPC were prepared as described [Miyake *et al.* (1996). *supra*]. Briefly, purified 30 Ad5d^l7001 virions (purified through an isopycnic CsCl gradient centered at 1.34 g/ml) were lysed by the addition of an equal volume of 8 M guanidine hydrochloride. The released Ad5d^l7001 DNA-TPC was then purified through a buoyant density gradient of 2.8 M CsCl/4 M guanidine hydrochloride by centrifugation for 16 hr at 55,000 rpm in a VT165 rotor (Beckman). Gradient fractions containing Ad5d^l7001 DNA-TPC were identified using an ethidium bromide spot test and then pooled, dialyzed extensively against TE buffer. BSA was then added to a final concentration of 0.5 mg/ml and aliquots were stored at -80°C. The

Ad5*dl*7001 DNA-TPC was then digested with *Scal* and then gel-filtered through a Sephadex G-50 spin column.

One hundred nanograms of the digested Ad5*dl*7001 DNA-TPC was mixed with 5 µg of pBHG11Δpol and used to transfect pol-expressing 293 cells (*i.e.*.. C-7). Approximately 10 days post-transfection, plaques were picked. The recombinant viruses were plaque purified and propagated using standard techniques (Graham and Prevac, *supra*). Viral DNA was isolated, digested with restriction enzymes and subjected to Southern blotting analysis to determine the organization of the recovered viruses. Two forms of virus containing the 612 bp pol deletion were recovered and termed Ad5ΔpolΔE3I and Ad5ΔpolΔE3II. One form of recombinant pol⁻ virus recovered, Ad5ΔpolΔE3I, underwent a double recombination event with the Ad5*dl*7001 sequences and contains the E3 deletion contained within Ad5*dl*7001 at the right end of the genome. The second form of recombinant pol⁻ virus, Ad5ΔpolΔE3II, retained pBHG11 sequences at the right end of the genome (*i.e.*.. contained the E3 deletion found within pBHG11). These results demonstrate the production of a recombinant Ad vector containing a deletion within the pol gene.

d) Characterization Of The E1+, pol- Viruses

To demonstrate that the deletion contained within these two pol⁻ viruses renders the virus incapable of producing functional polymerase, Ad5ΔpolΔE3I was used to infect 293 cells and pol-expressing 293 cells (B-6 and C-7 cell lines) and a viral replication-complementation assay was performed as described in Example 1e. Briefly, 293, B-6 and C-7 cells were seeded onto 60 mm dishes at a density of 2 x 10⁶ cells/dish and infected with H5*sub*100 or Ad5ΔpolΔE3I at an MOI of 0.25. The infected cells were then incubated at 37°C or 38.5°C for 16 hours, or at 32.0°C for 40 hours. Cells from each infected plate were then harvested and total DNA was extracted. Four micrograms of each DNA sample was digested with *Hind*III, electrophoresed through an agarose gel, transferred to a nylon membrane and probed with ³²P-labeled adenoviral DNA. The resulting autograph is shown in Figure 9. In Figure 9, each panel shows, from left to right, DNA extracted from 293, B-6 and C-7 cells, respectively infected with either H5*sub*100 or Ad5ΔpolΔE3I (labeled Ad5ΔPOL in Fig. 9).

As shown in Figure 9, the recombinant pol⁻ virus was found to be viable on pol-expressing 293 cells but not on 293 cells. These results demonstrates that recombinant Ad viruses containing the 612 bp deletion found within pΔpol lack the ability to express Ad

polymerase. These results also demonstrate that B-6 and C-7 cells efficiently complement the Δpol found within Ad5ΔpolΔE3I and Ad5ΔpolΔE3II. In addition, these results show that replication of the ts pTP mutant H5sub100 can be complemented by high level expression of the Ad polymerase with or without co-expression of pTP.

Because the expression of early genes is required for the expression of the late gene products, the ability of recombinant viruses containing the Δpol deletion to direct the expression of late gene products was examined. 293 and C-7 cells were infected with Ad5ΔpolΔE3I and 24 hours after infection cell extracts were prepared. The cell extracts were serially diluted and examined for the expression of the fiber protein (a late gene product) by immunoblot analysis. The immunoblot was performed as described in Example 3C with the exception that the primary antibody used was an anti-fiber antibody (FIBER-KNOB obtained from Robert Gerard, University of Texas Southwestern Medical School). The results of this immunoblotting analysis revealed that no fiber protein was detected from 293 cells infected with Ad5ΔpolΔE3I (at any dilution of the cell extract). In contrast, even a 1:1000 dilution of cell extract prepared from C-7 cells infected with Ad5ΔpolΔE3I produced a visible band on the immunoblot. Therefore, the pol deletion contained within Ad5ΔpolΔE3I resulted in a greater than 1000-fold decrease in fiber production.

The above results demonstrate that polymerase gene sequences can be deleted from the virus and that the resulting deleted virus will only grow on cells producing Ad-polymerase *in trans*. Using the pol-expressing cell lines described herein (e.g., B-6 and C-7), large quantities of the pol⁻ viruses can be prepared. A dramatic shut-down in growth and late gene expression is seen when cells which do not express Ad polymerase are infected with the pol⁻ viruses.

e) Generation Of E1⁻, Pol⁻ Ad Vectors

Ad5dl7001 used above to rescue virus containing the polymerase deletion is an E1-containing virus. The presence of E1 sequences on the recombinant pol⁻ viruses is undesirable when the recombinant virus is to be used to transfer genes into the tissues of animals: the E1 region encodes the transforming genes and such viruses replicate extremely well *in vivo* leading to an immune response directed against cells infected with the E1-containing virus.

E1⁻ viruses containing the above-described polymerase deletion are generated as follows. pBHG11Δpol is cotransfected into pol-expressing 293 cells (e.g., B-6 or C-7) along

with a shuttle vector containing the left-end Ad5 sequences including the packaging signals. Suitable shuttle vectors include pΔE1sp1A (Microbix), pΔE1sp1B (Microbix) or pAdBgII. The gene of interest is inserted into the polylinker region of the shuttle vector and this plasmid is then cotransfected into B-6 or C-7 cells along with pBHG11Δpol to generate a recombinant E1⁻, pol⁻ Ad vector containing the gene of interest.

EXAMPLE 4
Production Of Adenovirus Vectors
Deleted For E1 And Preterminal Protein Functions

10 In order to produce an Ad vectors deleted for E1 and preterminal protein functions, a small deletion was introduced into the Ad preterminal protein (pTP) gene contained within an E1-deleted Ad genome. The plasmid pBHG11 (Microbix) was used as the source of an E1-deleted Ad genome to maximize the cloning capacity of the resulting pTP⁻ vector. However, 15 other Ad backbones containing smaller deletions within the E3 region (e.g., pBHG10 which contains a deletion between 78.3 to 85.8 m.u.; Microbix) may be employed for the construction of pTP⁻ vectors using the strategy outlined below.

a) Construction Of pΔpTP

20 A deletion was introduced into the pTP coding region contained within pBSA-XB (Ex. 3) in such a manner that other key viral elements were not disturbed (e.g., the tripartite leader sequences, the i-leader sequences, the VA-RNA I and II genes, the 55 kD gene and the pol gene). The deletion of the pTP sequences was carried out as follows. pBSA-XB was digested with *Xba*I and EcoRV and the 7.875 kb fragment was isolated as described (Ex. 3). 25 Another aliquot of pBSA-XB was digested with *Mun*I and the ends were filled in using T4 DNA polymerase. The *Mun*I-digested, T4 polymerase filled DNA was then digested with *Xba*I and the 14.894 kb *Xba*I/*Mun*I(filled) fragment was isolated as described (Ex. 3). The 7.875 kb *Mun*I fragment and the 14.894 kb *Xba*I/*Mun*I(filled) fragment were ligated together to generate pΔpTP.

30

b) Construction Of pBHG11ΔpTP

pΔpol contains a 429 bp deletion within the pTP gene (bp 10.705 to 11.134; numbering relative to that of pBHG11) and lacks the 11.4 kb *Bam*HI fragment containing the right arm of the Ad genome found within pBHG11.

5 To provide the right arm of the Ad genome, pΔpTP was digested with *Bam*HI followed by treatment with shrimp alkaline phosphatase (SAP: U.S. Biochemicals, Cleveland, OH). pBHG11 was digested with *Bam*HI and the 11.4 kb fragment was isolated and purified using a QIAEX Gel Extraction Kit as described (Ex. 3). The purified 11.4 kb *Bam*HI fragment was ligated to the *Bam*HI/phosphatased pΔpTP to generate pBHG11ΔpTP. Proper
10 construction of pBHG11ΔpTP was confirmed restriction digestion.

c) Rescue And Propagation Of Ad Vectors Containing The pTP Deletion

The Ad genome contained within pBHG11ΔpTP lacks the Ad packaging signals.
15 Therefore, in order to recover virus containing the 612 bp deletion within the pol gene from pBHG11Δpol, this plasmid must be cotransfected into packaging cells along with DNA that provides a source of the Ad packaging signals. The Ad packaging signals may be provided by wild-type or mutant Ad viral DNA or alternatively may be provided using a shuttle vector which contains the left-end Ad5 sequences including the packaging signals such as
20 pΔE1sp1A, pΔE1sp1B (Microbix) or pAdBglII.

Recombinant Ad vectors containing the pTP deletion which contain a deletion within the E3 region are generated by cotransfection of pBHG11ΔpTP (the gene of interest is inserted into the unique *Pac*I site of pBHG11ΔpTP) with a E3-deleted Ad virus such as Ad5dl700 into pTP-expressing 293 cells (e.g., C-7); viral DNA-TPC are utilized as described
25 above in Example 3.

Recombinant vectors containing the pTP deletion which also contain deletions within the E1 and E3 regions are generated by cotransfection of pBHG11ΔpTP into pTP-expressing 293 cells (e.g., C-7) along with a shuttle vector containing the left-end Ad5 sequences including the packaging signals. Suitable shuttle vectors include pΔE1sp1A (Microbix),
30 pΔE1sp1B (Microbix) or pAdBglII. The gene of interest is inserted into the polylinker region of the shuttle vector and this plasmid is then cotransfected into B-6 or C-7 cells along with pBHG11ΔpTP to generate a recombinant E1⁻, pTP⁻ Ad vector containing the gene of interest.

EXAMPLE 5**Production Of Adenovirus Vectors Deleted For
E1. Polymerase And Preterminal Protein Functions**

5 In order to produce an Ad vectors deleted for E1, polymerase and preterminal protein functions. a deletion encompassing pol and pTP gene sequences was introduced into the Ad sequences contained within an E1-deleted Ad genome. The plasmid pBHG11ΔE4 was used as the source of an E1-deleted Ad genome to maximize the cloning capacity of the resulting pol⁻, pTP⁻ vector. pBHG11ΔE4 is a modified form of BHG11 which contains a deletion of all E4 genes except for the E4 ORF 6; the E4 region was deleted to create more room for the insertion of a gene of interest and to further disable the virus. However, other E1⁻ Ad backbones, such as pBHG11 and pBHG1 (Microbix; pBHG10 contains a smaller deletion within the E3 region as compared to pBHG11), may be employed for the construction of pol⁻, pTP⁻ vectors using the strategy outlined below.

10 Due to the complexity of the cloning steps required to introduce a 2.3 kb deletion that removes portions of both the pTP and pol genes, this deletion was generated using several steps as detailed below.

a) Construction Of pAXBΔpolΔpTPVARNA+t13

20 In order to create a plasmid containing Ad sequences that have a deletion within the pol and pTP genes, pAXBΔpolΔpTPVARNA+t13 was constructed as follows.

25 pBSA-XB was digested with *Bsp*EI and the 18 kb fragment was isolated and recircularized to create pAXBΔpolΔpTP; this plasmid contains a deletion of the sequences contained between the *Bsp*EI sites located at 8.773 and 12.513 (numbering relative to pBHG11).

30 A fragment encoding the VA-RNA3 sequence and the third leader of the tri-partite leader sequence was prepared using the PCR as follows. The PCR was carried out in a solution containing H5ts36 virion DNA (any Ad DNA, including wild-type Ad, may be used), 2 ng/mL of primers 4005E and 4006E, 10 mM TrisHCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin and *Pfu* polymerase. The forward primer, 4005E, [5'-TGCCGCAGCACCGGATGCATC-3' (SEQ ID NO:6)] contains sequences complementary to residues 12.551 to 12.571 of pBHG11 (SEQ ID NO:4). The reverse primer, 4006E, [5'-GCGTCCGGAGGCTGCCATG CGGCAGGG-3' (SEQ ID NO:7)] is complementary to

residues 11.091 to 11.108 of pBHG11 (SEQ ID NO:4) as well as a *Bsp*EI site (underlined). The predicted sequence of the ~1.6 kb PCR product is listed in SEQ ID NO:8.

PCR was performed with a Perkin Elmer 9600 Thermocycler utilizing the following cycling parameters: initial denaturation at 94°C for 3 min. 3 cycles of denaturation at 94°C for 30 sec. annealing at 50°C for 30 sec. and extension at 72°C for 60 sec. followed by another 27 cycles with an increased annealing temperature at 56°C. with a final extension at 72°C for 10 minutes. The ~1.6 kb PCR product was purified using a QIAEX Gel Extraction Kit as described (Ex. 3).

The purified PCR fragment was then digested with *Bsp*EI. pAXBΔpolΔpTP was digested with *Bsp*EI followed by treatment with SAP. The *Bsp*EI-digested PCR fragment and the *Bsp*EI-SAP-treated pAXBΔpolΔpTP were ligated together to create pAXBΔpolΔpTPVARNA+t13.

b) Construction Of pBHG11ΔpolΔpTPVARNA+t13

pAXBΔpolΔpTPVARNA+t13 contains a 2.3 kb deletion within the pol and pTP genes (bp 8.773 to 11.091; numbering relative to that of pBHG11) and lacks the 11.4 kb *Bam*HI fragment containing the right arm of the Ad genome.

To provide the right arm of the Ad genome, pAXBΔpolΔpTPVARNA+t13 was digested with *Bam*HI followed by treatment with SAP. pBHG11ΔE4 (pBHG11 or pBHG10 may be used in place of pBHG11ΔE4) was digested with *Bam*HI and the 11.4 kb fragment was isolated and purified using a QIAEX Gel Extraction Kit as described (Ex. 3). The purified 11.4 kb *Bam*HI fragment was ligated to the *Bam*HI/phosphatased pAXBΔpolΔpTPVARNA+t13 to generate pBHG11ΔpolΔpTPVARNA+t13. Proper construction of pBHG11ΔpolΔpTPVARNA+t13 was confirmed restriction digestion.

25

c) Rescue And Propagation Of Ad Vectors Containing The pol, pTP Double Deletion

The Ad genome contained within pBHG11ΔpolΔpTPVARNA+t13 lacks the Ad packaging signals. Therefore, in order to recover virus containing the 2.3 kb deletion within the pol and pTP genes from pBHG11ΔpolΔpTPVARNA+t13, this plasmid must be cotransfected into packaging cells along with DNA that provides a source of the Ad packaging signals. The Ad packaging signals may be provided by wild-type or mutant Ad viral DNA or alternatively may be provided using a shuttle vector which contains the left-end

Ad5 sequences including the packaging signals such as pΔE1sp1A, pΔE1sp1B (Microbix) or pAdBglII.

Recombinant vAd vectors containing the pol, pTP double deletion which also contain a deletion within the E3 region are generated by cotransfection of
5 pBHG11ΔpolΔpTPVARNA+t13 (the gene of interest is inserted into the unique *PacI* site of pBHG11ΔpolΔpTPVARNA+t13) with a E3-deleted Ad virus such as Ad5d17001 into pol- and pTP-expressing 293 cells (e.g., C-7); viral DNA-TPC are utilized as described (Ex. 3).

Recombinant vectors containing the pol, pTP double deletion which also contain deletions within the E1 and E3 regions are generated by cotransfection of
10 pBHG11ΔpolΔpTPVARNA+t13 into pol- and pTP-expressing 293 cells (e.g., C-7) along with a shuttle vector containing the left-end Ad5 sequences including the packaging signals. Suitable shuttle vectors include pΔE1sp1A (Microbix), pΔE1sp1B (Microbix) or pAdBglII. The gene of interest is inserted into the polylinker region of the shuttle vector and this plasmid is then cotransfected into B-6 or C-7 cells along with
15 pBHG11ΔpolΔpTPVARNA+t13 to generate a recombinant E1-, pol -, pTP- Ad vector containing the gene of interest.

EXAMPLE 6

20 Encapsidated Adenovirus Minichromosomes
Containing A Full Length Dystrophin cDNA

In this Example, the construction of an encapsidated adenovirus minichromosome (EAM) consisting of an infectious encapsidated linear genome containing Ad origins of replication, packaging signal elements, a β-galactosidase reporter gene cassette and a full length (14 kb) dystrophin cDNA regulated by a muscle specific enhancer/promoter is described. EAMs are generated by cotransfecting 293 cells with supercoiled plasmid DNA (pAd5βdys) containing an embedded inverted origin of replication (and the remaining above elements) together with linear DNA from E1-deleted virions expressing human placental alkaline phosphatase (hpAP). All proteins necessary for the generation of EAMs are provided in trans from the hpAP virions and the two can be separated from each other on equilibrium CsCl gradients. These EAMs are useful for gene transfer to a variety of cell types both *in vitro* and *in vivo*.

a) **Generation And Propagation Of Encapsidated Adenovirus Minichromosomes**

To establish a vector system capable of delivering full length dystrophin cDNA clones, the minimal region of Ad5 needed for replication and packaging was combined with a conventional plasmid carrying both dystrophin and a β -galactosidase reporter gene. In the first vector constructed, these elements were arranged such that the viral ITRs flanked (ITRs facing outward) the reporter gene and the dystrophin gene [i.e., the vector contained from 5' to 3' the right or 3' ITR (mu 100 to 99), the dystrophin gene and the reporter gene and the left or 5' ITR and packaging sequence (mu 1 to 0)]. Upon introduction of this vector along with helper virus into 293 cells, no encapsidated adenovirus minichromosomes were recovered.

The second and successful vector, pAd5 β dys (Fig. 10) contains 2.1 kb of adenovirus DNA, together with a 14 kb murine dystrophin cDNA under the control of the mouse muscle creatine kinase enhancer/promoter, as well as a β -galactosidase gene regulated by the human cytomegalovirus enhancer/promoter.

Figure 10 shows the structure of pAd5 β dys (27.8 kb). The two inverted adenovirus origins of replication are represented by a left and right inverted terminal repeat (LITR/RITR). Replication from these ITRs generates a linear genome whose termini correspond to the 0 and 100 map unit (mu) locations. Orientation of the origin with respect to wild type adenovirus serotype 5 sequences in mu is indicated above the figure (1 mu=360 bp). Encapsidation of the mature linear genome is enabled by five (AI-AV) packaging signals (Ψ). The *E. coli* β -galactosidase and *mus musculus* dystrophin cDNAs are regulated by cytomegalovirus (CMV) and muscle creatine kinase (MCK) enhancer/promoter elements, respectively. Both expression cassettes contain the SV40 polyadenylation (pA) signal. Since the E1A enhancer/promoter overlaps with the packaging signals, pAd5 β dys was engineered such that RNA polymerase transcribing from the E1A enhancer/promoter will encounter the SV40 late polyadenylation signal. Pertinent restriction sites used in constructing pAd5 β dys are indicated below the figure. An adenovirus fragment corresponding to mu 6.97 to 7.77 was introduced into pAd5 β dys during the cloning procedure (described below). P1 and P2 represent location of probes used for Southern blot analysis. Restriction sites destroyed during the cloning of the Ad5 origin of replication and packaging signal are indicated in parentheses.

WO 98/17783

pAd5 β dys was constructed as follows. pBSX (Ex. 3a) was used as the backbone for construction of pAd5 β dys. The inverted fused Ad5 origin of replication and five encapsidation signals were excised as a *Pst*I/*Xba*I fragment from pAd5ori, a plasmid containing the 6 kb *Hind*III fragment from pFG140 (Microbix Biosystems). This strategy also introduced a 290 bp fragment from Ad5 corresponding to map units 6.97 to 7.77 adjacent to the right inverted repeat (see Fig. 10). The *E. coli* β -galactosidase gene regulated by the human CMV immediate early (IE) promoter/enhancer expression cassette was derived as an *Eco*RI/*Hind*III fragment from pCMV β [MacGregor and Caskey (1989) Nucleic Acids Res. 17:2365]; the CMV IE enhancer/promoter is available from a number of suppliers as is the *E. coli* β -galactosidase gene]. The murine dystrophin expression cassette was derived as a *Bss*HII fragment from pCVAA, and contains a 3.3 kb MCK promoter/enhancer element [Phelps *et al.* (1995) Hum. Mol. Genet. 4:1251 and Jaynes *et al.* (1986) Mol. Cell. Biol. 6:2855]. The sequence of the ~3.3 kb MCK promoter/enhancer element is provided in SEQ ID NO:9 (in SEQ ID NO:9, the last nucleotide of SEQ ID NO:9 corresponds to nucleotide +7 of the MCK gene). The enhancer element is contained within a 206 bp fragment located -1256 and -1050 upstream of the transcription start site in the MCK gene.

It was hoped that the pAd5 β dys plasmid would be packageable into an encapsidated minichromosome when grown in parallel with an E1-deleted virus due to the inclusion of both inverted terminal repeats (ITR) and the major Ad packaging signals in the plasmid. The ITRs and packaging signals were derived from pFG140 (Microbix), a plasmid that generates E1-defective Ad particles upon transfection of human 293 cells.

hpAP is an E1 deleted Ad5 containing the human placental alkaline phosphatase gene [Muller *et al.* (1994) Circ. Res. 75:1039]. This virus was chosen to provide the helper functions so that it would be possible to monitor the titer of the helper virus throughout serial passages by quantitative alkaline phosphatase assays.

293 cells were cotransfected with pAd5 β dys and hpAP DNA as follows. Low passage 293 cells (Microbix Biosystems) were grown and passaged as suggested by the supplier. Five pAd5 β dys and hpAP DNA (5 and 0.5 μ g, respectively) were dissolved in 70 μ l of 20 mM HEPES buffer (pH 7.4) and incubated with 30 μ l of DOTAP (BMB) for 15 min. at room temperature. This mixture was resuspended in 2 mls of DMEM supplemented with 2% fetal calf serum (FCS) and added dropwise to a 60 mm plate of 293 cells at 80% confluency. Four hours post-transfection the media was replaced by DMEM with 10% FCS. Cytopathic effect was observed 6-12 days post-transfection.

Cotransfection of 293 cells with supercoiled pAd5 β dys and linear hpAP DNA produced Ad5 β dys EAMs (the encapsidated version of pAd5 β dys) approximately 6 to 12 days post transfection, as evidenced by the appearance of a cytopathic effect (CPE). Initially, the amount of Ad5 β dys EAMs produced was significantly lower than that of hpAP virions so the 5 viral suspension was used to re-infect fresh cultures, from which virus was isolated and used for serial infection of additional cultures (Fig. 11). Infection and serial passaging of 293 cells was carried out as follows.

Lysate from one 60 mm plate of transfected 293 cells was prepared by vigorously 10 washing the cells from the plate and centrifuging at 1 K rpm in a clinical centrifuge. Cells were resuspended in DMEM and 2% FCS, freeze-thawed in a dry ice-ethanol bath, cell debris removed by centrifugation, and approximately 75% of the crude lysate was used to infect 293 cells in DMEM supplemented with 2% FCS for 1 hour and then supplemented with 10% FCS thereafter. Infection was allowed to proceed for 18-20 hrs before harvesting the virus. The total number of cells infected in each serial passage is indicated in Figure 11.

In Figure 11, the total number of transducing adenovirus particles produced (output) 15 per serial passage on 293 cells, total input virus of either the helper (hpAP) or Ad5 β dys, and the total number of cells used in each infection is presented. The total number of input/output transducing particles were determined by infection of 293 cells plated in 6-well microtiter plates. Twenty four hours post-infection the cells were assayed for alkaline phosphatase or β -galactosidase activity (described below) to determine the number of cells transduced with 20 either Ad5 β dys or hpAP. The number of transducing particles were estimated by extrapolation of the mean calculated from 31 randomly chosen 2.5 mm² sectors of a 961 mm² plate. The intra-sector differences in total output of each type of virus are presented as the standard deviations, σ , in Figure 11. For each serial passage, 75% of the total output virus 25 from the previous passage was used for infection.

Alkaline phosphatase or β -galactosidase activity was determined as follows. For 30 detection of alkaline phosphatase, infected 293 cells on Petri dishes were rinsed twice with phosphate buffered saline (PBS) and fixed for 10 minutes in 0.5% glutaraldehyde in PBS. Cells were again rinsed twice with PBS for ten minutes followed by inactivation of endogenous alkaline phosphatase activity at 65°C for 1 hr. in PBS prior to the addition of the chromogenic substrate BCIP (5-bromo-4-chloro-3-indolyl phosphate) at 0.15 mg/ml and nitro blue tetrazolium at 0.3 mg/ml. Cells were incubated at 37°C in darkness for 3- 24 hrs. For β -galactosidase assays, the cells were fixed and washed as above, then assayed using standard

methods [MacGregor *et al.* (1991) In Murray (ed.), *Methods in Molecular Biology*: Vol. 7: *Gene Transfer and Expression Protocols*, Human Press Inc., Clifton, NJ, pp. 217-225].

As shown in Figure 11, the rate of increase in titer of Ad5 β dys EAMs between transfection and serial passage 6 was approximately 100 times greater than that for hpAP virions. This result indicated that Ad5 β dys has a replication advantage over the helper virus. probably due to the shorter genome length (a difference of approximately 8 kb) and hence an increased rate of packaging.

Interestingly, after serial passage 6 there was a rapid decrease in the total titer of hpAP virions whereas the titer of Ad5 β dys EAMs continued to rise. While not limiting the present invention to any particular mechanism, at least two possible mechanisms could be responsible for this observation. Firstly, a buildup of defective hpAP virions due to infections at high multiplicities may slowly out-compete their full length counterparts, a phenomenon that has been previously observed upon serial propagation of adenovirus [Daniell (1976) J. Virol. 19:685; Rosenwirth *et al.* (1974) Virology 60:431; and Burlingham *et al.* (1974) Virology 60:419]. Secondly, the emergence of replication competent virions due to recombination events between E1 sequences in cellular DNA and the hpAP genome could lead to a buildup of virus particles defective in expressing alkaline phosphatase [Lochmüller *et al.* (1994) Hum. Gene Ther. 5:1485].

Southern analysis of DNA prepared from serial lysates 3, 6, 9 and 12 indicated that full length dystrophin sequences were present in each of these lysates (Fig. 12A). In addition, the correct size restriction fragments were detected using both dystrophin and β -galactosidase probes against lysate DNA digested with several enzymes (Figs. 12A-B).

Figure 12 shows a Southern blot analysis of viral DNA from lysates 3, 6, 9 and 12, digested with the restriction enzymes *BssHII*, *NruI* and *EcoRV*, indicating the presence of a full length dystrophin cDNA in all lysates. Fragments from the C terminus of *mus musculus* dystrophin cDNA (A) or the N terminus of *E. coli* β -galactosidase (B) were labeled with dCTP³² and used as probes [Sambrook *et al.*, *supra*]. The position of these probes and the predicted fragments for each digest is indicated in Figure 10. Note that one end of each fragment (except the 17.8 kb *BssHII* dystrophin fragment) detected is derived from the end of the linearized Ad5 β dys genome (see Fig. 10). Low levels of shorter products, presumably derived from defective virions, become detectable only at high serial passage number.

At the later passages (9 and 12) there appeared to be an emergence of truncated Ad5 β dys sequences, suggesting that deletions and/or rearrangements may be occurring at later

passages. Hence, most experiments were performed with Ad5 β dys EAMs derived from the earlier passages. The possibility of the emergence of replication competent (E1-containing) viruses was also examined by infection of HeLa cells by purified and crude serial lysates, none of which produced any detectable CPE.

5

**b) Purification Of Encapsidated Adenovirus Minichromosomes
On CsCl Gradients**

The ability to separate Ad5 β dys EAMs from hpAP virions based on their buoyancy difference (due presumably to their different genome lengths) on CsCl gradients was 10 examined. Repeated fractionation of the viral lysate allows small differences in buoyancy to be resolved. CsCl purification of encapsidated adenovirus minichromosomes was performed as follows. Approximately 25% of the lysate prepared from various passages during serial infections was used to purify virions. Freeze-thawed lysate was centrifuged to remove the 15 cell debris. The cleared lysate was extracted twice with 1,1,2 tricholorotrifluoroethane (Sigma) and applied to CsCl step and self forming gradients.

Purification of virus was initially achieved by passing it twice through CsCl step gradients with densities of $\rho=1.45$ and $\rho=1.20$ in a SW28 rotor (Beckman). After isolation of the major band in the lower gradient, the virus was passed through a self forming gradient (initial $\rho=1.334$) at 37,000 rpm for 24 hrs followed by a relaxation of the gradient by 20 reducing the speed to 10,000 rpm for 10 hrs. in a SW41 rotor (Beckman) at 12°C [Anet and Strayer (1969) Biochem. Biophys. Res. Commun. 34:328]. The upper band from the gradient (composed mainly of Ad5 β dys virions) was isolated using an 18 gauge needle, reloaded on a fourth CsCl gradient ($\rho=1.334$) and purified at 37,000 rpm for 24 hrs followed by 10,000 rpm for 10 hrs at 12°C.

25 The Ad5 β dys-containing CsCl band was removed in 100 μ l fractions from the top of the centrifugation tube and CsCl was removed by chromatography on Sephadex G-50 (Pharmacia). Aliquots from each fraction were used to infect 293 cells followed by β -galactosidase and alkaline phosphatase assays to quantitate the level of contamination by hpAP virions in the final viral isolate.

30 Results of the physical separation between Ad5 β dys EAMs and hpAP virions are shown in Figure 13. Figure 13 shows the physical separation of Ad5 β dys from hpAP virions at the third (A) and final (B) stages of CsCl purification (initial $\rho=1.334$) in a SW41 tube. Aliquots of Ad5 β dys EAMs from the final stage were drawn through the top of the

centrifugation tube and assayed for β -galactosidase and alkaline phosphatase expression.

Results of these assays are presented in Figure 14.

In Figure 14. shows the level of contamination of Ad5 β dys EAMs by hpAP virions obtained from passage 6. Following four cycles of CsCl purification. aliquots were removed 5 from the top of the centrifugation tube and used for infection of 293 cells, which were fixed 24 hrs later and assayed for β -galactosidase or alkaline phosphatase activity (described below). The number of transducing particles are an underestimation of the actual totals as in some cases a positive cell may have been infected by more than one transducing particle. The ratio 10 of the two types of virions - Ad5 β dys EAMs (LacZ) or hpAP (AP) in each fraction is indicated in the lower graph.

The maximum ratio of transducing Ad5 β dys EAMs to hpAP virions reproducibly achieved in this study was 24.8 -- a contamination with helper virus corresponding to approximately 4% of the final viral isolate.

15 c) **Dystrophin And β -galactosidase Expression By Encapsidated
Adenovirus Minichromosomes In Muscle Cells**

To determine if the Ad5 β dys EAMs were able to express β -galactosidase and dystrophin in muscle cells. mouse *mdx* myogenic cultures were infected with CsCl purified EAMs.

20 i) **Propagation And Infection Of Muscle Cells**

MM14 and *mdx* myogenic cell lines were kindly provided by S. Hauschka (University of Washington) and were cultured as previously described [Linkhart *et al.* (1981) Dev. Biol. 86:19 and Clegg *et al.* (1987) J. Cell Biol. 105:949]. Briefly, myoblasts were grown on 25 plastic tissue culture plates coated with a 0.1% gelatin in Ham's F-10 medium containing 15% (v/v) horse serum, 0.8 mM CaCl₂, 200 ng/ml recombinant human basic fibroblast growth factor (b-FGF) and 60 μ g/ml genitimidin (proliferation medium). Cultures were induced to differentiate by switching to growth in the presence of growth medium lacking b-FGF and containing 10% horse serum (differentiation medium). Myoblasts or differentiated myotubes 30 (three days post switching) were infected at a multiplicity of infection of 2.2 Ad5 β dys EAMs per cell. Fractions containing minimal contamination with hpAP virions (3, 4 and 5 of passage 6) were used for western and immunofluorescence analysis. Infection was allowed to proceed for 3 days for both the myoblasts and myotubes before harvesting cells.

ii) Total Protein Extraction And Immunoblot Analysis

For protein extraction, muscle cells were briefly trypsinized, transferred to a microcentrifuge tube, centrifuged at 14 K for 3 min at room temp and resuspended two times in PBS. After an additional centrifugation, the cell pellet was resuspended in 80 µl of RIPA buffer (50 mM Tris-Cl, pH 7.5; 150 mM NaCl; 1% Nonidet P-40; 0.5% sodium deoxycholate; 0.1% SDS) (Sambrook *et al.*, *supra*). The sample was briefly sheared using a 22 gauge needle to reduce viscosity and total protein concentration assayed using the bicinchoninic acid protein assay reagent (Pierce, Rockford, IL). Expression of full length dystrophin or β-galactosidase in infected *mdx* and MM14 myoblasts or myotubes was analyzed by electrophoresis of 40 µg of total protein extract on a 6% SDS-PAGE gel (in 25 mM Tris, 192 mM glycine, 10 mM β-mercaptoethanol, 0.1% SDS). After transferring to Gelman Biotrace NT membrane (in 25 mM Tris, 192 mM glycine, 10 mM β-mercaptoethanol, 0.05% SDS, 20% methanol), the membrane was blocked with 5% non-fat milk and 1% goat-serum in Tris-buffered saline-Tween (TBS-T) for 12 hrs at 4°C. Immunostaining was done according to the protocol for the ECL western blotting detection reagents (Amersham Life Sciences, Buckingham, UK). The primary antibodies used were Dys-2 (Vector Laboratories) and anti-β-galactosidase (BMB, Indianapolis, IN) with a horseradish peroxidase-conjugated anti-mouse secondary antibody.

Western blot analysis of EAM-infected *mdx* myoblasts and myotubes (three days post-fusion) indicated that EAMs were able to infect both of these cell types (Figure 15). In Figure 15, immunoblots of protein extracts from *mdx* myoblasts and myotubes demonstrating the expression of β-galactosidase (A) and dystrophin (B) in cells infected with Ad5βdys EAMs. Total protein was extracted 3 days post infection in all cases. Myotubes were infected at three days following a switch to differentiation media. In Figure 15A, lane 1 contains total protein extract from 293 cells infected with a virus expressing β-galactosidase as a control (RSV-LacZ); lanes 2-5 contain total protein extracts from uninfected *mdx* myoblasts, *mdx* myoblasts infected with Ad5βdys EAMs, *mdx* myotubes and *mdx* myotubes derived from *mdx* myoblasts infected with Ad5βdys EAMs, respectively. In Figure 15B, lanes 1 and 7 contain total protein from mouse muscle ("C57") while lane 2 contains protein from wild type MM14 myotubes, as controls. Lanes 3-5 contain total protein extracts from uninfected *mdx* myoblasts, *mdx* myoblasts infected with Ad5βdys EAMs, *mdx* myotubes and *mdx* myotubes derived from *mdx* myoblasts infected with Ad5βdys EAMs, respectively.

WO 98/17783

As shown in Figure 15, expression of β -galactosidase was detected in both the infected *mdx* myoblasts and myotubes indicating that the CMV promoter was active at both these early stages of differentiation in muscle cells. However, only infected *mdx* myotubes produced protein detected by dys-2, an antibody recognizing the 17 C-terminal amino acids of dystrophin (Fig. 15). No dystrophin expression was detected in infected myoblasts by western analysis, indicating that the muscle creatine kinase promoter functions minimally, if at all, within the Ad5 β dys EAM prior to terminal differentiation of these cells.

Dystrophin expression in *mdx* cells infected with EAMs was confirmed by immunofluorescence studies using N-terminal dystrophin antibodies. In agreement with the western analysis, dystrophin expression from the MCK promoter was detected only in differentiated *mdx* myotubes infected by Ad5 β dys EAMs (Fig. 16). Figures 16A-C show immunofluorescence of dystrophin in wild type MM14 myotubes (A), uninfected *mdx* (B) and infected *mdx* myotubes (C), respectively. The results shown in Figure 16 demonstrate the transfer and expression of recombinant dystrophin to differentiated *mdx* cells by Ad5 β dys EAMs.

Immunofluorescence of myogenic cells was performed as follows. Approximately 1.5×10^6 MM14 or *mdx* myoblasts were plated on Poly-L-lysine (Sigma) coated glass slides (7 x 3 cm) which had been previously etched with a 0.05% chromium potassium sulfate and 0.1% gelatin solution. For myotube analysis, the cultures were switched to differentiation media [Clegg *et al.* (1987), *supra*] 48 hours after plating, immediately infected and then allowed to fuse for 3 days, whereas myoblasts were continuously propagated in proliferation media [Clegg *et al.* (1987), *supra*]. Cells were washed three times with PBS at room temperature and fixed in 3.7% formaldehyde. For immunostaining, cells were incubated in 0.5% Triton X-100, blocked with 1% normal goat serum and incubated with an affinity purified antibody against the N-terminus of murine dystrophin for 2 hrs. followed by extensive washing in PBS and 0.1% Tween-20 with gentle shaking. Cells were incubated with a 1:200 dilution of biotin conjugated anti-rabbit antibody (Pierce) for one hour and washed as above. Cells were further incubated with a 1:300 dilution of streptavidin-fluorescein isothiocyanate conjugate (Vectorlabs, Burlingam, CA) for one hour and washed as above, followed by extensive washing in PBS.

The above results show that embedded inverted Ad origins of replication coupled to an encapsidation signal can convert circular DNA molecules to linear forms in the presence of helper virus and that these genomes can be efficiently encapsidated and propagated to high

titors. Such viruses can be purified on a CsCl gradient and maintain their ability to transduce cells *in vitro*, and their increased cloning capacity allows the inclusion of large genes and tissue specific gene regulatory elements. The above results also show that the dystrophin gene was expressed in cells transduced by such viruses and that the protein product was correctly localized to the cell membrane. The above method for preparing EAMs theoretically enables virtually any gene of interest to be inserted into an infectious minichromosome by conventional cloning in plasmid vectors, followed by cotransfection with helper viral DNA in 293 cells. This approach is useful for a variety of gene transfer studies *in vitro*. The observation that vectors completely lacking viral genes can be used to transfer a full-length dystrophin cDNA into myogenic cells indicates that this method may be used for the treatment of DMD using gene therapy.

10
15
d) A Modified MCK Enhancer Increases Expression Of Linked Genes In Muscle

The DNA fragment containing enhancer/promoter of the MCK gene utilized in the Ad5 β dys EAM plasmid is quite large (~3.3 kb). In order to provide a smaller DNA fragment capable of directing high levels of expression of linked genes in muscle cells, portions of the 3.3 kb MCK enhancer/promoter were deleted and/or modified and inserted in front of a reporter gene (*lacZ*). The enhancer element of the MCK gene was modified to produce the 2RS5 enhancer; the sequence of the 2RS5 enhancer is provided in SEQ ID NO:10. The first 6 residues of SEQ ID NO:10 represent a *Kpn*I site added for ease of manipulation of the modified MCK enhancer element. Residue number 7 of SEQ ID NO:10 corresponds to residue number 2164 of the wild-type MCK enhancer sequence listed in SEQ ID NO:9 (position 2164 of SEQ ID NO:9 corresponds to position -1256 of the MCK gene). Residue number 174 of SEQ ID NO:10 corresponds to residue number 2266 of the wild-type MCK enhancer sequence listed in SEQ ID NO:9.

20
25
30
These MCK/*lacZ* constructs were used to transfect cells in culture (*i.e.*, myogenic cultures) or were injected as naked DNA into the muscle of mice and β -galactosidase activity was measured. Figure 17 provides a schematic of the MCK/*lacZ* constructs tested. The first construct shown in Figure 17 contains the 3.3 kb wild-type MCK enhancer/promoter fragment linked to the *E. coli* *lacZ* gene. The wild-type enhancer element (-1256 to -1056) is depicted by the box containing "E": the core promoter element (-358 to -80) is indicated by the light cross-hatching and the minimal promoter element (-80 to +7) is indicated by the dark

cross-hatching. The core promoter element is required in addition to the minimal promoter element (which is required for basal expression) in order to achieve increased muscle-specific expression in tissue culture [Shield *et al.* (1996) Mol. Cell. Biol. 16:5058]. The modified enhancer element, the 2RS5 enhancer, is indicated by the box labeled "E*." The box labeled "mi nx" contains a synthetic intron derived from adenovirus and is used to increase expression of the constructs (any intron may be utilized for this purpose). The box labeled "CMV" depicts the CMV IE enhancer/promoter which was used a positive control.

In figure 17, β -galactosidase activity is expressed relative to the activity of the wild-type MCK enhancer/promoter construct shown at the top of the figure. As shown in Figure 10 17, a construct containing the 2RS5 enhancer (SEQ ID NO:10) linked to either the minimal MCK promoter (a ~ 261 bp element) or the core and minimal MCK promoter elements (a ~539 bp element) directs higher levels of expression of the reporter gene in muscle cells as compared to the ~3.3 kb fragment containing the wild-type enhancer element. These modified 15 enhancer/promoter elements are considerably smaller than the ~3.3 kb fragment used in the Ad5 β dys EAM plasmid and are useful for directing the expression of foreign genes in muscle cells. These smaller elements are particularly useful for driving the expression of genes in the context of self-propagating adenoviral vectors which have more severe constraints on the amount of foreign DNA which can be inserted in comparison to the used of "gutted" adenoviruses such as the EAMs described above.

20

EXAMPLE 7

Generation Of High Titer Stocks Of Encapsidated Adenovirus Minichromosomes Containing Minimal Helper Virus Contamination

The results presented in Example 6 demonstrated that encapsidated adenovirus minichromosomes (EAMs) can be prepared that lack all viral genes and which can express full-length dystrophin cDNAs in a muscle specific manner. The propagation of these EAMs requires the presence of helper adenoviruses that contaminate the final EAM preparation with conventional adenoviruses (about 4% of the total preparation). In this example the EAM 25 system is modified to enable the generation of high titer stocks of EAMs with minimal helper virus contamination. Preferably the EAM stocks contain helper virus representing less than 30 1%. preferably less than 0.1% and most preferably less than 0.01% of the final viral isolate. Purified EAMs are then injected *in vivo* in muscles of dystrophin minus *mdx* mice to

determine whether these vectors lead to immune rejection and whether they can alleviate dystrophic symptoms in *mdx* muscles.

The amount of helper virus present in the EAM preparations is reduced in two ways. The first is by selectively controlling the relative packaging efficiency of the helper virus versus the EAM virus. The second is to improve physical methods for separating EAM from helper virus. These approaches enable the generation of dystrophin-expressing EAMs that are contaminated with minimal levels of helper virus.

10 a) **Development And Characterization Of Adenovirus Packaging
Cell Lines Expressing The Cre Recombinase From
Bacteriophage P1**

15 Cell lines expressing a range of *Cre* levels are used to optimize the amount of helper virus packaging that occurs during growth of the EAM vectors. The *Cre-loxP* system [Sauer and Henderson (1988) Proc. Natl. Acad. Sci. USA 85:5166] is employed to selectively disable helper virus packaging during growth of EAMs. The bacterial *Cre* recombinase catalyzes efficient recombination between a 34 bp target sequence called *loxP*. To delete a desired sequence, *loxP* sites are placed at each end of the sequence to be deleted in the same orientation: in the presence of *Cre* recombinase the intervening DNA segment is efficiently excised.

20 Cell lines expressing a range of *Cre* recombinase levels are generated. The expression of too little *Cre* protein may result in high levels of helper virus being generated, which leads to unacceptably high levels of helper virus contaminating the final EAM preparation. If very high levels of *Cre* expression are present in a cell line, excision of the packaging signal from the helper virus would be 100% efficient (*i.e.*, it would completely prevent helper virus packaging). As shown in Example 6, serial passage of EAM preparations containing low levels of helper virus increased the titer of the EAM. Therefore, it is desirable, at least in the initial passages of a serial passage that some helper virus capable of being packaged is present. A low level of packagable helper virus may be provided by using a cell line expressing levels of *Cre* recombinase which are not high enough to achieve excision of the packaging signals from 100% of the helper virus; these cell lines would be used early in the serial passaging of the EAM stock and a cell line expressing high enough levels of *Cre* recombinase to completely prevent helper virus packaging would be used for the final passage.

Alternatively, EAMs may be prepared using a packaging cell line that supports high efficiency *Cre* recombinase-mediated excision of the packaging signals from the helper virus by transfection of the *Cre*-expressing cell line with the EAM plasmid followed by infection of these cells with *loxP*-containing helper virus using an MOI of ≥ 1.0 .

5 Human 293 cell lines that express a variety of levels of *Cre* recombinase are generated as follows. An expression vector containing the *Cre* coding region, pOG231, was cotransfected into 293 cells along with pcDNA3 (Invitrogen); pcDNA3 contains the *neo* gene under the control of the SV40 promoter. pOG231 uses the human CMV enhancer/promoter [derived from CDM8 (Invitrogen)] to express a modified *Cre* gene [pOG231 was obtained 10 from S. O'Gorman]. The modified *Cre* gene contained within pOG231 has had a nuclear localization signal inserted into the coding region to increase the efficiency of recombination.

pOG231 was constructed as follows. A *Bgl*/II site was introduced into the 5' *Xba*I site of the synthetic intron of pMLSISCAT [Haung and Gorman (1990) Nucleic Acids Res. 18:937] by linker tailing. A *Bgl*/II site in the synthetic intron of pMLSISCAT was destroyed 15 and a *Bam*HI linker was inserted into the *Pst*I site at the 3' end of the synthetic intron in pMLSISCAT. *Bgl*/II and *Sma*I sites and a nuclear localization signal were introduced into the 5' end of pMC-Cre [Gu *et al.* (1993) Cell 73:1155] using a PCR fragment that extended from the novel *Bgl*/II and *Sma*I sites to the *Bam*HI site in the *Cre* coding region. This PCR 20 fragment was ligated to a *Bam*HI/*Sal*I fragment containing a portion of the *Cre* coding region derived from pIC-Cre (Gu *et al.*, *supra*) and the intron plus *Cre* coding sequence was inserted into a modified form of pOG44 [O'Gorman *et al.* (1991) Science 251:1351] to generate pOG231. The predicted sequence of pOG231 from the *Bgl*/II site to the *Bam*HI site located in the middle of the *Cre* coding sequence is listed in SEQ ID NO:11.

One 60 mm dish of 293 cells (Microbix) were transfected with 10 μ g of *Pvu*II-linearized pOG231 and 1 μ g of *Not*I-linearized pcDNA3 using a standard calcium phosphate precipitation protocol. Two days after the addition of DNA, the transfected cells were split 25 into three 100 mm dishes and 1000 μ g/ml of active G418 was added to the medium. The cells were fed periodically with G418-containing medium and three weeks later, 24 G418-resistant clones were isolated.

30 The isolated clones were expanded for testing. Aliquots were frozen in liquid nitrogen at the earliest possible passage. The neomycin resistant cell lines were examined for the expression of *Cre* recombinase using following transfection assay. The neomycin resistant cells were transfected with PGK-1-GFP-lacZ (obtained from Sally Camper, Univ. of

Michigan, Ann Arbor, MI), which contains a green fluorescent protein (GFP) expression cassette that can be excised by *Cre* recombinase to allow expression of β -galactosidase; transfection was accomplished using standard calcium phosphate precipitation. Figure 18 provides a schematic of a GFP/ β -gal reporter construct suitable for assaying the expression of *Cre* recombinase in mammalian cells; GFP sequences and β -gal (*i.e.*, *lacZ*) sequences are available from commercial sources (*e.g.*, Clonetech, Palo Alto, CA and Pharmacia Biotech, Piscataway, NJ, respectively).

Control experiments verified that 293 cells transfected with PGK-1-GFP-lacZ expressed significant amounts of β -galactosidase only if these cells also expressed *Cre* recombinase. β -galactosidase assays were performed as described in Example 6. Neomycin resistant cells expressing *Cre* recombinase were grouped as high, medium or low expressors based upon the amount of β -galactosidase activity produced (estimated by direct counting of β -galactosidase-positive cells per high-power field and by observing the level of staining and the rapidity with which the blue stain was apparent) when these cell lines were transfected with the GFP/ β -gal reporter construct. Thirteen positive (*i.e.*, *Cre*-expressing) lines, D608#12, #7, #22, #18, #17, #4, #8, #2, #2/2, #13, #5, #15 and #21 were retained for further use.

The results of this transfection analysis revealed that cultures of 293 cells expressing medium to high levels of *Cre* recombinase could be generated without apparent toxicity.

20 **b) Generation Of Helper Adenovirus Strains That Contain *loxP* Sites Flanking The Adenovirus Packaging Signals**

Studies of EAM production demonstrated that the EAM vector has a packaging advantage over the helper adenovirus (Ex. 6). While not limiting the present invention to a particular mechanism, it is hypothesized that this packaging and replication advantage can be greatly increased by using helper viruses that approach the packaging size limits of Ad5 [Bett *et al.* (1993) J. Virol. 67:5911], by using viruses with mutations in E4 and/or E2 genes [Yeh *et al.* (1996) J. Virol. 70:559; Gorziglia *et al.* (1996) J. Virol. 70:4173; and Amalfitano *et al.* (1996) Proc. Natl. Acad. Sci. USA 93:3352], by inclusion of mutations or alterations in the packaging signals of the helper virus [Immler *et al.* (1995) Hum. Gene Ther. 6:711] and by combining these strategies.

The *Cre-loxP* excision method is used to disable the packaging signals from the helper virus genomes. The Ad5 packaging domain extends from nucleotide 194 to 358 and is composed of five distinct elements that are functionally redundant [Hearing *et al.* (1987) J.

Virol. 61:2555]. Theoretically, any molecule containing the Ad5 origin of replication and packaging elements should replicate and be packaged into mature virions in the presence of non-defective helper virus. Disabling the packaging signals should allow replication and gene expression to proceed, but will prevent packaging of viral DNA into infectious particles. This in turn should allow the ratio of EAM to helper virus to be increased greatly.

To disable the packaging signals within the helper virus used to encapsidate the EAMs, the *loxP* sequences are incorporated into a helper virus that has a genome approaching the maximal packaging size for Ad [~105 map units; Bett *et al.* (1993), *supra*] which further decreases the efficiency of helper virus packaging. Final virus size can be adjusted by the choice of introns inserted into the reporter gene, by the choice of reporter genes, or by including a variety of DNA fragments of various sizes to act as "stuffer" fragments. A convenient reporter gene is the alkaline phosphatase gene (see Ex. 6). The optimized *Cre-loxP* system is also incorporated into a helper viral backbone containing disruptions of any or all of the E1-E4 genes. Use of such deleted genomes requires viral growth on appropriate complementing cell lines, such as 293 cells expressing E2, and/or E4 gene products. The *loxP* sequences are incorporated into the helper virus by placing the *loxP* sequences on either side of the packaging signals on a shuttle vector. This modified shuttle vector is then used to recombine with the Ad DNA derived from a virus containing disruptions of any or all of the E1-E4 genes to produce the desired helper virus containing the packaging signals flanked by *loxP* sequences.

pAdBglII, an adenovirus shuttle plasmid containing Ad sequences from 0-1 and 9-16 map units (mu) was used as the starting material. Synthetic oligonucleotides were used to create a polylinker which was inserted at 1 mu within pAdBglII as follows. The BglII LoxP oligo [5'-GAAGATCTATAACTTCGTATAATGTATGCTA
25 TACGAAGTTATTACCGAAGAAATGGCTCGAGATCTTC-3' (SEQ ID NO:12) and its reverse complement [5'-GAAGATCTCGAGCCATTCTCGGTAATAACTTCGT
ATAGCATACTACAGAAGTTAGATCTTC-3' (SEQ ID NO:13)] were synthesized. The AflIII LoxP oligo [5'-CCACATGTATAACTTCGTATAGCATACA
30 TTATACGAAGTTACATGTGG-3' (SEQ ID NO:14)] and its reverse complement [5'-CCACATGTATAACTTCGTATAATGTATGCTATACGAAGTTACATG TGG-3' (SEQ ID NO:15)] were synthesized. The double stranded form of each *loxP* oligonucleotide was digested with the appropriate restriction enzyme (*e.g.*, *Bgl*II or *Afl*III) and inserted into pAdBglII which had been digested with *Bgl*II and *Afl*III. This resulted in the insertion of

5 *LoxP* sequences into the shuttle vector flanking the packaging signals that are located between 0.5 and 1 mu of Ad5 (one mu equals 360 bp in the Ad5 genome; the sequence of the Ad5 genome is listed in SEQ ID NO:1). The 3' *loxP* sequence was inserted into the *Bg*/II site within pAdBgIII. The 5' *loxP* sequence was inserted into the *Af*/III site located at base 143 (~0.8 mu) (numbering relative to Ad5).

10 DNA sequencing was used to verify the final structure of the modified shuttle plasmid between 0-1 mu. If *Cre* recombinase-mediated excision of the packaging signals is found to be too efficient (as judged by the production of too little helper virus), alternate sites for the insertion of the *loxP* sequences are used that would result in deletion of 2, 3 or 4 packaging 15 sequences rather than all 5 [Grable and Hearing (1990) J. Virol. 64:2047]. The insertion of *loxP* sequences at sites along the Ad genome contained within the shuttle vector which would result in the deletion 2, 3 or 4 packaging sequences are easily made using the technique of recombinant PCR [Higuchi (1990) In: *PCR Protocols: A Guide to Methods and Applications*. Innis et al. (eds.) Academic Press, San Diego, CA, pp. 177-183]. The optimal 20 amount of *Cre* recombinase-mediated excision of the packaging signals is that amount which permits the production of enough packaged helper virus to permit the slow spread of virus on the first plate of cells co-transfected with helper virus DNA (containing the *loxP* sequences) and the EAM vector. This permits serial passage of the EAM preparation onto a subsequent lawn of cells to increase the titer of the EAM preparation. Alternatively, if *Cre* recombinase- 25 mediated excision of the packaging signals is essentially 100% efficient in all *Cre*-expressing cells lines (*i.e.*, regardless of the level of *Cre*-expression, that is even a cell line expressing a low level of *Cre* as judged by the GFP/β-gal assay described above), the packaged EAMs may be used along with helper virus (used at a MOI of ~1.0) to infect the second or subsequent lawn of cells to permit serial passaging to increase the titer of the EAM preparation.

30 Following introduction of the *loxP* sequences into the shuttle vector, the human placental alkaline phosphatase (HpAp) cDNA under control of the RSV promoter was inserted into the polylinker to provide a reporter gene for the helper virus. This is the same reporter used previously during EAM generation (Ex. 6). The HpAp sequences were inserted as follows. The *loxP*-containing shuttle vector was linearized with *Xba*I and the hpAp cassette was ligated into the *Xba*I site (a *Xba*I site was inserted into pAdBgIII during the insertion of the *loxP* sequences as a *Xba*I site was located on the 3' end of the *loxP* sequences inserted into the *Bg*/II site of pAdBgIII). The HpAp cassette was constructed as follows.

WO 98/17783

pRSVhAPT40 (obtained from Gary Nabel, Univ. of Michigan, Ann Arbor, MI) was digested with *Eco*RI to generate an *Eco*RI fragment containing the HpAP cDNA and the SV40 intron and polyadenylation sequences. pRc/RSV (Invitrogen) was digested with *Hind*III, then partially digested with *Eco*RI. A 5.208 bp fragment was then size selected on an agarose gel. 5 treated with calf alkaline phosphatase, and ligated to the *Eco*RI fragment derived from pRSVhAPT40 to generate pRc/RSVAP. pRc/RSVAP was then digested with *Sall* and *Xhol* to liberate the RSV promoter linked to the HpAP cDNA cassette (including the SV40 intron and polyadenylation sequences). This *Sall-Xhol* fragment was inserted into the *loxP*-containing shuttle vector which had been digested with *Sall* and *Xhol* to generate pADLoxP-RSVAP.

10 Helper virus containing *loxP* sites flanking the Ad packaging signals is generated by co-transfection of the *LoxP* shuttle plasmid (pADLoxP-RSVAP) and *Clal*-digested Ad5d_l7001 DNA into 293 cells [Graham and Prevec (1991) Manipulation of Adenovirus Vectors. In *Methods in Molecular Biology*, Vol. 7: *Gene Transfer and Expression Protocols*. Murray (ed.). Humana Press Inc., Clifton, NJ, pp. 109-128]. Figure 19 provides a schematic showing the recombination event between the *loxP* shuttle vector and the Ad5d_l7001 genome. 15 Co-transfection is carried out as described in Example 3c.

15 Alternatively, the reporter gene may be inserted into the E3 region of pBHG10 or pBHG11 (using the unique *Pac*I site) rather than into the polylinker located in the E1 region of the shuttle vector. The reporter gene-containing pBHG10 or 11 is then used in place of Ad5d_l7001 for cotransfection of 293 cells along with the *loxP*-containing pAdBgII.

Following cotransfection, recombinant plaques are picked, plaque purified, and tested for incorporation of both hpAp and *loxP* sequences by PCR and Southern analysis (Ex. 3). Viruses which contain *loxP* sites flanking the packaging signals and the marker gene (hpAp) are retained, propagated and purified.

25 The isolated helper virus containing *loxP* sites flanking the packaging signals and the marker gene is then used to infect both 293 cells and the 293 cell lines that express *Cre* (section a. above). *Cre* recombinase-expressing cell lines that produce optimal levels of *Cre* recombinase when infected with the *loxP*-containing helper virus are then used for the generation of EAMs as described below.

30

c) **Generation Of Encapsidated Adenovirus Minichromosomes
That Express Dystrophin**

The growth of EAMs is optimized using the following methods. In the first method. plasmid DNA from the EAM vector (Ex. 6) are co-transfected into 293 cells with purified 5 viral DNA from the helper virus. and viruses are harvested 10-14 days later after appearance of a viral cytopathic effect (CPE) as described in Example 6. This approach is simple, yet potentially increases helper virus levels by allowing viral spread throughout the culture dishes.

In the second method, the co-transfected 293 cells are overlaid with agar and single 10 plaques are picked and tested for EAM activity by the ability to express β -galactosidase activity following infection of Hela cells (Ex. 6). This second approach is more time consuming. but will result in less contamination by helper.

The ability of these two methods to generate EAMs are directly compared. The preferred method is that which produces the highest titer of EAM with the lowest 15 contamination of helper virus. The efficiency of EAM generation may also be increased by using helper virus DNA that retains the terminal protein (TP) (*i.e.*, the helper virus is used as a viral DNA-TPC as described in Ex. 3) The use of viral DNA-TPC has been shown to increase the efficiency of viral production following transfection of 293 cells by an order of magnitude [Miyake *et al.* (1996), *supra*].

The initial transfection will utilize 293 cells that do not express *Cre* recombinase, so 20 that efficient spread of the helper can lead to large scale production of EAM. The method producing the highest ratio of EAM to helper virus is then employed to optimize conditions for the serial propagation of the EAM on 293 cells expressing *Cre* recombinase. This optimization is conducted using cell lines expressing different levels of *Cre* recombinase. The following variables are tested: 1) the ratio of input viral titer to cell number, 2) the number 25 of serial passages to use for EAM generation, 3) the use of cell lines producing different levels of *Cre* to achieve the optimal ratio between high EAM titer and low helper titer, 4) continuous growth on *Cre*-producing 293 cells versus alternating between *Cre*-producing cells and the parental 293 cells, or to alternate between high and low *Cre*-producing cells and 5) CsCl purification of EAMs prior to re-infection of 293 cells increases the ratio of the final 30 EAM/helper titers. The protocols that result in the highest yield of EAM with minimal helper virus are used to generate large volumes of crude viral lysates for purification by density gradient centrifugation (Ex. 6).

EAMs were purified from helper virus using standard CsCl density gradient centrifugation protocols in Example 6 and resulted in preparations containing ~4% helper virus. In order to improve the physical separation of EAMs and helper virus, a variety of different centrifugation conditions are possible, including changing the gradient shape, type of rotor and tube used, combinations of step and continuous gradients, and the number of gradients used.

5 Materials with better resolving powers than CsCl can also be employed. These include rubidium chloride and potassium bromide [Reich and Zarybnicky (1979) *Annal. Biochem.* 94:193].

10 **d) Use Of EAMs Encoding Dystrophin For Long Term
Expression Of Dystrophin in Muscle**

To demonstrate the ability of the purified dystrophin expressing EAMs (prepared as described above) to deliver and express dystrophin in the muscle of an animal, the following experiment is conducted. First, purified dystrophin-EAMs are delivered to the muscle by direct intramuscular injection into newborn, 1 month, and adult (3 month) mouse quadriceps muscle. The dystrophin expressing EAM Ad5 β Dys are injected into *mdx* mice and into transgenic *mdx* mice that express β -galactosidase in the pituitary gland [Tripathy *et al.* (1996) *Nature Med.* 2:545]. These latter mice are used to avoid potential immune-rejection of cells expressing β -galactosidase from the Ad5 β Dys vector. An alternate EAM lacking the β -galactosidase reporter gene may also be employed; however, the presence of the β -Gal reporter simplifies EAM growth and purification (vectors lacking β -Gal have their purity estimated by PCR assays rather than by β -Gal assays).

Following intramuscular injection of EAM, animals are sacrificed at intervals between 1 week and 6 months to measure dystrophin expression [by western blot analysis and by immunofluorescence (Phelps *et al.* (1995) *Hum. Mol. Genet.* 4:1251 and Rafael *et al.* (1996) *J. Cell Biol.* 134:93] and muscle extracts will also be assayed for β -Gal activity [MacGregor *et al.* (1991), *supra*]. These results are compared with previous results obtained using current generation viral vectors (*i.e.*, containing deletions in E1 and E3 only) to demonstrate that EAMs improve the prospects for long term gene expression in muscle.

e) **Use Of Dystrophin-EAMs To Prevent, Halt, Or Reverse The Dystrophic Symptoms That Develop In The Muscles Of *mdx* Mice**

To demonstrate that beneficial effects on dystrophic muscle are achieved by delivery
5 of dystrophin expressing EAMs to *mdx* mice, the following experiments are conducted.
Central nuclei counts are performed on soleus muscle at intervals following injection of EAM
into newborn, 1 month, and 3 month (adult) mice (Phelps *et al.*, 1995). Central nuclei arise
in mouse muscle only after a myofiber has undergone dystrophic necrosis followed by
regeneration, and is a quantitative measure of the degree of dystrophy that has occurred in a
10 muscle group (Phelps *et al.*, 1995).

More informative assays are also contemplated. These assays require administration of
EAMs to mouse diaphragm muscles.

The diaphragm is severely affected in *mdx* mice (Stedman *et al.*, 1991; Cox *et al.*,
1993), and displays dramatic decreases in both force and power generation. Administration of
15 virus to the diaphragm will allow the strength of the muscles to be measured at intervals
following dystrophin delivery. The force and power generating assays developed by the
Faulkner lab are used to measure the effect of dystrophin transgenes (Shrager *et al.*, 1992;
Rafael *et al.*, 1994; Lynch *et al.*, 1996).

To determine whether dystrophin delivery to dystrophic muscle reverses dystrophy or
20 stabilizes muscle, varying amounts of the dystrophin EAM are delivered to the diaphragm
at different stages of the dystrophic process and then strength is measured at intervals
following EAM administration. First, various titers of EAM are tested to determine the
minimal amount of virus needed to transduce the majority of muscle fibers in the diaphragm.
It has been shown that conventional adenovirus vectors can transduce the majority of
25 diaphragm fibers when 10^8 pfu are administrated by direct injection into the intraperitoneal
cavity [Huard *et al.* (1995) Gene Therapy 2:107]. In addition, it has been shown that
transduction of a simple majority of fibers in a muscle group is sufficient to prevent virtually
all the dystrophic symptoms in mice [Rafael *et al.* (1994) Hum. Mol. Genet. 3:1725 and
Phelps *et al.* (1995) Hum. Mol. Genet. 4:1251]. Virus is administered to *mdx* animals at three
30 different ages (neonatal, 1 month, and 3 months). Animals are sacrificed for physiological
analysis of diaphragm muscle at two different times post infection (1 month and 3 months).
Error control is achieved by performing these experiments in sextuplicate. Control animals
consist of mock injected wild-type (C57Bl/10) and dystrophic (*mdx*) mice. Three month old

mdx mice display a 40% reduction in force and power generation compared with wild-type mice, while 6 month animals display a greater than 50% reduction (Cox *et al.* (1993) *Nature* 364:725; Rafael *et al.* (1994), *supra*; Phelps *et al.* (1995), *supra*; and Corrado *et al.* (1996) *J. Cell. Biol.* 134:873].

5

EXAMPLE 8

Improved Shuttle Vectors For The Production Of Helper Virus Containing *LoxP* Sites

10 In the previous example, a shuttle vector containing adenoviral sequences extending from 9 mu to 16 mu of the Ad5 genome was modified to contain *loxP* sequences surrounding the packaging signals (the *LoxP* shuttle vector). This modified shuttle vector was then recombined with an Ad virus to produce a helper virus containing the *loxP* sequences. This helper virus was then used to infect cells expressing *Cre* recombinase along with DNA comprising a minichromosome containing the dystrophin gene, a reporter gene and the packaging signals and ITRs of Ad in order to preferentially package the minichromosomes. Using this approach the helper virus, which has had the packaging signals removed by *Cre-loxP* recombination, contains the majority of the Ad genome (only a portion of the E3 region is deleted). Thus, if low levels of helper virus are packaged and appear in the EAM preparation, the EAM preparation has the potential of passing on helper virus capable of directing the expression of Ad proteins in cells which are exposed to the EAM preparation. The expression of Ad proteins may lead to an immune response directed against the infected cells.

15

20 Another approach to reducing the possibility that the EAM preparation contains helper virus capable of provoking an immune response is to use helper viruses containing deletions and/or mutations within the pol and pTP genes. Helper virus containing a deletion in the pol and/or pTP genes is cotransfected with the EAM construct into 293-derived cell lines expressing pol or pol and pTP to produce EAMs. Any helper virus present in the purified EAM preparation will be replication defective due to the deletion in the pol and/or pTP genes.

25

30 As shown in Example 3, viruses containing a deletion in the pol gene are incapable of directing the expression of viral late genes; therefore, helper viruses containing a deletion in the pol gene or the pol and pTP genes should not be capable of provoking an immune response (*i.e.*, a CTL response) against late viral proteins synthesized *de novo*. Shuttle

vectors contain deletions within the Ad pol and/or pTP genes are constructed as described below.

a) Construction Of A Shuttle Vector Containing The Δ pol Deletion

5 pAdBglII was modified to contain sequences corresponding to 9 to 40 mu of the Ad5 genome as follows. pAdBglII was digested with *Bgl*II and a linker/adapter containing an *Ascl* site was added to create pAdBglIIAsc. pAdBglIIAsc was then digested with *Bst*1107I. Ad5d δ 7001 viral DNA was digested with *Ascl* and the ends were filled in using T4 DNA polymerase. The *Ascl*-digested, T4 DNA polymerase filled Ad5d δ 7001 viral DNA was then 10 digested with *Bst*1107I and the ~9.9 kb *Ascl-Bst*1107I(filled) fragment containing the pol and pTP genes was isolated (as described in Ex. 3) and ligated to the *Bst*1107I-digested pAdBglIIAsc to generate pAdAsc. pAdAsc is a shuttle vector which contains the genes encoding the DNA polymerase and preterminal protein (the inserted *Ascl-Bst*1107I fragment corresponds to nucleotides 5767 to 15,671 of the Ad5 genome).

15 A shuttle vector, pAdAsc Δ pol, which contains the 612 bp deletion in the pol gene (described in Ex. 3) was constructed as follows. Ad5 Δ pol Δ E3I viral DNA (Ex. 3) was digested with *Ascl* and the ends were filled in using T4 DNA polymerase. The *Ascl*-digested, T4 DNA polymerase filled Ad5 Δ pol Δ E3I viral DNA was then digested with *Bst*1107I and the ~9.3 kb *Ascl-Bst*1107I(filled) fragment containing the deleted pol gene and the pTP gene was 20 isolated (as described in Ex. 3) and ligated to *Bst*1107I-digested pAdBglIIAsc to generate pAdAsc Δ pol.

b) Construction Of A Shuttle Vector Containing The Δ pol Δ pTP Deletion

A shuttle vector, pAdAsc Δ pol Δ pTP, which contains a 2.3 kb deletion within the pol 25 and pTP genes (described in Ex. 5) was constructed as follows.

pAXB Δ pol Δ pTPVARNA+t13 (Ex. 5b) was digested with *Ascl* and the ends were filled in using T4 DNA polymerase. The *Ascl*-digested, T4 DNA polymerase filled pAXB Δ pol Δ pTPVARNA+t13 DNA was then digested with *Bst*1107I and the ~7.6 kb *Ascl-Bst*1107I(filled) fragment containing the deleted pol gene and the pTP gene was isolated (as 30 described in Ex. 3) and ligated to *Bst*1107I-digested pAdBglIIAsc to generate pAdAsc Δ pol Δ pTP.

In order to reduce the packaging of the above helper viruses, the pol $^+$ or pol $^+$, pTP $^+$ helper viruses can be modified to incorporate *loxP* sequences on either side of the packaging

signals as outlined in Example 7. The *loxP*-containing pol⁺ or pol⁻, pTP⁻ shuttle vectors (pTP- shuttle vectors may also be employed) are cotransfected into 293 cells expressing *Cre* recombinase and pol or *Cre* recombinase, pol and pTP, respectively along with an appropriate E1⁻ viral DNA-TPC (the E1- viral DNA may also contain deletions elsewhere in the genome such as in the E4 genes or in the E2a gene as packaging cell lines expressing the E4 ORF 6 or 6/7 and lines expressing E2a genes are available) to generate helper virus containing *loxP* sites flanking the packaging signals as well as a deletion in the pol gene or the pol and pTP genes. The resulting helper virus(es) is used to cotransfect 293 cells expressing pol or pol and pTP along with the desired EAM construct. The resulting EAM preparation should contain little if any helper virus and any contaminating helper virus present would be replication defective and incapable of expressing viral late gene products. Helper viruses containing *loxP* sequences and deletions in all essential early genes may be employed in conjunction with *Cre* recombinase-expressing cell lines expressing *in trans* the E1, E4 ORF 6, E2a, and E2b (e.g., Ad polymerase and pTP) proteins (the E3 proteins are dispensable for growth in culture). Cell lines coexpressing E1, polymerase and pTP are provided herein. Cell lines expressing E1 and E4 proteins have been recently described [Krougliak and Graham (1995) Hum. Gene Ther. 6:1575 and Wang *et al.* (1995) Gene Ther. 2:775] and cell lines expressing E1 and E2a proteins have been recently described [Zhou *et al.* (1996) J. Virol. 70:7030]. Therefore, a cell line co-expressing E1, E2a, E2b, and E4 is constructed by introduction of expression plasmids containing the E2a and E4 coding regions into the E1-, Ad polymerase- and pTP-expressing cell lines of the present invention. These packaging cell lines are used in conjunction with helper viruses containing deletions in the E1, E2a, E2b and E4 regions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Chamberlain, Jeffrey S.
 Amalfitano, Andrea
 Hauser, Michael A.
 Kumar-Singh, Rajendra
 Hartigan-O'Connor, Dennis J.

(ii) TITLE OF INVENTION: IMPROVED ADENOVIRUS VECTORS

(iii) NUMBER OF SEQUENCES: 15

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Medlen & Carroll, LLP
 (B) STREET: 220 Montgomery Street, Suite 2200
 (C) CITY: San Francisco
 (D) STATE: California
 (E) COUNTRY: United States Of America
 (F) ZIP: 94104

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US
 (B) FILING DATE:
 (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Ingolia, Diane E.
 (B) REGISTRATION NUMBER: 40,027
 (C) REFERENCE/DOCKET NUMBER: UM-02484

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (415) 705-8410
 (B) TELEFAX: (415) 397-8338

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35935 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CATCATCAAT AATATAACCTT ATTTTGATT GAAGCCAATA TGATAATGAG GGGGTGGAGT	60
TTGTGACGTG GCGCGGGCG TGGGAACGGG GCGGGTGACG TAGTAGTGTG GCGGAAGTGT	120
GATGTTGCAA GTGTGGCGGA ACACATGTAA GCGACGGATG TGGCAAAAGT GACGTTTTG	180
GTGTGCGCCG GTGTACACAG GAAGTGACAA TTTTCGCGCG GTTTAGGCG GATGTTGTAG	240
TAAATTTGGG CGTAACCGAG TAAGATTTGG CCATTTCGC GGGAAAATG AATAAGAGGA	300
AGTGAAATCT GAATAATTTT GTGTTACTCA TAGCGCGTAA TATTTGTCTA GGGCCGCGGG	360
GACTTTGACC GTTTACGTGG AGACTCGCCC AGGTGTTTT CTCAGGTGTT TTCCGCGTTC	420
CGGGTCAAAG TTGGCGTTT ATTATTATAG TCAGCTGACG TGTAGTGTAT TTATACCCGG	480

WO 98/17783

PCT/US97/19541

TGAGTTCCTC AAGAGGCCAC TCTTGAGTGC CAGCGAGTAG AGTTTCTCC TCCGAGCCGC 540
 TCCGACACCG GGACTGAAAA TGAGACATAT TATCTGCCAC GGAGGTGTTA TTACCGAAGA 600
 AATGGCCGCC AGTCTTTGG ACCAGCTGAT CGAAGAGGTA CTGGCTGATA ATCTTCCACC 660
 TCCTAGCCAT TTTGAACAC CTACCCCTCA CGAACTGTAT GATTTAGACG TGACGGCCCC 720
 CGAAGATCCC AACGAGGAGG CGGTTTCGCA GATTTTCCC GACTCTGAA TGTTGGCGGT 780
 GCAGGAAGGG ATTGACTTAC TCACCTTCC GCCGGCGCCC GGTTCTCCGG AGCCGCCTCA 840
 CCTTCCCGG CAGCCCGAGC AGCCGGAGCA GAGAGCCTTG GGTCCGGTTT CTATGCCAAA 900
 CCTTGTACCG GAGGTGATCG ATCTTACCTG CCACGAGGCT GGCTTCCAC CCAGTGACGA 960
 CGAGGATGAA GAGGGTGAGG AGTTTGTGTT AGATTATGTG GAGCACCCCCG GGCACGGTTG 1020
 CAGGTCTTGT CATTATCACC GGAGGAATAC GGGGGACCCA GATATTATGT GTTCGCTTTG 1080
 CTATATGAGG ACCTGTGGCA TGTTTGTCTA CAGTAAGTGA AAATTATGGG CAGTGGGTGA 1140
 TAGAGTGGTG GGTGGGTGT GGTAATTTTT TTTTTAATTT TTACAGTTTT GTGGTTAAA 1200
 GAATTTGTA TTGTGATTT TTTAAAAGGT CCTGTGTCTG AACCTGAGCC TGAGCCCGAG 1260
 CCAGAACCGG AGCCTGCAAG ACCTACCCGC CGTCCTAAAA TGGCGCCTGC TATCCTGAGA 1320
 CGCCCGACAT CACCTGTGTC TAGAGAATGC AATAGTAGTA CGGATAGCTG TGACTCCGGT 1380
 CCTTCTAACCA CACCTCCTGA GATACACCCG GTGGTCCCGC TGTGCCCAT TAAACCAGTT 1440
 GCCGTGAGAG TTGGTGGCG TCGCCAGGCT GTGGAATGTA TCGAGGACTT GCTTAACGAG 1500
 CCTGGGCAAC CTTTGGACTT GAGCTGTAAA CGCCCCAGGC CATAAGGTGT AAACCTGTGA 1560
 TTGCGTGTGT GGTTAACGCC TTTGTTGCT GAATGAGTTG ATGTAAGTTT AATAAAGGGT 1620
 GAGATAATGT TTAACCTGCA TGGCGTGTAA AATGGGGCGG GGCTTAAAGG GTATATAATG 1680
 CGCCGTGGGC TAATCTTGGT TACATCTGAC CTCATGGAGG CTTGGAGTG TTGGAAAGAT 1740
 TTTTCTGCTG TGCCTAACCTT GCTGGAACAG AGCTCTAACCA GTACCTCTTG GTTTGGAGG 1800
 TTTCTGTGGG GCTCATCCCA GCAAAGTTA GTCTGCAGAA TTAAGGAGGA TTACAAGTGG 1860
 GAATTTGAAG AGCTTTGAA ATCCTGTGGT GAGCTGTTT ATTCTTGAA TCTGGTCAC 1920
 CAGGCGCTTT TCCAAGAGAA GGTCTCATCAAG ACTTTGGATT TTTCCACACC GGGCGCGCT 1980
 GCGGCTGCTG TTGTTTTT GAGTTTATA AAGGATAAA GGAGCGAAGA AACCCATCTG 2040
 AGCGGGGGGT ACCTGCTGGA TTTTCTGGCC ATGCATCTGT GGAGAGCGGT TGTGAGACAC 2100
 AAGAATCGCC TGCTACTGTT GTCTTCCGTC CGCCCGGCCA TAATACCGAC GGAGGAGCAG 2160
 CAGCAGCAGC AGGAGGAAGC CAGGCGCGG CGGCAGGAGC AGAGCCCATG GAACCCGAGA 2220
 GCCGGCCTGG ACCCTCGGGA ATGAATGTTG TACAGGTGGC TGAACGTAT CCAGAACTG 2280
 GACGCATTT GACAATTACA GAGGATGGGC AGGGCTAAA GGGGGTAAAG AGGGAGCGGG 2340
 GGGCTTGTGA GGCTACAGAG GAGGCTAGGA ATCTAGCTTT TAGCTTAATG ACCAGACACC 2400
 GTCCTGAGTG TATTACTTT CAACAGATCA AGGATAATTG CGCTAATGAG CTTGATCTGC 2460
 TGGCGCAGAA GTATTCCATA GAGCAGCTGA CCACTTACTG GCTGCAGCCA GGGGATGATT 2520
 TTGAGGAGGC TATTAGGGTA TATGCAAAGG TGGCACTTAG GCCAGATTGC AAGTACAAGA 2580

TCAGCAAAC TGTAAATATC AGGAATTGTT GCTACATTC TGGGAACGGG GCCGAGGTGG	2640
AGATAGATAc GGAGGATAGG GTGGCCTTTA GATGTAGCAT GATAAATATG TGGCCGGGG	2700
TGCTTGGCAT GGACGGGTG GTTATTATGA ATGTAAGGTT TACTGGCCCC AATTTAGCG	2760
GTACGGTTT CCTGGCCAAT ACCAACCTTA TCCTACACGG TGTAAGCTTC TATGGGTTTA	2820
ACAATACCTG TGTGGAAGCC TGACCGATG TAAGGGTTCG GGGCTGTGCC TTTTACTGCT	2880
GCTGGAAGGG GGTGGTGTGT CGCCCCAAAA GCAGGGCTTC AATTAAGAAA TGCCTCTTG	2940
AAAGGTGTAC CTTGGGTATC CTGTCTGAGG GTAACTCCAG GGTGCGCCAC AATGTGGCCT	3000
CCGACTGTGG TTGCTTCATG CTAGTGAAA GCGTGGCTGT GATTAAGCAT AACATGGTAT	3060
GTGGCAACTG CGAGGACAGG GCCTCTCAGA TGCTGACCTG CTCGGACGGC AACTGTCACC	3120
TGCTGAAGAC CATTACGTA GCCAGCCACT CTCGCAAGGC CTGGCCAGTG TTTGAGCATA	3180
ACATACTGAC CCGCTGTTCC TTGCATTGTTG GTAACAGGAG GGGGGTGTTC CTACCTTACC	3240
AATGCAATTG GAGTCACACT AAGATATTGC TTGAGCCGA GAGCATGTCC AAGGTGAACC	3300
TGAACGGGGT GTTTGACATG ACCATGAAGA TCTGGAAGGT GCTGAGGTAC GATGAGACCC	3360
GCACCAGGTG CAGACCCCTGC GAGTGTGGCG GTAAACATAT TAGGAACCAG CCTGTGATGC	3420
TGGATGTGAC CGAGGAGCTG AGGCCGATC ACTTGGTGT GGCCTGCACC CGCGCTGAGT	3480
TTGGCTCTAG CGATGAAGAT ACAGATTGAG GTACTGAAAT GTGTGGCGT GGCTTAAGGG	3540
TGGGAAAGAA TATATAAGGT GGGGGTCTTA TGTAGTTTG TATCTGTTT GCAGCAGCCG	3600
CCGCCGCCAT GAGCACCAAC TCGTTTGATG GAAGCATTGT GAGCTCATAT TTGACAACGC	3660
GCATGCCCCC ATGGGCCGGG GTGCGTCAGA ATGTGATGGG CTCCAGCATT GATGGTCGCC	3720
CCGTCCCTGCC CGCAAACCTCT ACTACCTTGA CCTACGAGAC CGTGTCTGGA ACGCCGTTGG	3780
AGACTGCAGC CTCCGGGCC GCTTCAGCCG CTGCAGCCAC CGCCCGCGGG ATTGTGACTG	3840
ACTTTGCTTT CCTGAGCCCG CTTGCAAGCA GTGCAAGCTTC CCGTTCATCC GCCCCGCGATG	3900
ACAAGTTGAC GGCTCTTTG GCACAATTGG ATTCTTGAC CCGGAACTT AATGTCGTTT	3960
CTCAGCAGCT GTTGGATCTG CGCCAGCAGG TTTCTGCCCT GAAGGCTTCC TCCCCTCCCA	4020
ATGCGGTTTA AAACATAAAAT AAAAACCCAG ACTCTGTTG GATTGGATC AAGCAAGTGT	4080
CTTGCTGTCT TTATTTAGGG GTTTGCGCG CGCGGTAGGC CCGGGACCAG CGGTCTCGGT	4140
CGTTGAGGGT CCTGTGTATT TTTTCCAGGA CGTGGTAAAG GTGACTCTGG ATGTTCAGAT	4200
ACATGGGCAT AAGCCGTCT CTGGGGTGGG GGTAGCACCA CTGCAGAGCT TCATGCTGCC	4260
GGGTGGGTGTT GTAGATGATC CAGTCGTAGC AGGAGCGCTG GGCGTGGTGC CTAAAAATGT	4320
CTTTCACTGAG CAAGCTGATT GCCAGGGCA GGCCCTTGGT GTAAGTGTGTT ACAAAAGCGGT	4380
TAAGCTGGGA TGGGTGCATA CGTGGGGATA TGAGATGCAT CTTGGACTGT ATTTTTAGGT	4440
TGGCTATGTT CCCAGCCATA TCCCTCCGGG GATTCACTGTT GTGCAGAAC ACCAGCACAG	4500
TGTATCCGGT GCACCTGGGA AATTTGTCAT GTAGCTTAGA AGGAAATGCG TGGAAAGAACT	4560
TGGAGACGCC CTTGTGACCT CCAAGATTTT CCATGCATTC GTCCATAATG ATGGCAATGG	4620
CCCCACGGGC GGCGGCCTGG GCGAAGATAT TTCTGGGATC ACTAACGTCA TAGTTGTGTT	4680

WO 98/17783

PCT/US97/19541

CCAGGATGAG ATCGTCATAG GCCATTTTA CAAAGCGCGG GCGGAGGGTG CCAGACTGCG	4740
GTATAATGGT TCCATCCGC CCAGGGCGT AGTTACCCCTC ACAGATTTGC ATTTCCCACG	4800
CTTTGAGTTC AGATGGGGG ATCATGTCTA CCTGCGGGGC GATGAAGAAA ACGGTTTCCG	4860
GGGTAGGGGA GATCAGCTGG GAAGAAAAGCA GGTTCCCTGAG CAGCTGCAC TTACCGCAGC	4920
CGGGGGGCC GTAAATCACA CCTATTACCG GGTGCAACTG GTAGTTAAGA GAGCTGCAGC	4980
TGCCGTCATC CCTGAGCAGG GGGGCCACTT CGTTAACGCAT GTCCCTGACT CGCATGTTT	5040
CCCTGACCAA ATCCGCCAGA AGGCCTCGC CGCCCAGCGA TAGCAGTTCT TGCAAGGAAG	5100
CAAAGTTTT CAACGGTTTG AGACCGTCCG CCGTAGGCAT GCTTTGAGC GTTTGACCAA	5160
GCAGTTCCAG GCGGTCCCAC AGCTCGGTCA CCTGCTCTAC GGCATCTCGA TCCAGCATAT	5220
CTCCTCGTT CGCGGGTTGG GGCGGCTTTC GCTGTACGGC AGTAGTCGGT GCTCGTCCAG	5280
ACGGGCCAGG GTCATGTCTT TCCACGGGCG CAGGGCTCTC GTCAGCGTAG TCTGGGTCAC	5340
GGTGAAGGGG TGCCTCCGG GCTGCGCGCT GGCCAGGGTG CGCTTGAGGC TGGTCCTGCT	5400
GGTGCTGAAG CGCTGCCGGT CTTCGCCCTG CGCGTCGGCC AGGTAGCATT TGACCATGGT	5460
GTCATAGTCC AGCCCCCTCCG CGCGTGGCC CTTGGCGCG AGCTTGCCCT TGGAGGGAGGC	5520
GCCGCACGAG GGGCAGTGCA GACTTTTGAG GGCGTAGAGC TTGGCGCGA GAAATACCGA	5580
TTCCGGGGAG TAGGCATCCG CGCCGCAGGC CCCGCAGACG GTCTCGCATT CCACGAGCCA	5640
GGTGAGCTCT GGCGGTTCGG GGTCAAAAAC CAGGTTTCCC CCATGCTTT TGATGCGTTT	5700
CTTACCTCTG GTTTCCATGA GCCGGTGTCC ACGCTCGGTG ACGAAAAGGC TGTCCGTGTC	5760
CCCGTATAACA GACTTGAGAG GCCTGTCCTC GAGCGGTGTT CCGCGGTCCCT CCTCGTATAG	5820
AAACTCGGAC CACTCTGAGA CAAAGGCTCG CGTCCAGGCC AGCACGAAGG AGGCTAAGTG	5880
GGAGGGTAG CGGTCGTGT CCACTAGGGG GTCCACTCGC TCCAGGGTGT GAAGACACAT	5940
GTCGCCCTCT TCGGCATCAA GGAAGGTGAT TGGTTGTAG GTGTAGGCCA CGTGACCGGG	6000
TGTTCCCTGAA GGGGGCTAT AAAAGGGGGT GGGGGCGCGT TCGTCCTCAC TCTCTTCCGC	6060
ATCGCTGTCT GCGAGGGCCA GCTGTTGGGG TGAGTACTCC CTCTGAAAAG CGGGCATGAC	6120
TTCTGCGCTA AGATTGTCAG TTTCCAAAAA CGAGGAGGAT TTGATATTCA CCTGGCCCGC	6180
GGTGATGCCT TTGAGGGTGG CGCGATCCAT CTGGTCAGAA AAGACAATCT TTTTGTGTC	6240
AAGCTTGGTG GCAAACGACC CGTAGAGGGC GTTGGACAGC AACTTGGCGA TGGAGCGCAG	6300
GGTTTGGTTT TTGTCGCGAT CGGCGCGCTC CTTGGCCCG ATGTTAGCT GCACGTATTTC	6360
GCGCGAACG CACCGCCATT CGGGAAAGAC GGTGGTGCAC TCGTCGGCGA CCAGGTGCAC	6420
GCGCCAACCG CGGTTGTGCA GGGTGACAAG GTCAACGCTG GTGGCTACCT CTCCGCGTAG	6480
GCGCTCGTTG GTCCAGCAGA GGCGGCCGCC CTTGCGCGAG CAGAATGGCG GTAGGGGGTC	6540
TAGCTGCGTC TCGTCCGGGG GGTCTGCGTC CACGGTAAAG ACCCCGGGCA GCAGGCGCGC	6600
GTCGAAGTAG TCTATCTTGC ATCCTTGCA GTCTAGCGCC TGCTGCCATG CGCGGGCGGC	6660
AAGCGCGCGC TCGTATGGGT TGAGTGGGG ACCCCATGGC ATGGGGTGGG TGAGCGCGGA	6720
GGCGTACATG CCCAAATGT CGTAAACGTA GAGGGCTCT CTGAGTATTTC CAAGATATGT	6780

AGGGTAGCAT	CTTCCACCGC	GGATGCTGGC	GCGCACGTA	TCTGATAGTT	CGTGCGAGGG	6840
AGCGAGGAGG	TCGGGACCGA	GGTGCTACG	GGCGGGCTGC	TCTGCTCGGA	AGACTATCTG	6900
CCTGAAGATG	GCATGTGAGT	TGGATGATAT	GGTTGGACGC	TGAAAGACGT	TGAAGCTGGC	6960
GTCTGTGAGA	CCTACCGCGT	CACCGACGAA	GGAGGCCTAG	GAGTCGCGCA	GCTTGTGAC	7020
CAGCTCGGCG	GTGACCTGCA	CGTCTAGGGC	GCAGTAGTCC	AGGGTTTCC	TGATGATGTC	7080
ATACTTATCC	TGTCCCTTTT	TTTCCACAG	CTCGCGGTTG	AGGACAAACT	CTTCGCGGTC	7140
TTTCCAGTAC	TCTTGGATCG	GAAACCCGTC	GGCCTCCGAA	CGGTAAGAGC	CTAGCATGTA	7200
GAAC TGGTTG	ACGGCCTGGT	AGGCGCAGCA	TCCCTTTCT	ACGGGTAGCG	CGTATGCC	7260
CGGGGCC	CGGAGCGAGG	TGTGGGTGAG	CGCAAAGGTG	TCCCTGACCA	TGACTTTGAG	7320
GTACTGGTAT	TTGAAGTCAG	TGTCGTCGCA	TCCGCC	TCCCAGAGCA	AAAAGTCCGT	7380
GCGCTTTTG	GAACGCGGAT	TTGGCAGGGC	GAAGGTGACA	TGTTGAAGA	GTATTTCC	7440
CGCGCGAGGC	ATAAGTTGC	GTGTGATGCG	GAAGGGTCCC	GGCACCTCGG	AACGGTTGTT	7500
AATTACCTGG	GCGCGAGCA	CGATCTCGTC	AAAGCCGTTG	ATGTTGTGGC	CCACAATGTA	7560
AAGTTCCAAG	AAGCGGGGA	TGCCCTTGAT	GGAAGGCAAT	TTTTAAGTT	CCTCGTAGGT	7620
GAGCTCTTCA	GGGGAGCTGA	GCCCCGTGCTC	TGAAAGGGCC	CAGTCTGCAA	GATGAGGGTT	7680
GGAAGCGACG	AATGAGCTCC	ACAGGTCA	GGCCATTAGC	ATTTGCAGGT	GGTCGCGAAA	7740
GGTCCTAAC	TGGCGACCTA	TGGCCATT	TTCTGGGTG	ATGCAGTACA	AGGTAAGCGG	7800
GTCTTGT	CAGCGGTCCC	ATCCAAGGTT	CGCGGCTAGG	TCTCGCGCG	CAGTCACTAG	7860
AGGCTCATCT	CCGCCGA	ACTCATGACCAG	CATGAAGGGC	ACGAGCTGCT	TCCCAAAGGC	7920
CCCCATCCAA	GTATAGGTCT	CTACATCGTA	GGTGACAAAG	AGACGCTCGG	TGCGAGGATG	7980
CGAGCCGATC	GGGAAGAA	ACTGGATCCCG	CCACCAATTG	GAGGAGTGGC	TATTGATGTC	8040
GTGAAAGTAG	AACTCCCTGC	GACGGGCCGA	ACACTCGTC	TGGCTTTGT	AAAAACGTGC	8100
GCAGTACTGG	CAGCGGTGCA	CGGGCTGTAC	ATCCTGCACG	AGGTTGACCT	GACGACCGCG	8160
CACAAGGAAG	CAGAGTGGGA	ATTTGAGCCC	CTCGCCTGGC	GGGTTGGCT	GGTGGCTTC	8220
TACTTCGGCT	GCTTGT	GACCGTCTGG	CTGCTCGAGG	GGAGTTACGG	TGGATCGGAC	8280
CACCA	CGCGAGCCC	AAGTCCAGAT	GTCCGCGCGC	GGCGGTGGA	GCTTGATGAC	8340
AACATCGCGC	AGATGGGAGC	TGTCCATGGT	CTGGAGCTCC	CGCGCGTCA	GGTCAGGCGG	8400
GAGCTCCTGC	AGGTTACCT	CGCATAGACG	GGTCAGGGCG	CGGGCTAGAT	CCAGGTGATA	8460
CCTAATT	AGGGGCTGGT	TGGTGGCGGC	GTGATGGCT	TGCAAGAGGC	CGCATCCCCG	8520
CGGCGCGACT	ACGGTACCGC	GCGCGGGCG	GTGGGCCGCG	GGGGTGTCT	TGGATGATGC	8580
ATCTAAAAGC	GGTGACCGG	GCGAGCCCC	GGAGGTAGGG	GGGGCTCCGG	ACCCGCCGGG	8640
AGAGGGGGCA	GGGGCACGTC	GGCGCCGCGC	GCGGGCAGGA	GCTGGTGCTG	CGCGCGTAGG	8700
TTGCTGGCGA	ACGCGACGAC	GCGCGGTTG	ATCTCCTGAA	TCTGGCGCCT	CTGCGTGAAG	8760
ACGACGGGCC	CGGTGAGCTT	GAGCCTGAA	GAGAGTTCGA	CAGAATCAAT	TTCGGTGTCG	8820
TTGACGGCGG	CCTGGCGAA	AATCTCCTGC	ACGTCTCCTG	AGTTGTCTTG	ATAGGCGATC	8880

WO 98/17783

PCT/US97/19541

TCGGCCATGA ACTGCTCGAT CTCTCCTCC TGGAGATCTC CGCGTCCGGC TCGCTCCACG	8940
GTGGCGGCGA GGTCGTTGGA AATGCGGGCC ATGAGCTGCG AGAAGGC GTT GAGGCCTCCC	9000
TCGTTCCAGA CGCGGCTGTA GACCACGCC CCGTCGGCAT CGCGGGCGCG CATGACCACC	9060
TGCGCGAGAT TGAGCTCCAC GTGCCGGCG AAGACGGCGT AGTTTGCAG GCGCTGAAAG	9120
AGGTAGTTGA GGGTGGTGGC GGTGTGTTCT GCCACGAAGA AGTACATAAC CCAGCGTCGC	9180
AACGTGGATT CGTTGATATC CCCCAAGGCC TCAAGGCCT CCATGGCCTC GTAGAAAGTCC	9240
ACGGCGAAGT TGAAAAACTG GGAGTTGCGC GCCGACACGG TTAACTCCTC CTCCAGAAGA	9300
CGGATGAGCT CGGCGACAGT GTCGCGCACCC TCGCGCTCAA AGGCTACAGG GGCGCTTTCT	9360
TCTTCTTCAA TCTCCTCTTC CATAAGGGCC TCCCCCTTCTT CTTCTTCTGG CGGCGGTGGG	9420
GGAGGGGGGA CACGGCGCG ACCACGGCGC ACCGGGAGGC GGTCGACAAA GCGCTCGATC	9480
ATCTCCCCGC GGCGACGGCG CATGGTCTCG GTGACGGCGC GGCGTTCTC GCGGGGGCGC	9540
AGTTGGAAGA CGCCGCCCCGT CATGTCCCCG TTATGGGTTG GCAGGGGGCT GCCATGCGGC	9600
AGGGATAACGG CGCTAACGAT GCATCTAAC AATTGTTGTG TAGGTACTCC GCCGCCGAGG	9660
GACCTGAGCG AGTCCGCATC GACCGGATCG GAAAACCTCT CGAGAAAGGC GTCTAACCAG	9720
TCACAGTCGC AAGTAGGCT GAGCACCGTG GCGGGCGGCA GCGGGCGCG GTCGGGGTTG	9780
TTTCTGGGG AGGTGCTGCT GATGATGTAA TTAAAGTAGG CGGTCTTGAG ACGGCGGATG	9840
GTCGACAGAA GCACCATGTC CTTGGGTCCG GCCTGCTGAA TGCAGGGCG GTCGGCCATG	9900
CCCCAGGCCTT CGTTTGACA TCGGCGCAGG TCTTTGTAGT AGTCTTGCAT GAGCCTTCT	9960
ACCGGCACCTT CTTCTTCTCC TTCTCTTGT CCTGCATCTC TTGCATCTAT CGCTGCGCG	10020
GCGGCGGAGT TTGGCCGTAG GTGGCGCCCT CTTCTCCCA TGCAGGGCG GTCGGCCATG	10080
CTCATCGGCT GAAGCAGGGC TAGGTGGCG ACAACGGCT CGGCTAATAT GGCGTGTG	10140
ACCTGCGTGA GGGTAGACTG GAAGTCATCC ATGTCCACAA AGCGGTGGTA TGCGCCCGTG	10200
TTGATGGTGT AAGTGCAGTT GGCCATAACG GACCAAGTTAA CGGTCTGGTG ACCCGGCTGC	10260
GAGAGCTCGG TGTACCTGAG ACGCGAGTAA GCCCTCGAGT CAAATACGTA GTCGTTGCAA	10320
GTCCGCACCA GGTACTGGTA TCCCACCAAA AAGTGCAGCG GCGGCTGGCG GTAGAGGGGC	10380
CAGCGTAGGG TGGCGGGGC TCCGGGGCG AGATCTTCCA ACATAAGGCAG ATGATATCCG	10440
TAGATGTACC TGGACATCCA GGTGATGCGG GCGGCGGTGG TGGAGGCGCG CGGAAAGTCG	10500
CGGACCGGGT TCCAGATGTT GCGCAGCGG AAAAGTGCT CCATGGTCGG GACGCTCTGG	10560
CCGGTCAGGC GCGCGCAATC GTTGACGCTC TAGACCGTGC AAAAGGAGAG CCTGTAAGCG	10620
GGCACTCTTC CGTGGTCTGG TGGATAAAATT CGCAAGGGTA TCATGGCGGA CGACCGGGGT	10680
TCGAGCCCCG TATCCGGCCG TCCGCCGTGA TCCATGCCTG TACCGCCCGC GTGTCGAACC	10740
CAGGTGTGCG ACGTCAAGACA ACGGGGGGAGT GCTCCTTTG GCTTCCTTCC AGGCGCGGGCG	10800
GCTGCTGCGC TAGCTTTTTT GGCCACTGGC CGCGCGCAGC GTAAGCGGTT AGGCTGGAAA	10860
GCGAAAGCAT TAAGTGGCTC GCTCCCTGTA GCCGGAGGGT TATTTTCCAA GGGTTGAGTC	10920
GCGGGACCCC CGGTTCGAGT CTCGGACCGG CGGGACTGCG GCGAACGGGG GTTGCCTCC	10980

CCGTCATGCA AGACCCCGCT TGCAAATTCC TCCGGAAACA GGGACGAGCC CCTTTTTTGC	11040
TTTTCCCAGA TGCATCCGGT GCTGCGGCAG ATGCCCCCCC CTCCCTCAGCA GCGGCAAGAG	11100
CAAGAGCAGC GGCAGACATG CAGGGCACCC TCCCCCTCCTC CTACCGCGTC AGGAGGGGCG	11160
ACATCCGCGG TTGACCGGGC AGCAGATGGT GATTACGAAC CCCCGCGGCG CGGGGCCCGG	11220
CACTACCTGG ACTTGGAGGA GGGCGAGGGC CTGGCGCGGC TAGGAGCGCC CTCTCCTGAG	11280
CGGTACCCAA GGGTGCAGCT GAAGCGTGAT ACGCGTGAGG CGTACGTGCC GCGGCAGAAC	11340
CTGTTTCGCG ACCCGCAGGG AGAGGAGCCC GAGGAGATGC GGGATCGAAA GTTCCACGCA	11400
GGGCGCGAGC TGCGGCATGG CCTGAATCGC GAGCGGTTGC TGCGCGAGGA GGACTTTGAG	11460
CCCGACGCGC GAACCGGGAT TAGTCCCGCG CGCGCACACG TGGCGGCCGC CGACCTGGTA	11520
ACCGCATACG AGCAGACGGT GAACCAGGAG ATTAACTTTC AAAAAGCTT TAACAACCAC	11580
GTGCGTACCG TTGTGGCGCG CGAGGAGGTG GCTATAGGAC TGATGCATCT GTGGGACTTT	11640
GTAAGCGCGC TGGAGCAAAA CCCAAATAGC AAGCCGCTCA TGGCGCAGCT GTTCCTTATA	11700
GTGCAGCACA GCAGGGACAA CGAGGCATTC AGGGATGCGC TGCTAACAT AGTAGAGCCC	11760
GAGGGCCGCT GGCTGCTCGA TTTGATAAAC ATCCTGCAGA GCATAGTGGT GCAGGAGCGC	11820
AGCTTGAGCC TGGCTGACAA GGTGGCCGCC ATCAACTATT CCATGCTTAG CCTGGGCAAG	11880
TTTTACGCCG CCAAGATATA CCATACCCCT TACGTTCCA TAGACAAGGA GGTAAAGATC	11940
GAGGGGTTCT ACATGCGCAT GGCCTGAAG GTGCTTACCT TGAGCGACGA CCTGGCGTT	12000
TATCGCAACG AGCGCATCCA CAAGGCCGTG AGCGTGAGCC GGCGCGCGA GCTCAGCGAC	12060
CGCGAGCTGA TGCACAGCCT GCAAAGGGCC CTGGCTGGCA CGGGCAGCGG CGATAGAGAG	12120
GCCGAGTCCT ACTTTGACGC GGGCGCTGAC CTGCGCTGGG CCCCCAAGCCG ACGCGCCCTG	12180
GAGGCAGCTG GGGCCGGACC TGGGCTGGCG GTGGCACCCG CGCGCGCTGG CAACGTCGGC	12240
GGCGTGGAGG AATATGACGA GGACGATGAG TACGAGCCAG AGGACGGCGA GTACTAAGCG	12300
GTGATGTTTC TGATCAGATG ATGCAAGACG CAACGGACCC GGCGGTGCGG CGGGCGCTGC	12360
AGAGCCAGCC GTCCGGCCTT AACTCCACGG ACGACTGGCG CCAGGTCAATG GACCGCATCA	12420
TGTCGCTGAC TGCGCGCAAT CCTGACCGGT TCCGGCAGCA GCCGCAGGCC AACCGGCTCT	12480
CCGCAATTCT GGAAGCGGTG GTCCCGCGC GCGCAAACCC CACGCACGAG AAGGTGCTGG	12540
CGATCGTAAA CGCGCTGGCC GAAAACAGGG CCATCCGGCC CGACGAGGCC GGCGTGGTCT	12600
ACGACGGCGCT GCTTCAGCGC GTGGCTCGTT ACAACAGCGG CAACGTGCAG ACCAACCTGG	12660
ACCGGCTGGGT GGGGGATGTG CGCGAGGCCG TGGCGCAGCG TGAGCGCGCG CAGCAGCAGG	12720
GCAACCTGGG CTCCATGGTT GCACTAAACG CCTTCCTGAG TACACAGCCC GCCAACGTGC	12780
CGCGGGGACA GGAGGACTAC ACCAACCTTG TGAGCGCACT GCGGCTAATG GTGACTGAGA	12840
CACCGCAAAG TGAGGTGTAC CAGTCTGGGC CAGACTATTT TTTCCAGACC AGTAGACAAG	12900
GCCTGCAGAC CGTAAACCTG AGCCAGGCC TCAAAAACCTT GCAGGGCTG TGGGGGGTGC	12960
GGGCTCCAC AGGCGACCGC GCGACCGTGT CTAGCTTGCT GACGCCAAC TCGCGCCTGT	13020
TGCTGCTGCT AATAGCGCCC TTCACGGACA GTGGCAGCGT GTCCCGGGAC ACATACCTAG	13080

WO 98/17783

GTCACTTGCT GACACTGTAC CGCGAGGCCA TAGGTCAGGC GCATGTGGAC GAGCATACTT	13140
TCCAGGAGAT TACAAGTGTC AGCCGCGCGC TGGGGCAGGA GGACACGGGC AGCCTGGAGG	13200
CAACCCCTAAA CTACCTGCTG ACCAACCGGC GGCAGAAAGAT CCCCTCGTTG CACAGTTAA	13260
ACAGCGAGGA GGAGCGCATT TTGCGCTACG TGCAGCAGAG CGTGAGCCTT AACCTGATGC	13320
GCGACGGGGT AACGCCAGC GTGGCGCTGG ACATGACCGC GCGCAACATG GAACCGGGCA	13380
TGTATGCCTC AAACCGGCCG TTTATCAACC GCCTAATGGA CTACTTGCAT CGCGCGGCCG	13440
CCGTGAACCC CGAGTATTC ACCAATGCCA TCTTGAACCC GCACTGGCTA CCGCCCCCTG	13500
GTTTCTACAC CGGGGGATTC GAGGTGCCCG AGGGTAACGA TGGATTCCCTC TGGGACGACA	13560
TAGACGACAG CGTGTTCAGC CCGCAACCGC AGACCCCTGCT AGAGTTGCAA CAGCGCGAGC	13620
AGGCAGAGGC GGCGCTGCGA AAGGAAAGCT TCCGCAGGCC AAGCAGCTTG TCCGATCTAG	13680
GCGCTGCGGC CCCGCGGTCA GATGCTAGTA GCCCATTTC AAGCTTGATA GGGTCTCTTA	13740
CCAGCACTCG CACCACCCGC CCGCGCCTGC TGGGCGAGGA GGAGTACCTA AACAACTCGC	13800
TGCTGCAGCC GCAGCGCGAA AAAAACCTGC CTCCGGCATT TCCCACAAAC GGGATAGAGA	13860
GCCTAGTGGA CAAGATGAGT AGATGGAAGA CGTACGCCA GGAGCACAGG GACGTGCCAG	13920
GCCCCGCGCC GCCCACCCGT CGTCAAAGGC ACGACCGTCA GCGGGGTCTG GTGTGGGAGG	13980
ACGATGACTC GGCAGACGAC AGCAGCGTCC TGGATTGGG AGGGAGTGGC AACCCGTTTG	14040
CGCACCTTCG CCCCAGGCTG GGGAGAATGT TTTAAAAAAA AAAAACATG ATGAAAATA	14100
AAAAACTCAC CAAGGCCATG GCACCGAGCG TTGGTTTCT TGTATTCCCC TTAGTATGCG	14160
GCGCGCGCG ATGTATGAGG AAGGTCTCC TCCCTCTAC GAGAGTGTGG TGAGCGCGC	14220
GCCAGTGGCG CGGGCGCTGG GTTCTCCCTT CGATGCTCCC CTGGACCCGC CGTTTGTGCC	14280
TCCGCGGTAC CTGCGGCCTA CGGGGGGAG AAACAGCATC CGTTACTCTG AGTTGGCACC	14340
CCTATTGAC ACCACCCGTG TGTACCTGGT GGACAACAAG TCAACGGATG TGGCATCCCT	14400
GAACTACCAG AACGACCACA GCAACTTTCT GACCACGGTC ATTCAAAACA ATGACTACAG	14460
CCCCGGGGAG GCAAGCACAC AGACCATCAA TCTTGACGAC CGGTGCACT GGGGCGCGA	14520
CCTGAAAACC ATCCTGCATA CCAACATGCC AAATGTGAAC GAGTTCATGT TTACCAATAA	14580
GTTTAAGGCG CGGGTGATGG TGTGCGCTT GCCTACTAAG GACATCAGG TGGAGCTGAA	14640
ATACGAGTGG GTGGAGTTCA CGCTGCCGA GGGCAACTAC TCCGAGACCA TGACCATAGA	14700
CCTTATGAAC AACCGCAGTC TGGAGCACTA CTTGAAAGTG GGCAGACAGA ACGGGGTTCT	14760
GGAAAGCGAC ATCGGGGTAA AGTTTGACAC CCGCAACTTC AGACTGGGGT TTGACCCCGT	14820
CACTGGTCTT GTCATGCCCTG GGGTATATAC AAACGAAGCC TTCCATCCAG ACATCATTTC	14880
GCTGCCAGGA TGCGGGGTGG ACTTCACCCA CAGCCGCTG AGCAACTTGT TGGGCATCCG	14940
CAAGCGCAA CCCTTCCAGG AGGGCTTAG GATCACCTAC GATGATCTGG AGGGTGGTAA	15000
CATTCCCGCA CTGTTGGATG TGGACGCCCTA CCAGGGCGAGC TTGAAAGATG ACACCGAAC	15060
GGCGGGGGT GGCGCAGGCC GCAAGCAACAG CAGTGGCAGC GGCGCGGAAG AGAACTCCAA	15120
CGCGGGCAGCC CGGGCAATGC AGCCGGTGGA GGACATGAAC GATCATGCCA TTCGCGCGA	15180

CACCTTGCC	ACACGGGCTG	AGGAGAAGCG	CGCTGAGGCC	GAAGCAGCGG	CCGAAGCTGC	15240
CGCCCCSCT	GCGCAACCCG	AGGTGAGAA	GCCTCAGAAG	AAACCGGTGA	TCAAACCCCT	15300
GACAGAGGAC	AGCAAGAAC	GCAGTTACAA	CCTAATAAGC	AATGACAGCA	CCTTCACCCA	15360
GTACCGCAGC	TGGTACCTTG	CATACAACTA	CGGCGACCCT	CAGACCGGAA	TCCGCTCATG	15420
GACCCTGCTT	TGCACTCCTG	ACGTAACCTG	CGGCTCGGAG	CAGGTCTACT	GGTCGTTGCC	15480
AGACATGATG	CAAGACCCG	TGACCTTCCG	CTCCACGCGC	CAGATCAGCA	ACTTTCCGGT	15540
GGTGGGCGCC	GAGCTGTTGC	CCGTGCACTC	CAAGAGCTTC	TACAACGACC	AGGCCGTCTA	15600
CTCCCAACTC	ATCCGCCAGT	TTACCTCTCT	GACCCACGTG	TTCAATCGCT	TTCCCGAGAA	15660
CCAGATTTG	GCGCGCCCGC	CAGCCCCCAC	CATCACCACC	GTCAGTGAAA	ACGTTCTGC	15720
TCTCACAGAT	CACGGGACGC	TACCGCTGCG	CAACAGCATT	GGAGGAGTCC	AGCGAGTGAC	15780
CATTACTGAC	GCCAGACGCC	GCACCTGCC	CTACGTTAC	AAGGCCCTGG	GCATAGTCTC	15840
GCCGCGCGTC	CTATCGAGCC	GCACCTTTG	AGCAAGCATG	TCCATCCTTA	TATCGCCCAG	15900
CAATAACACA	GGCTGGGGCC	TGCGCTTCCC	AAGCAAGATG	TTTGGGGGGG	CCAAGAAGCG	15960
CTCCGACCAA	CACCCAGTGC	GCGTGCACGG	GCACCTACCGC	GCGCCCTGGG	GCGCGCACAA	16020
ACGCGGCCGC	ACTGGGCGCA	CCACCGTCGA	TGACGCCATC	GACGCGGTGG	TGGAGGAGGC	16080
GCGCAACTAC	ACGCCCACGC	CGCCACCAGT	GTCCACAGTG	GACGCGGCCA	TTCAAGACCGT	16140
GGTGCACGGA	GCCCCGGCGCT	ATGCTAAAAT	GAAGAGACGG	CGGAGGCGCG	TAGCACGTCG	16200
CCACCGCCGC	CGACCCGGCA	CTGCCGCCCA	ACGCGCGCG	GCGCCCTGC	TTAACCGCGC	16260
ACGTCGCACC	GGCCGACGGG	CGGCCATGCG	GGCCGCTCGA	AGGCTGGCCG	CGGGTATTGT	16320
CACTGTGCC	CCCAGGTCCA	GGCGACGAGC	GGCCGCGCGA	GCAGCCGCGG	CCATTAGTGC	16380
TATGACTCAG	GGTCGCAGGG	GCAACGTGTA	TTGGGTGCGC	GACTCGTTA	GCGGCCTGCG	16440
CGTGCCTGTG	CGCACCCGCC	CCCCCGCAA	CTAGATTGCA	AGAAAAAAACT	ACTTAGACTC	16500
GTACTGTTGT	ATGTATCCAG	CGGCGCGGC	GCGCAACGAA	GCTATGTCCA	AGCGCAAAT	16560
CAAAGAAGAG	ATGCTCCAGG	TCATCGCGCC	GGAGATCTAT	GGCCCCCGA	AGAAGGAAGA	16620
GCAGGATTAC	AAGCCCCGAA	AGCTAAAGCG	GGTCAAAAG	AAAAAGAAAG	ATGATGATGA	16680
TGAACCTGAC	GACGAGGTGG	AACTGCTGCA	CGCTACCGCG	CCCAGGCGAC	GGGTACAGTG	16740
GAAAGGTCGA	CGCGTAAAC	GTGTTTGCG	ACCCGGCACCC	ACCGTAGTCT	TTACGCCCGG	16800
TGAGCGCTCC	ACCCGCACCT	ACAAGCGCGT	GTATGATGAG	GTGTACGGCG	ACGAGGACCT	16860
GCTTGAGCAG	GCCAACGAGC	GCCTCGGGGA	TTTGCCCTAC	GGAAAGCGGC	ATAAGGACAT	16920
GCTGGCGTTG	CCGCTGGACG	AGGGCAACCC	AACACCTAGC	CTAAAGCCCG	TAACACTGCA	16980
GCAGGTGCTG	CCCGCGCTTG	CACCGTCCGA	AGAAAAGCGC	GGCCTAAAGC	GCGAGTCTGG	17040
TGACTTGGCA	CCCACCGTGC	AGCTGATGGT	ACCCAAGCGC	CAGCGACTGG	AAGATGTCTT	17100
GGAAAAAAATG	ACCGTGAAC	CTGGGCTGGA	GCCCGAGGTC	CGCGTGCACGC	CAATCAAGCA	17160
GGTGGCGCCG	GGACTGGCG	TGCAGACCGT	GGACGTTCA	ATACCCACTA	CCAGTAGCAC	17220
CAGTATTGCC	ACCGCCACAG	AGGGCATGGA	GACACAAACG	TCCCCGGTTG	CCTCAGCGGT	17280

GGCGGATGCC	GCGGTGCAGG	CGGTCGCTGC	GGCCGCGTCC	AAGACCTCTA	CGGAGGTGCA	17340
AACGGACCCG	TGGATGTTTC	GGGTTTCAGC	CCCCCGGCGC	CCGCGGGTT	CGAGGAAGTA	17400
CGGCGCCGCC	AGCGCGCTAC	TGCCCGAATA	TGCCCTACAT	CCTTCCATTG	CGCCTACCCC	17460
CGGCTATCGT	GGCTACACCT	ACCGCCCCAG	AAGACGAGCA	ACTACCCGAC	GCCGAACCAC	17520
CACTGGAACC	CGCCGCCGCC	GTCGCCGTG	CCAGCCCGTG	CTGGCCCCGA	TTTCCGTGCG	17580
CAGGGTGGCT	CGCGAAGGAG	GCAGGACCCCT	GGTGCTGCCA	ACAGCGCGCT	ACCACCCAG	17640
CATCGTTAA	AAGCCGGTCT	TTGTGGTTCT	TGCAGATATG	GCCCTCACCT	GCCGCCTCCG	17700
TTTCCCGGTG	CCGGGATTCC	GAGGAAGAAT	GCACCGTAGG	AGGGGCATGG	CCGGCCACGG	17760
CCTGACGGGC	GGCATGGCTC	GTGCGCACCA	CCGGCGGCCG	CGCGCGTCGC	ACCGTCGCAT	17820
GCAGCGCGGT	ATCCTGCCCT	TCCTTATTCC	ACTGATGCC	GCAGCGATTG	GCAGCGTGCC	17880
CGGAATTGCA	TCCGTGGCCT	TGCAGGCGCA	GAGACACTGA	TTAAAAACAA	GTGCAATGTG	17940
GAAAAATCAA	AATAAAAAGT	CTGGACTCTC	ACGCTCGCTT	GGTCCTGTAA	CTATTTGTA	18000
GAATGGAAGA	CATCAACTTT	GGCTCTCTGG	CCCCGCGACA	CGGCTCGCGC	CCGTTCATGG	18060
GAAACTGGCA	AGATATCGGC	ACCAAGAATA	TGAGCGGTGG	CGCCTTCAGC	TGGGGCTCGC	18120
TGTGGAGCGG	CATTAAAAAT	TTCGGTTCCA	CCGTTAAGAA	CTATGGCAGC	AAGGCCTGGA	18180
ACAGCAGCAC	AGGCCAGATG	CTGAGGGATA	AGTTGAAAGA	GCAAAATTTC	CAACAAAAGG	18240
TGGTAGATGG	CCTGGCCTCT	GGCATTAGCG	GGGTGGTGG	CCTGGCCAAC	CAGGCAGTGC	18300
AAAAATAAGAT	TAACAGTAAG	CTTGATCCCC	GCCCTCCCGT	AGAGGAGCCT	CCACCGGCCG	18360
TGGAGACAGT	GTCTCCAGAG	GGCGTGGCG	AAAAGCGTCC	CGCAGCCGAC	AGGGAAAGAAA	18420
CTCTGGTGAC	GCAAATAGAC	GAGCCTCCCT	CGTACGAGGA	GGCACTAAAG	CAAGGCCTGC	18480
CCACCACCCG	TCCCATCGCG	CCCATGGCTA	CCGGAGTGCT	GGGCCAGCAC	ACACCCGTAA	18540
CGCTGGACCT	GCCTCCCCCC	GCCGACACCC	AGCAGAAACC	TGTGCTGCCA	GGCCCGACCG	18600
CCGTTGTTGT	AACCCGTCC	AGCCGCGCGT	CCCTGCGCCG	CGCCGCCAGC	GGTCCGCGAT	18660
CGTTGCGGCC	CGTAGGCCAGT	GGCAACTGGC	AAAGCACACT	GAACAGCATC	GTGGGTCTGG	18720
GGGTGCAATC	CCTGAAGCGC	CGACGATGCT	TCTGAATAGC	TAACGTGTG	TATGTGTGTC	18780
ATGTATGCGT	CCATGTCGCC	GCCAGAGGAG	CTGCTGAGCC	GCCGCGCGCC	CGCTTTCCAA	18840
GATGGCTACC	CCTTCGATGA	TGCCGCAGTG	GTCTTACATG	CACATCTCGG	GCCAGGACGC	18900
CTCGGGAGTAC	CTGAGCCCCG	GGCTGGTGCA	GTGGCCCGC	GCCACCGAGA	CGTACTTCAG	18960
CCTGAATAAC	AAGTTTAGAA	ACCCCACGGT	GGCGCCTACG	CACGACGTGA	CCACAGACCG	19020
GTCCCAGCGT	TTGACGCTGC	GGTCATCCC	TGTGGACCGT	GAGGATACTG	CGTACTCGTA	19080
CAAGGCGCGG	TTCACCCCTAG	CTGTGGGTGA	TAACCGTGTG	CTGGACATGG	CTTCCACGTA	19140
CTTTGACATC	CGCGCGGTGC	TGGACAGGGG	CCCTACTTT	AAGCCCTACT	CTGGCACTGC	19200
CTACAACGCC	CTGGCTCCCA	AGGGTGGCCC	AAATCCTG	GAATGGGATG	AAGCTGCTAC	19260
TGCTCTTGAA	ATAAACCTAG	AAGAAGAGGA	CGATGACAAC	GAAGACGAAG	TAGACGAGCA	19320
AGCTGAGCAG	CAAAAAACTC	ACGTATTTGG	GCAGGCGCCT	TATTCTGGTA	TAAATATTAC	19380

AAAGGAGGGT ATTCAAATAG GTGTCGAAGG TCAACACCT AAATATGCCG ATAAAACATT	19440
TCAACCTGAA CCTCAAATAG GAGAATCTCA GTGGTACGAA ACTGAAATTA ATCATGCAGC	19500
TGGGAGAGTC CTTAAAAGA CTACCCCAAT GAAACCATGT TACGGTTCAT ATGCAAAACC	19560
CACAAATGAA AATGGAGGGC AAGGCATTCT TGTAAGCAA CAAATGGAA AGCTAGAAAG	19620
TCAAGTGGAA ATGCAATTT TCTCAACTAC TGAGGCAGCC GCAGGCAATG GTGATAACTT	19680
GACTCCTAAA GTGGTATTGT ACAGTGAAGA TGTAGATATA GAAACCCCAG ACACTCATAT	19740
TTCTTACATG CCCACTATTA AGGAAGGTA CTCACGAGAA CTAATGGCC AACAACTAT	19800
GCCCAACAGG CCTAATTACA TTGCTTTAG GGACAATTT ATTGGTCTAA TGTATTACAA	19860
CAGCACGGGT AATATGGGTG TTCTGGCGGG CCAAGCATCG CAGTGAATG CTGTTGTAGA	19920
TTTGCAAGAC AGAAACACAG AGCTTCATA CCAGCTTTG CTTGATTCCA TTGGTGATAG	19980
AACCAGGTAC TTTCTATGT GGAATCAGGC TGTTGACAGC TATGATCCAG ATGTTAGAAT	20040
TATTGAAAAT CATGGAACTG AAGATGAAC TCCAAATTAC TGCTTCCAC TGGGAGGTGT	20100
GATTAATACA GAGACTCTTA CCAAGGTAAA ACCTAAAACA GGTCAAGAAA ATGGATGGGA	20160
AAAAGATGCT ACAGAATTTT CAGATAAAAA TGAAATAAGA GTTGGAAATA ATTTGCCAT	20220
GGAAATCAAT CTAAATGCCA ACCTGTGGAG AAATTCCTG TACTCCAACA TAGCGCTGTA	20280
TTTGGCCGAC AAGCTAAAGT ACAGTCCTTC CAACGTAAAA ATTTCTGATA ACCCAAACAC	20340
CTACGACTAC ATGAACAAGC GAGTGGTGGC TCCCAGGTTA GTGGACTGCT ACATTAACCT	20400
TGGAGCACGC TGGTCCCTTG ACTATATGGA CAACGTCAAC CCATTTAACCC ACCACCGCAA	20460
TGCTGGCCTG CGCTACCGCT CAATGTTGCT GGGCAATGGT CGCTATGTGC CCTTCCACAT	20520
CCAGGTGCCT CAGAAGTTCT TTGCCATTAA AAACCTCCTT CTCCTGCCGG GCTCATACAC	20580
CTACGAGTGG AACTTCAGGA AGGATGTTAA CATGGTTCTG CAGAGCTCCC TAGGAAATGA	20640
CCTAAGGGTT GACGGAGCCA GCATTAAGTT TGATAGCATT TGCCCTTACG CCACCTTCTT	20700
CCCCATGGCC CACAACACCG CCTCCACGCT TGAGGCCATG CTTAGAAACG ACACCAACGA	20760
CCAGTCCTT AACGACTATC TCTCCGCCGC CAACATGCTC TACCTATAC CCGCCAACGC	20820
TACCAACGTG CCCATATCCA TCCCCTCCCG CAACTGGCG GCTTCCCGCG GCTGGCCTT	20880
CACGCGCCTT AAGACTAAGG AAACCCCATC ACTGGGCTCG GGCTACGACC CTTATTACAC	20940
CTACTCTGGC TCTATAACCT ACCTAGATGG AACCTTTAC CTCAACCACA CTTTAAGAA	21000
GGTGGCCATT ACCTTGACT CTTCTGTCACTG CTGGCCTGGC AATGACCGCC TGCTTACCC	21060
CAACGAGTTT GAAATTAAGC GCTCAGTGA CGGGGAGGGT TACAACGTTG CCCAGTGTAA	21120
CATGACCAAA GACTGGTCC TGGTACAAAT GCTAGCTAAC TACAACATTG GCTACCAGGG	21180
CTTCTATATC CCAGAGAGCT ACAAGGACCG CATGTAATCC TTCTTAGAA ACTTCCAGCC	21240
CATGAGCCGT CAGGTGGTGG ATGATACTAA ATACAAGGAC TACCAACAGG TGGGCATCCT	21300
ACACCAACAC ACAACTCTG GATTTGTTGG CTACCTGCC CCCACCATGC GCGAAGGACA	21360
GGCCTACCCCT GCTAACTTCC CCTATCCGCT TATAGGCAAG ACCGCAGTTG ACAGCATTAC	21420
CCAGAAAAAG TTTCTTGCG ATCGCACCCCT TTGGCGCATC CCATTCTCCA GTAACTTTAT	21480

GTCCATGGGC GCACTCACAG ACCTGGCCA AACCTTCTC TACGCCAAT CCGCCCACGC	21540
GCTAGACATG ACTTTGAGG TGGATCCCATT GGACGAGCCC ACCCTCTTT ATGTTTGTT	21600
TGAAGTCTT GACGTGGTCC GTGTGCACCG GCCGCACCGC GGCGTCATCG AAACCGTGTAA	21660
CCTGCGCACG CCCTTCTCGG CGGGCAACGC CACAACATAA AGAAGCAAGC AACATCAACAA	21720
ACAGCTGCCG CCATGGGCTC CAGTGAGCAG GAACTGAAAG CCATTGTCAA AGATCTTGGT	21780
TGTGGGCCAT ATTTTTGGG CACCTATGAC AAGCGCTTC CAGGCTTGT TTCTCCACAC	21840
AAGCTCGCCT GCGCCATAGT CAATACGGCC GGTCGCGAGA CTGGGGCGT ACACTGGATG	21900
GCCTTGCGCT GGAACCCGCA CTCAAAAACA TGCTACCTCT TTGAGCCCTT TGGCTTTCT	21960
GACCAGCGAC TCAAGCAGGT TTACCAAGT GAGTACGAGT CACTCCTGCG CCGTAGCGCC	22020
ATTGCTTCTT CCCCCGACCG CTGTATAACG CTGGAAAAGT CCACCCAAAG CGTACAGGGG	22080
CCCAACTCGG CCGCCTGTGG ACTATTCTGC TGCATGTTTC TCCACGCCTT TGCCAACTGG	22140
CCCCAAACTC CCATGGATCA CAACCCACC ATGAACCTTA TTACCGGGT ACCCAAACCTCC	22200
ATGCTCAACA GTCCCCAGGT ACAGCCCACC CTGCGTCGCA ACCAGGAACA GCTCTACAGC	22260
TTCCCTGGAGC GCCACTCGCC CTACTTCCGC AGCCACAGTG CGCAGATTAG GAGCGCCACT	22320
TCTTTTGTC ACTTGAAAAA CATGTAAAAA TAATGTACTA GAGACACTTT CAATAAAGGC	22380
AAATGTTTT ATTGTACAC TCTCGGGTGA TTATTTACCC CCACCCCTGC CGTCTGCGCC	22440
GTTTAAAAAT CAAAGGGGTT CTGCCGCGCA TCGCTATGCG CCACTGGCAG GGACACGTTG	22500
CGATACTGGT GTTTAGTGCT CCACTTAAAC TCAGGCACAA CCATCCGCGG CAGCTCGGTG	22560
AAGTTTTAC TCCACAGGCT GCGCACCATC ACCAACGCGT TTAGCAGGTC GGGCGCCGAT	22620
ATCTTGAACT CGCAGTTGGG GCCTCCGCC TGCGCGCG AGTTGCGATA CACAGGGTTG	22680
CAGCACTGGA ACACATACAG CGCCGGGTGG TGCACGCTGG CCAGCACGCT CTTGTCGGAG	22740
ATCAGATCCG CGTCAGGTC CTCCGCGTT CTCAGGGCGA ACGGAGTCAA CTTTGGTAGC	22800
TGCCTTCCA AAAAGGGCGC GTGCCAGGC TTTGAGTTGC ACTCGCACCG TAGTGGCATC	22860
AAAAGGTGAC CGTGCCCGGT CTGGCGTTA GGATACAGCG CCTGCATAAA AGCCTTGATC	22920
TGCTTAAAG CCACCTGAGC CTTTGCCT TCAGAGAAGA ACATGCCGCA AGACTTGCG	22980
GAAAAGTGT GGGCGGACA GGCGCGTCG TGCGCGCAG ACCTTGCCTC GGTGTTGGAG	23040
ATCTGCACCA CATTGCGCC CCACCGGTT TTCACGATCT TGGCCTTGCT AGACTGCTCC	23100
TTCAGCGCGC GCTGCCCGTT TCGCTCGTC ACATCCATT CAATCACGTG CTCCATTATT	23160
ATCATAATGC TTCCGTGTAG ACACCTAACG TCGCCTCGA TCTCAGCGCA GCGGTGCAGC	23220
CACAACGCGC AGCCCGTGGG CTCGTGATGC TTGTAGGTCA CCTCTGCAAA CGACTGCAGG	23280
TACGCCCTGCA GGAATCGCCC CATCATCGTC ACAAAAGGTCT TGTGCTGGT GAAGGGTCAGC	23340
TGCAACCCGC GGTGCTCCTC GTTCAGGCCAG GTCTTGCATA CGGGCGCCAG AGCTTCCACT	23400
TGGTCAGGCA GTAGTTTGAA GTTCGCTTT AGATCGTTAT CCACGTGGTA CTTGTCCATC	23460
AGCGCGCGC CAGCCCTCCAT GCCCTTCTCC CACGCAGACA CGATCGGCAC ACTCAGCGGG	23520
TTCATCACCG TAATTTCACT TTCCGCTTCG CTGGGCTCTT CCTCTTCCCTC TTGCGTCCGC	23580

ATACCACGCG	CCACTGGGTC	GTCTTCATT	AGCCGCCGCA	CTGTGCGCTT	ACCTCCTTG	23640
CCATGTTGA	TTAGCACCGG	TGGGTTGCTG	AAACCCACCA	TTTGTAGCGC	CACATCTTCT	23700
CTTTCTTCCT	CGCTGTCCAC	GATTACCTCT	GGTGATGGCG	GGCGCTCGGG	CTTGGGAGAA	23760
GGGCCTTCT	TTTTCTTCTT	GGCGCAATG	GCCAAATCCG	CCGCCGAGGT	CGATGGCCGC	23820
GGGCTGGGTG	TGCGCGGCAC	CAGCGCGTCT	TGTGATGAGT	CTTCCTCGTC	CTCGGACTCG	23880
ATACGCCGCC	TCATCCGCTT	TTTGGGGGC	GCCCGGGGAG	GC GGCGGCGA	CGGGGACGGG	23940
GACGACACGT	CCTCCATGGT	TGGGGGACGT	CGCGCCGCAC	CGCGTCCGCG	CTCGGGGGTG	24000
GTTCGCGCT	GCTCCTCTTC	CCGACTGGCC	ATTCCTTCT	CCTATAGGCA	GAAAAAGATC	24060
ATGGAGTCAG	TCGAGAAGAA	GGACAGCCTA	ACCGCCCCCT	CTGAGTTCGC	CACCACCGCC	24120
TCCACCGATG	CCGCCAACGC	GCCTACCACC	TTCCCCGTG	AGGCACCCCC	GCTTGAGGAG	24180
GAGGAAGTGA	TTATCGAGCA	GGACCCAGGT	TTTGTAAAGCG	AAGACGACGA	GGACCGCTCA	24240
GTACCAACAG	AGGATAAAAAA	GCAAGACCAG	GACAACGCAG	AGGCAAACGA	GGAACAAGTC	24300
GGGCGGGGGG	ACGAAAGGC	TGGCGACTAC	CTAGATGTGG	GAGACGACGT	GCTGTTGAAG	24360
CATCTGCAGC	GCCAGTGC	CATTATCTGC	GACCGTTGC	AAGAGCGCAG	CGATGTGCC	24420
CTCGCCATAG	CGGATGTCAG	CCTTGCTAC	GAACGCCACC	TATTCTCACC	GCGCGTACCC	24480
CCCAAACGCC	AAGAAAACGG	CACATGCGAG	CCCAACCCGC	GCCTCAACTT	CTACCCCGTA	24540
TTTGCCGTGC	CAGAGGTGCT	TGCCACCTAT	CACATCTTT	TCCAAAATG	CAAGATAACCC	24600
CTATCCTGCC	GTGCCAACCG	CAGCCGAGCG	GACAAGCAGC	TGGCCTTGCG	GCAGGGCGCT	24660
GTCATACCTG	ATATCGCTC	GCTCAACGAA	GTGCCAAAAA	TCTTGAGGG	TCTTGGACGC	24720
GACGAGAACG	GCGCGGCAAA	CGCTCTGCAA	CAGGAAAACA	GCGAAAATGA	AAGTCACTCT	24780
GGAGTGTG	TGGAACCTGA	GGGTGACAAC	GCGCGCCTAG	CCGTACTAAA	ACGCAGCATC	24840
GAGGTCACCC	ACTTTGCC	CCCAGCACTT	AACCTACCCC	CCAAGGTCAT	GAGCACAGTC	24900
ATGAGTGAGC	TGATCGTGC	CCGTGCGCAG	CCCCTGGAGA	GGGATGCAA	TTTGCAAGAA	24960
CAAACAGAGG	AGGGCCTACC	CGCAGTTGGC	GACGAGCAGC	TAGCGCGCTG	GCTTCAAACG	25020
CGCGAGCCTG	CCGACTTGGA	GGAGCGACGC	AAACTAATGA	TGGCCGCAGT	GCTCGTTACC	25080
GTGGAGCTTG	AGTGCATGCA	GCGTTCTT	GCTGACCCGG	AGATGCAGCG	CAAGCTAGAG	25140
GAAACATTGC	ACTACACCTT	TCGACAGGGC	TACGTACGCC	AGGCCTGCAA	GATCTCCAAC	25200
GTGGAGCTCT	GCAACCTGGT	CTCCTACCTT	GGAAATTTC	ACGAAAACCG	CCTTGGGCAA	25260
AACGTGCTTC	ATTCCACGCT	CAAGGGCGAG	GCGCGCCGCG	ACTACGTCCG	CGACTGCGTT	25320
TACTTATTTC	TATGCTACAC	CTGGCAGACG	GCCATGGGGC	TTTGGCAGCA	GTGCTTGGAG	25380
GAGTGCAACC	TCAAGGAGCT	GCAGAAAATG	CTAAAGCAA	ACTTGAAGGA	CCTATGGACG	25440
GCCTTCAACG	AGCGCTCCGT	GGCGCGCAC	CTGGCGGACA	TCATTTCCC	CGAACGCC	25500
CTTAAAACCC	TGCAACAGGG	TCTGCCAGAC	TTCACCAGTC	AAAGCATGTT	GCAGAACTTT	25560
AGGAACCTTA	TCCTAGAGCG	CTCAGGAATC	TTGCCCGCCA	CCTGCTGTGC	ACTTCCTAGC	25620
GA CTTTGTC	CCATTAAGTA	CCCGGAATGC	CCTCCGCC	TTTGGGGCCA	CTGCTACCTT	25680

CTGCAGCTAG CCAAATACCT TGCCTACCAAC TCTGACATAA TGGAAGACGT GAGCGGTGAC	25740
GGTCTACTGG AGTGTCACTG TCGCTGCAAC CTATGCACCC CGCACCGCTC CCTGGTTTGC	25800
AATTGCGAGC TGCTTAACGA AAGTCAAATT ATCGGTACCT TTGAGCTGCA GGGTCCCTCG	25860
CCTGACGAAA AGTCCGCGGC TCCGGGTTG AACTCACTC CGGGGCTGTG GACGTGGCT	25920
TACCTTCGCA AATTGTACC TGAGGACTAC CACGCCACG AGATTAGGTT CTACGAAGAC	25980
CAATCCCGCC CGCCAAATGC GGAGCTTACC GCCTGCGTCA TTACCCAGGG CCACATTCTT	26040
GGCCAATTGC AAGCCATCAA CAAAGCCCGC CAAGAGTTTC TGCTACGAAA GGGACGGGGG	26100
GTTTACTTGG ACCCCCAGTC CGGCGAGGAG CTCAACCCAA TCCCCCGCC GCCGCAGCCC	26160
TATCAGCAGC AGCCGGGGC CCTTGCTTCC CAGGATGGCA CCCAAAAAGA AGCTGCAGCT	26220
GCCGCCGCCA CCCACGGACG AGGAGGAATA CTGGGACAGT CAGGCAGAGG AGGTTTTGGA	26280
CGAGGAGGAG GAGGACATGA TGGAAGACTG GGAGAGCCTA GACGAGGAAG CTTCCGAGGT	26340
CGAAGAGGTG TCAGACGAAA CACCGTCACC CTCGGTCGA TTCCCCTCGC CGGCGCCCA	26400
GAAATCGGCA ACCGGTTCCA GCATGGCTAC AACCTCCGCT CCTCAGGCGC CGCCGGCACT	26460
GCCC GTTGC CGACCCAACC GTAGATGGGA CACCACTGGA ACCAGGGCCG GTAAGTCAA	26520
GCAGCCGCCG CCGTTAGCCC AAGAGCAACA ACAGCGCAA GGCTACCGCT CATGGCGCG	26580
GCACAAGAAC GCCATAGTTG CTTGCTTGCA AGACTGTGGG GGCAACATCT CCTTCGCCG	26640
CCGCTTCTT CTCTACCATC ACGGCGTGGC CTTCCCCGT AACATCCTGC ATTACTACCG	26700
TCATCTCTAC AGCCCATACT GCACCGGCCG CAGCGCAGC GGCAGCAACA GCAGCGCCA	26760
CACAGAAGCA AAGGGACCG GATAGCAAGA CTCTGACAAA GCCCAAGAAA TCCACAGCGG	26820
CGGCAGCAGC AGGAGGAGGA GCGCTGCGTC TGGCGCCAA CGAACCCGTA TCGACCCGCG	26880
AGCTTAGAAA CAGGATTTT CCCACTCTGT ATGCTATATT TCAACAGAGC AGGGGCCAAG	26940
AACAAGAGCT GAAAATAAA AACAGGTCTC TGCGATCCCT CACCCGCAGC TGCTGTATC	27000
ACAAAAGCGA AGATCAGCTT CGGCGCACGC TGGAAGACGC GGAGGCTCTC TTCAGTAAAT	27060
ACTGCGCGCT GACTCTTAAG GACTAGTTTC GCGCCCTTTC TCAAATTAA GCGCGAAAAC	27120
TACGTCATCT CCAGCGCCA CACCCGGCGC CAGCACCTGT CGTCAGCGCC ATTATGAGCA	27180
AGGAAATTCC CACGCCCTAC ATGTGGAGTT ACCAGCCACA AATGGGACTT GCGGCTGGAG	27240
CTGCCAAGA CTACTCAACC CGAATAAAACT ACATGAGCGC GGGACCCAC ATGATATCCC	27300
GGGTCAACGG AATCCGCGCC CACCGAAACC GAATTCTT GGAAACAGGCG GCTATTACCA	27360
CCACACCTCG TAATAACCTT AATCCCCGTA GTTGGCCCGC TGCCCTGGTG TACCAAGAAA	27420
GTCCCGCTCC CACCACTGTG GTACTTCCCA GAGACGCCA GGCGGAAGTT CAGATGACTA	27480
ACTCAGGGGC GCAGCTTGC GGGCGCTTTC GTCACAGGGT GCGGTCGCC GGGCAGGGTA	27540
TAACTCACCT GACAATCAGA GGGCGAGGT AATGCTCAA CGACGAGTCG GTGAGCTCCT	27600
CGCTTGGTCT CCGTCCGGAC GGGACATTTG AGATCGGGCG CGCCGGCCGT CCTTCATTCA	27660
CGCCTCGTCA GGCAATCCTA ACTCTGCAGA CCTCGCCTC TGAGCCGCGC TCTGGAGGCA	27720
TTGGAACCTCT GCAATTATT GAGGAGTTTG TGCCATCGGT CTACTTTAAC CCCTTCTCGG	27780

GACCTCCCCG	CCACTATCCG	GATCAATTAA	TTCCTAACCT	TGACCGGGTA	AAGGACTCGG	27840		
CGGACGGCTA	CGACTGAATG	TTAAGTGGAG	AGGCAGAGCA	ACTGCGCCTG	AAACACCTGG	27900		
TCCACTGTG	CGGCCACAAG	TGCTTGC	CGACTCCGG	TGAGTTTG	TACTTTGAAT	27960		
TGCCCCGAGGA	TCATATCGAG	GGCCCGGC	ACGGCGTCCG	GCTTACCGCC	CAGGGAGAGC	28020		
TTGCCCGTAG	CCTGATTG	GAGTTACCC	AGCGCCCCCT	GCTAGTTGAG	CGGGACAGGG	28080		
GACCTGTGT	TCTCACTGTG	ATTGCAACT	GTCCTAACCT	TGGATTACAT	CAAGATCTT	28140		
GTTGCCATCT	CTGTG	TATAATAAT	ACAGAAATTA	AAATATACTG	GGGCTCCTAT	28200		
CGCCATCCTG	TAAACGCCAC	CGTCTTCACC	CGCCAAGCA	AACCAAGGCG	AACCTTACCT	28260		
GGTACTTTA	ACATCTCTCC	CTCTG	TACAACAGIT	TCAACCCAGA	CGGAGTGAGT	28320		
CTACGAGAGA	ACCTCTCCGA	GCTCAGCTAC	TCCATCAGAA	AAAACACCAC	CCTCCTTACC	28380		
TGCCGGGAAC	GTACGAGTGC	GTCACCGGCC	GCTGCAC	ACCTACCGCC	TGACCGTAAA	28440		
CCAGACTTTT	TCCGGACAGA	CCTCAATAAC	TCTGTTTAC	AGAACAGGAG	GTGAGCTTAG	28500		
AAAACCTTA	GGGTATTAGG	CCAAAGGCGC	AGCTACTGTG	GGGTTATGA	ACAATTCAAG	28560		
CAACTCTACG	GGCTATTCTA	ATTCA	GAGTTT	CTCTAGAATC	GGGGTTGGGG	TTATTCTCTG	28620	
TCTTG	GATT	CTCTTATTTC	TTATACTAAC	GCTTCTCTGC	CTAAGGCTCG	CCGCCTGCTG	28680	
TGTGCACATT	TGCATT	TATT	GTCA	GCTTTT	TAAACGCTGG	GGTCGCCACC	CAAGATGATT	28740
AGGTACATAA	TCCTAGGTTT	ACTCACCC	CGTCAGCCC	ACGGTAC	ACACCC	CCAAAAGGTG	28800	
GATTTAAGG	AGCCAGCCTG	TAATGTTACA	TTCGCAGCTG	AAGCTAATGA	GTGCACC	ACT	28860	
CTTATAAAAT	GCACCACAGA	ACATGAAAG	CTGCTTATTC	GCCACAAAAA	CAAATTGGC	28920		
AAGTATGCTG	TTTATGCTAT	TTGGCAGCCA	GGTGACACTA	CAGAGTATAA	TGTTACAGTT	28980		
TTCCAGGGTA	AAAGTCATAA	AACTTTATG	TATACTTTC	CATT	TTATGA	AATGTGCGAC	29040	
ATTACCATGT	ACATGAGCAA	ACAGTATAAG	TTGTGGCCCC	CACAAAATTG	TGTGGAAAAC	29100		
ACTGGCACTT	TCTGCTGCAC	TGCTATGCTA	ATTACAGTGC	TCGCTTGGT	CTGTACCC	TA	29160	
CTCTATATTA	AATACAAAAG	CAGACGCAGC	TTTATTGAGG	AAAAGAAAAT	GCCTTAATT	29220		
ACTAAGTTAC	AAAGCTAATG	TCACCACTAA	CTGCTTACT	CGCTGCTTGC	AAAACAAATT	29280		
CAAAAAGTTA	GCATTATAAT	TAGAATAGGA	TTTAAACCCC	CCGGTCATTT	CCTGCTCAAT	29340		
ACCATTCCCC	TGAACAATTG	ACTCTATGTG	GGATATGCTC	CAGCGCTACA	ACCTTGAAGT	29400		
CAGGCTTCC	GGATGTCAGC	ATCTGACTTT	GGCCAGCACC	TGTCCCGCGG	ATTGTTCCA	29460		
GTCCAAC	TAC	AGCGACCCAC	CCTAACAGAG	ATGACCAACA	CAACCAACGC	GGCCGCCGCT	29520	
ACCGGACTTA	CATCTACCAC	AAATACACCC	CAAGTTCTG	CCTTGTCAA	TAAC	TTGGGAT	29580	
AACTTGGGCA	TGTGGTGGTT	CTCCATAGCG	CTTATGTTG	TATGCCTTAT	TATTATGTGG	29640		
CTCATCTGCT	GCCTAAAGCG	CAAACGCGCC	CGACCACCC	TCTATAGTCC	CATCATTGTG	29700		
CTACACCCAA	ACAATGATGG	AATCCATAGA	TTGGACGGAC	TGAAACACAT	GTTCTTTCT	29760		
CTTACAGTAT	GATTAAATGA	GACATGATT	CTCGAGTTT	TATATTACTG	ACCC	TTGTTG	29820	
CGCTTTTTG	TGCGTGCTCC	ACATTGGCTG	CGGTTCTCA	CATCGAAGTA	GACTGCATTC	29880		

WO 98/17783

PCT/US97/19541

CAGCCTTCAC AGTCTATTTG CTTTACGGAT TTGTCACCCCT CACGCTCATC TGCAGCCTCA	29940
TCACTGTGGT CATGCCCTT ATCCAGTGCA TTGACTGGGT CTGTGTGCGC TTTGCATATC	30000
TCAGACACCCA TCCCCAGTAC AGGGACAGGA CTATAGCTGA GCTTCTTAGA ATTCTTTAAT	30060
TATGAAATT ACTGTGACTT TTCTGCTGAT TATTTGCACC CTATCTGCGT TTTGTTCCCC	30120
GACCTCCAAG CCTCAAAGAC ATATATCATG CAGATTCACT CGTATATGGA ATATTCCAAG	30180
TTGCTACAAT GAAAAAAAGCG ATCTTCCGA AGCCTGGTTA TATGCAATCA TCTCTGTTAT	30240
GGTGTCTGC AGTACCATCT TAGCCCTAGC TATATATCCC TACCTTGACA TTGGCTGGAA	30300
ACGAATAGAT GCCATGAACC ACCCAACTT CCCCAGGCC GCTATGCTTC CACTGCAACA	30360
AGTTGTTGCC GGCGGTTTG TCCCAGCCAA TCAGCCTCGC CCCACTTCTC CCACCCCCAC	30420
TGAAATCAGC TACTTTAACAT TAACAGGAGG AGATGACTGA CACCCTAGAT CTAGAAATGG	30480
ACGGAATTAT TACAGAGCAG CGCCTGCTAG AAAGACGCAG GGCAAGGGCC GAGCAACAGC	30540
GCATGAATCA AGAGCTCCAA GACATGGTTA ACTTGCACCA GTGCAAAAGG GGTATCTTT	30600
GTCTGGTAAA GCAGGCCAA GTCACCTACG ACAGTAATAC CACCGACAC CGCCTTAGCT	30660
ACAAGTTGCC AACCAAGCGT CAGAAATTGG TGGTCATGGT GGGAGAAAAG CCCATTACCA	30720
TAACTCAGCA CTCGGTAGAA ACCGAAGGCT GCATTCACTC ACCTTGTCAA GGACCTGAGG	30780
ATCTCTGCAC CCTTATTAAG ACCCTGTGCG GTCTCAAAGA TCTTATTCCC TTTAACTAAT	30840
AAAAAAAAAT AATAAAGCAT CACTTACTTA AAATCAGTTA GCAAATTCT GTCCAGTTTA	30900
TTCAGCAGCA CCTCCTTGCC CTCCCTCCAG CTCTGGTATT GCAGCTTCCT CCTGGCTGCA	30960
AACTTCTCC ACAATCTAAA TGGAATGTCA GTTTCCTCCT GTTCCGTGCC ATCCGCACCC	31020
ACTATCTTCA TGTTGTTGCA GATGAAGCGC GCAAGACCGT CTGAAGATAC CTTCAACCCC	31080
GTGTATCCAT ATGACACGGA AACCGGTCCCT CCAACTGTGC CTTTCTTAC TCCTCCCTTT	31140
GTATCCCCA ATGGGTTCA AGAGAGTCCC CCTGGGGTAC TCTCTTGCG CCTATCCGAA	31200
CCTCTAGTTA CCTCCAATGG CATGCTTGCG CTCAAAATGG GCAACGGCCT CTCTCTGGAC	31260
GAGGCCGGCA ACCTTACCTC CCAAAATGTA ACCACTGTGA GCCCACCTCT CAAAAAAACC	31320
AAGTCAAACA TAAACCTGGA AATATCTGCA CCCCTCACAG TTACCTCAGA AGCCCTAACT	31380
GTGGCTGCCG CCGCACCTCT AATGGTCGCG GGCAACACAC TCACCATGCA ATCACAGGCC	31440
CCGCTAACCG TGCACGACTC CAAACTTAGC ATTGCCACCC AAGGACCCCT CACAGTGTCA	31500
GAAGGAAAGC TAGCCCTGCA AACATCAGGC CCCCTCACCA CCACCGATAG CAGTACCCCTT	31560
ACTATCACTG CCTCACCCCC TCTAACTACT GCCACTGGTA GCTTGGGCAT TGACTTGAAA	31620
GAGCCCATT ATACACAAAA TGGAAAAGTA GGACTAAAGT ACGGGGCTCC TTTGCATGTA	31680
ACAGACGACC TAAACACTTT GACCGTAGCA ACTGGTCCAG GTGTGACTAT TAATAAACT	31740
TCCTTGCAAA CTAAAGTTAC TGGAGCCTTG GGTTTGATT CACAAGGCAA TATGCAACTT	31800
AATGTAGCAG GAGGACTAAG GATTGATTCT CAAACAGAC GCCTTATACT TGATGTTAGT	31860
TATCCGTTTG ATGCTAAAA CCAACTAAAT CTAAGACTAG GACAGGGCCC TCTTTTATA	31920
AACTCAGCCC ACAACTTGGA TATTAACTAC AACAAAGGCC TTTACTTGTT TACAGCTTCA	31980

AACAATTCCA AAAAGCTTGA GGTTAACCTA AGCACTGCCA AGGGGTTGAT GTTGACGCT	32040
ACAGCCATAG CCATTAATGC AGGAGATGGG CTTGAATTG GTTCACCTAA TGCACCAAAC	32100
ACAAATCCCC TCAAAACAAA AATTGGCCAT GGCTAGAAT TTGATTCAAA CAAGGCTATG	32160
GTTCCCTAAC TAGGAACTGG CCTTAGTTT GACAGCACAG GTGCCATTAC AGTAGGAAAC	32220
AAAAATAATG ATAAGCTAAC TTTGTGGACC ACACCAGCTC CATCTCCTAA CTGTAGACTA	32280
AATGCAGAGA AAGATGCTAA ACTCACTTG GTCTTAACAA AATGTGGCAG TCAAATACTT	32340
GCTACAGTTT CAGTTTGGC TGTTAAAGGC AGTTTGGCTC CAATATCTGG AACAGTTCAA	32400
AGTGCTCATC TTATTATAAG ATTTGACGAA AATGGAGTGC TACTAAACAA TTCCTTCCTG	32460
GACCCAGAAT ATTGGAACIT TAGAAATGGA GATCTTACTG AAGGCACAGC CTATACAAAC	32520
GCTGTTGGAT TTATGCCTAA CCTATCAGCT TATCCAAAAT CTCACGGTAA AACTGCCAAA	32580
AGTAACATTG TCAGTCAAGT TTACTTAAAC GGAGACAAAA CTAAACCTGT AACACTAAC	32640
ATTACACTAA ACGGTACACA GGAAACAGGA GACACAACTC CAAGTGCATA CTCTATGTCA	32700
TTTTCATGGG ACTGGTCTGG CCACAACTAC ATTAATGAAA TATTTGCCAC ATCCTCTTAC	32760
ACTTTTCAT ACATTGCCA AGAATAAAGA ATCGTTGTG TTATGTTCA ACGTGTATTAT	32820
TTTTCAATTG CAGAAAATT CAAGTCATTT TTCATTCACT AGTATAGCCC CACCACCACA	32880
TAGCTTATAC AGATCACCGT ACCCTTAATCA AACTCACAGA ACCCTAGTAT TCAACCTGCC	32940
ACCTCCCTCC CAACACACAG AGTACACAGT CCTTCTCCC CGGCTGGCCT TAAAAAGCAT	33000
CATATCATGG GTAACAGACA TATTCTTAGG TGTTATATTC CACACGGTTT CCTGTCGAGC	33060
CAAACGCTCA TCAGTGATAT TAATAAACTC CCCGGGCAGC TCACTTAAGT TCATGTCGCT	33120
GTCCAGCTGC TGAGCCACAG GCTGCTGTCC AACTTGCAGT TGCTTAACGG GCGGCGAAGG	33180
AGAAGTCCAC GCCTACATGG GGGTAGAGTC ATAATCGTGC ATCAGGATAG GCGGGTGGTG	33240
CTGCAGCAGC GCGCGAATAA ACTGCTGCCG CCGCCGCTCC GTCTGCAGG AATACAACAT	33300
GGCAGTGGTC TCCTCAGCGA TGATTGCGAC CGCCCGCAGC ATAAGGGGCC TTGTCCCTCCG	33360
GGCACAGCAG CGCACCCCTGA TCTCACTTAA ATCAGCACAG TAACTGCAGC ACAGCACCCAC	33420
AATATTGTTA AAAATCCCAC AGTGCAAGGC GCTGTATCCA AAGCTCATGG CGGGGACCAC	33480
AGAACCCACG TGGCCATCAT ACCACAAGCG CAGGTAGATT AAGTGGCGAC CCCTCATAAA	33540
CACGCTGGAC ATAAACATTA CCTCTTTGG CATGTTGTAATTCACCCACCT CCCGGTACCA	33600
TATAAACCTC TGATTAACAC TGGCGCCATC CACCACCATC CTAAACCAGC TGGCCAAAAC	33660
CTGCCCGCCG GCTATACACT GCAGGGAACCC GGGACTGGAA CAATGACAGT GGAGAGCCCA	33720
GGACTCGTAA CCATGGATCA TCATGCTCGT CATGATATCA ATGTTGGCAC AACACAGGCA	33780
CACGTGCATA CACTCCTCA GGATTACAAG CTCCCTCCGC GTTAGAACCA TATCCCAGGG	33840
AACAACCCAT TCCTGAATCA GCGTAAATCC CACACTGCAG GGAAGACCTC GCACGTAAC	33900
CACGTTGTGC ATTGTCAAAG TGTTACATTG GGGCAGCAGC GGATGATCCT CCAGTATGGT	33960
AGCGCGGGTT TCTGTCTCAA AAGGAGGTAG ACGATCCCTA CTGTACGGAG TGCGCCGAGA	34020
CAACCGAGAT CGTGTGGTC GTAGTGTCAATGCCAAATGGA ACGCCGGACG TAGTCATATT	34080

TCCTGAAGCA AAACCAGGTG CGGGCGTGAC AAACAGATCT GCGTCTCCGG TCTCGCCGCT 34140
 TAGATCGCTC TGTGTAGTAG TTGTAGTATA TCCACTCTCT CAAAGCATCC AGGCGCCCCC 34200
 TGGCTTCGGG TTCTATGTAA ACTCCTTCAT GCGCCGCTGC CCTGATAACA TCCACCACCG 34260
 CAGAATAAGC CACACCCAGC CAACCTACAC ATTCGTTCTG CGAGTCACAC ACGGGAGGAG 34320
 CGGGAAGAGC TGGAAAGAACC ATGTTTTTTT TTTTATTCCA AAAGATTATC CAAAACCTCA 34380
 AAATGAAGAT CTATTAAGTG AACCGCGCTCC CCTCCGGTGG CGTGGTCAAA CTCTACAGCC 34440
 AAAGAACAGA TAATGGCATT TGTAAGATGT TGCAACAATGG CTTCCAAAAG GCAAACGGCC 34500
 CTCACGTCCA AGTGGACGTA AAGGCTAAAC CCTTCAGGGT GAATCTCCTC TATAAACATT 34560
 CCAGCACCTT CAACCATGCC CAAATAATT TCATCTCGCC ACCTTCTCAA TATATCTCTA 34620
 AGCAAATCCC GAATATTAAG TCCGGCCATT GTAAAAATCT GCTCCAGAGC GCCCTCCACC 34680
 TTCAGCCTCA AGCAGCGAAT CATGATTGCA AAAATTCAAG TTCTCACAG ACCTGTATAA 34740
 GATTCAAAAG CGGAACATTA ACAAAAATAC CGCGATCCCG TAGGTCCCTT CGCAGGGCCA 34800
 GCTGAACATA ATCGTGCAGG TCTGCACGGA CCAGCGCGC CACTTCCCCG CCAGGAACCT 34860
 TGACAAAAGA ACCCACACTG ATTATGACAC GCATACTCGG AGCTATGCTA ACCAGCGTAG 34920
 CCCCAGATGTA AGCTTTGTTG CATGGCGGC GATATAAAAT GCAAGGTGCT GCTCAAAAAA 34980
 TCAGGCAAAG CCTCGCGCAA AAAAGAAAGC ACATCGTAGT CATGCTCATG CAGATAAAAGG 35040
 CAGGTAAGCT CGGGAACAC CACAGAAAAA GACACCATT TTCTCTCAA CATGTCTGCG 35100
 GGTTTCTGCA TAAACACAAA ATAAAATAAC AAAAAAACAT TTAAACATTA GAAGCCTGTC 35160
 TTACAACAGG AAAAACAAACC CTTATAAGCA TAAGACGGAC TACGCCATG CCGCGTGAC 35220
 CGTAAAAAAA CTGGTCACCG TGATTAAAAA GCACCACCGA CAGCTCCTCG GTCATGTCCG 35280
 GAGTCATAAT GTAAGACTCG GTAAACACAT CAGGTTGATT CATGGTCAG TGCTAAAAAG 35340
 CGACCGAAAT AGCCCCGGGG AATACATACC CGCAGGCGTA GAGACAACAT TACAGCCCCC 35400
 ATAGGAGGTA TAACAAAATT ATAGGAGAG AAAAACACAT AAACACCTGA AAAACCTCC 35460
 TGCCTAGGCA AAATAGCACC CTCCCGCTCC AGAACAAACAT ACAGCGCTTC ACAGCGGCAG 35520
 CCTAACAGTC AGCCTTACCA GTAAAAAAGA AAACCTATTA AAAAAACACC ACTCGACACG 35580
 GCACCAGCTC AATCACTCAC AGTGTAAAAA AGGGCCAAGT GCAGAGCGAG TATATATAGG 35640
 ACTAAAAAAT GACGTAACGG TTAAAGTCCA CAAAAAACAC CCAGAAAACC GCACGCGAAC 35700
 CTACGCCAG AAACGAAAGC CAAAAAACCC ACAACTTCCT CAAATCGTCA CTTCCGTTTT 35760
 CCCACGTTAC GTAACCTCCC ATTTTAAGAA AACTACAATT CCCAACACAT ACAAGTTACT 35820
 CCGCCCTAAA ACCTACGTCA CCCGCCCCGT TCCCACGCC CGCGCCACGT CACAAACTCC 35880
 ACCCCCTCAT TATCATATTG GCTTCAATCC AAAATAAGGT ATATTATTGA TGATG 35935

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TTCATTTAT GTTTCAGGTT CAGGG

25

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTACCGCCAC ACTCGCAGGG

20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34303 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTATTTGGA TTGAAGCAA TATGATAATG AGGGGGTGA GTTTGTGACG TGGCGCGGGG	60
CGTGGGAACG GGGCGGGTGA CGTAGTAGTG TGGCGGAAGT GTGATGTTGC AAGTGTGGCG	120
GAACACATGT AAGCGACGGA TGTGGCAAAA GTGACGTTT TGGTGTGCGC CGGATCCACA	180
GGACGGGTGT GGTGCCATG ATCGCGTAGT CGATAGTGGC TCCAAGTAGC GAAGCGAGCA	240
GGACTGGGCG GC GGCCAAAG CGGTCGGACA GTGCTCCGAG AACGGGTGCG CATAGAAATT	300
GCATCAACGC ATATAGCGCT AGCAGCACGC CATA GTGACT GGCGATGCTG TCGGAATGGA	360
CGATATCCCC CAAGAGGCC GGCAGTACCG GCATAACCAA GCCTATGCCT ACAGCATCCA	420
GGGTGACGGT GCCGAGGATG ACGATGAGCG CATTGTTAGA TTCATACAC GGTGCCTGAC	480
TGCGTTAGCA ATTAACTGT GATAAACTAC CGCATTAAG CTTATCGATG ATAAGCTGTC	540
AAACATGAGA ATTCTTGAAG ACGAAAGGGC CTCGTGATAC GCCTATTTT ATAGGTTAAT	600
GTCATGATAA TAATGGTTTC TTAGACGTCA GGTGGCACTT TTCGGGGAAA TGTGCGCGGA	660
ACCCCTATTT GTTTATTTT CTAAATACAT TCAAATATGT ATCCGCTCAT GAGACAATAA	720
CCCTGATAAA TGCTTCAATA ATATTGAAAA AGGAAGAGTA TGAGTATTCA ACATTTCCGT	780
GTCGCCCTTA TTCCCTTTT TGCAGCATTG TGCCTTCCTG TTTTGCTCA CCCAGAAACG	840
CTGGTAAAG TAAAAGATGC TGAAGATCAG TTGGGTGCAC GAGTGGTTA CATCGAACTG	900
GATCTCAACA GCGGTAAGAT CCTTGAGAGT TTTCGCCCCG AAGAACGTTT TCCAATGATG	960
AGCACTTTA AAGTTCTGCT ATGTGGCGCG GTATTATCCC GTGTTGACGC CGGGCAAGAG	1020
CAACTCGGTC GCCGCATACA CTATTCTCAG AATGACTTGG TTGAGTACTC ACCAGTCACA	1080

GAAAAGCATC TTACGGATGG CATGACAGTA AGAGAATTAT GCAGTGCTGC CATAACCATG	1140
AGTGATAACA CTGCGGCCAA CTTACTCTG ACAACGATCG GAGGACCGAA GGAGCTAAC	1200
GCTTTTTGC ACAACATGGG GGATCATGTA ACTCGCCTTG ATCGTTGGGA ACCGGAGCTG	1260
AATGAAGCCA TACCAAACGA CGAGCGTGC ACCACGATGC CTGCAGCAAT GGCAACAAAC	1320
TTGCGAAC TATTAACTGG CGAACTACTT ACTCTAGCTT CCCGGCAACA ATTAATAGAC	1380
TGGATGGAGG CGGATAAAAGT TGCAGGACCA CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG	1440
TTTATTGCTG ATAAATCTGG AGCCGGTGAG CGTGGGTCTC GCGGTATCAT TGCAGCACTG	1500
GGGCCAGATG GTAAGCCCTC CGGTATCGTA GTTATCTACA CGACGGGGAG TCAGGCAACT	1560
ATGGATGAAC GAAATAGACA GATCGCTGAG ATAGGTGCCT CACTGATTAA GCATTGGTAA	1620
CTGTCAGACC AAGTTTACTC ATATATACTT TAGATTGATT TAAAACTTCA TTTTTAATT	1680
AAAAGGATCT AGGTGAAGAT CCTTTTGAT AATCTCATGA CCAAAATCCC TTAACGTGAG	1740
TTTCGTTCC ACTGAGCGTC AGACCCCGTA GAAAAGATCA AAGGATCTTC TTGAGATCCT	1800
TTTTTCTGC GCGTAATCTG CTGCTTGCAA ACAAAAAAAC CACCGCTACC AGCGGTGGTT	1860
TGTTTGCAGG ATCAAGAGCT ACCAACTCTT TTTCCGAAGG TAACTGGCTT CAGCAGAGCG	1920
CAGATACCAA ATACTGTCCT TCTAGTGTAG CCGTAGTTAG GCCACCACCT CAAGAACTCT	1980
GTAGCACCGC CTACATACCT CGCTCTGCTA ATCCTGTTAC CAGTGGCTGC TGCCAGTGGC	2040
GATAAGTCGT GTCTTACCGG GTTGGACTCA AGACGATACT TACCGGATAA GGCAGCAGCG	2100
TCGGGCTGAA CGGGGGGTTG GTGCACACAG CCCAGCTTGG AGCGAACGAC CTACACCGAA	2160
CTGAGATAACC TACAGCGTGA GCATTGAGAA AGCGCCACGC TTCCCGAAGG GAGAAAGGCG	2220
GACAGGTATC CGGTAAGCGG CAGGGTCGGA ACAGGAGAGC GCACGAGGGA GCTTCCAGGG	2280
GGAAACGCCT GGTATTTTA TAGTCCTGTC GGGTTTCGCC ACCTCTGACT TGAGCGTCGA	2340
TTTTTGTGAT GCTCGTCAGG GGGGCGGAGC CTATGGAAAA ACGCCAGCAA CGCGGCCTTT	2400
TTACGGTCCC TGGCCTTTTG CTGGCCTTTT GCTCACATGT TCTTCTGTC GTTATCCCCT	2460
GATTCTGTGG ATAACCGTAT TACCGCCTTT GAGTGAGCTG ATACCGCTCG CGCGAGCCGA	2520
ACGACCGAGC GCAGCGAGTC AGTGAGCGAG GAAGCGGAAG AGCGCCTGAT GCGGTATTTT	2580
CTCCTTACGC ATCTGTGCGG TATTTCACAC CGCATATGGT GCACTCTCAG TACAATCTGC	2640
TCTGATGCCG CATACTTAAG CCAGTATACA CTCCGCTATC GCTACGTGAC TGGGTATGG	2700
CTGGCCCCCG ACACCCGCCA ACACCCGCTG ACACGCCCTG ACAGGCTTGT CTGCTCCCGG	2760
CATCCGCTTA CAGACAAGCT GTGACCGTCT CCGGGAGCTG CATGTGTCAG AGGTTTCAC	2820
CGTCATCACC GAAACCGCG AGGCAGTCTA GACAATAGTA GTACGGATAG CTGTGACTCC	2880
GGTCCTTCTA ACACACCTCC TGAGATAACAC CCGGTGGTCC CGCTGTGCC CATTAAACCA	2940
GTTGCCGTGA GAGTTGGTGG CGCTCGCCAG GCTGTGGAAT GTATCGAGGA CTTGCTTAAC	3000
GAGCCTGGGC AACCTTTGGA CTTGAGCTGT AAACGCCCA GGCCATAAGG TGTAAACCTG	3060
TGATTGCGTG TGTGGTTAAC GCCTTGTGTT GCTGAATGAG TTGATGTAAG TTTAATAAAG	3120
GGTGAGATAA TGTTAACTT GCATGGCGTG TTAAATGGGG CGGGGCTTAA AGGGTATATA	3180

ATGCGCCGTG	GGCTAATCTT	GGTTACATCT	GACCTCATGG	AGGCTTGGGA	GTGTTTGGAA	3240
GATTTTTCTG	CTGTGCGTAA	CTTGCTGGAA	CAGAGCTCTA	ACAGTACCTC	TTGGTTTGG	3300
AGGTTTCTGT	GGGGCTCATC	CCAGGCAAAG	TTAGTCTGCA	GAATTAAGGA	GGATTACAAG	3360
TGGGAATTG	AAGAGCTTT	GAATCCTGT	GGTGAGCTGT	TTGATTCTTT	GAATCTGGGT	3420
CACCAGGCGC	TTTCCAAGA	GAAGGTCATC	AAGACTTGG	ATTTTCCAC	ACCGGGGCGC	3480
GCTGCGGCTG	CTGTTGCTTT	TTTGAGTTT	ATAAAGGATA	AATGGAGCGA	AGAAACCCAT	3540
CTGAGCGGGG	GGTACCTGCT	GGATTTCTG	GCCATGCATC	TGTGGAGAGC	GGTTGTGAGA	3600
CACAAGAAC	GCCTGCTACT	GTTGCTTCC	GTCCGCCCGG	CGATAATACC	GACGGAGGAG	3660
CAGCAGCAGC	AGCAGGAGGA	AGCCAGGCGG	CGGCGGCAGG	AGCAGAGCCC	ATGGAACCCG	3720
AGAGCCGGCC	TGGACCCTCG	GGAATGAATG	TTGTACAGGT	GGCTGAACCTG	TATCCAGAAC	3780
TGAGACGCAT	TTTGACAATT	ACAGAGGATG	GGCAGGGGCT	AAAGGGGTA	AAGAGGGAGC	3840
GGGGGGCTTG	TGAGGCTACA	GAGGAGGCTA	GGAATCTAGC	TTTAGCTTA	ATGACCAGAC	3900
ACCGTCCTGA	GTGTATTACT	TTCAACAGA	TCAAGGATAA	TTGCGCTAAT	GAGCTTGATC	3960
GCTGGCGCA	GAAGTATTCC	ATAGAGCAGC	TGACCACTTA	CTGGCTGCAG	CCAGGGGATG	4020
ATTTTGAGGA	GGCTATTAGG	GTATATGCAA	AGGTGGCACT	TAGGCCAGAT	TGCAAGTACA	4080
AGATCAGCAA	ACTTGTAAAT	ATCAGGAATT	GTTGCTACAT	TTCTGGAAC	GGGGCCGAGG	4140
TGGAGATAGA	TACGGAGGAT	AGGGTGGCCT	TTAGATGTAG	CATGATAAT	ATGTGGCCGG	4200
GGGTGCTTGG	CATGGACGGG	GTGGTTATTA	TGAATGTAAG	GTTTACTGGC	CCCAATTAA	4260
GCGGTACGGT	TTCTCTGGCC	AATACCAACC	TTATCCTACA	CGGTGTAAGC	TTCTATGGGT	4320
TTAACAAATAC	CTGTGTGGAA	GCCTGGACCG	ATGTAAGGGT	TCGGGGCTGT	GCCTTTACT	4380
GCTGCTGGAA	GGGGGTGGTG	TGTCGCCCA	AAAGCAGGGC	TTCAATTAAG	AAATGCCTCT	4440
TTGAAAGGTG	TACCTGGGT	ATCCTGTCTG	AGGGTAACTC	CAGGGTGC	CACAATGTGG	4500
CCTCCGACTG	TGGTTGCTTC	ATGCTAGTGA	AAAGCGTGGC	TGTGATTAAG	CATAACATGG	4560
TATGTGGCAA	CTGCGAGGAC	AGGGCCTCTC	AGATGCTGAC	CTGCTGGAC	GGCAACTGTC	4620
ACCTGCTGAA	GACCATTAC	GTAGCCAGCC	ACTCTCGCAA	GGCCTGGCCA	GTGTTTGAGC	4680
ATAACATACT	GACCCGCTGT	TCCTTGCA	TGGGTAACAG	GAGGGGGGTG	TTCTACCTT	4740
ACCAATGCAA	TTTGAGTCAC	ACTAAGATAT	TGCTTGAGCC	CGAGAGCATG	TCCAAGGTGA	4800
ACCTGAACGG	GGTGTGGAC	ATGACCATGA	AGATCTGAA	GGTGCTGAGG	TACGATGAGA	4860
CCCGCACCAAG	GTGCAGACCC	TGCGAGTGTG	GCGGTAAACA	TATTAGGAAC	CAGCCTGTGA	4920
TGCTGGATGT	GACCGAGGAG	CTGAGGCCCG	ATCACTTGGT	GCTGGCCTGC	ACCCGGCGCTG	4980
AGTTTGGCTC	TAGCGATGAA	GATACAGATT	GAGGTACTGA	AATGTGTGGG	CGTGGCTTAA	5040
GGGTGGAAA	GAATATATAA	GGTGGGGGTC	TTATGTAGTT	TTGTATCTGT	TTTGCAGCAG	5100
CCGCCGCCGC	CATGAGCACC	AACTCGTTG	ATGGAAGCAT	TGTGAGCTCA	TATTTGACAA	5160
CGCGCATGCC	CCCATGGGCC	GGGGTGC	AGAATGTGAT	GGGCTCCAGC	ATTGATGGTC	5220
GCCCCGTCT	GCCCCGAAAC	TCTACTACCT	TGACCTACGA	GACCGTGTCT	GGAACGCCGT	5280

TGGAGACTGC AGCCTCCGCC	GGCGCTTCAG CCGCTGCAGC	CACCGCCCGC	GGGATTGTGA	5340
CTGACTTTGC TTTCCTGAGC	CCGCTTGCAA GCAGTGCAGC	TTCCCGTTCA	TCCGCCCGCG	5400
ATGACAAGTT GACGGCTCTT	TTGGCACAAT TGGATTCTT	GACCCGGAA	CTTAATGTCG	5460
TTTCTCAGCA GCTGTTGGAT	CTGCGCCAGC AGGTTTCTGC	CCTGAAGGCT	TCCCTCCCCTC	5520
CCAATGCGGT TTAAAACATA	AATAAAAAAC CAGACTCTGT	TTGGATTGG	ATCAAGCAAG	5580
TGTCTTGCTG TCTTTATTTA	GGGGTTTGC GCGCGCGTA	GGCCCGGGAC	CAGCGGTCTC	5640
GGTCGTTGAG GGTCTGTGT	ATTTTTCCA GGACGTGGTA	AAGGTGACTC	TGGATGTTCA	5700
GATACATGGG CATAAGCCCG	TCTCTGGGGT GGAGGTAGCA	CCACTGCAGA	GCTTCATGCT	5760
GCGGGGTGGT GTTGTAGATG	ATCCAGTCGT AGCAGGAGCG	CTGGCGTGG	TGCCTAAAAA	5820
TGTCTTCAG TAGCAAGCTG	ATTGCCAGGG GCAGGCCCTT	GGTGTAAAGTG	TTTACAAAGC	5880
GGTTAACGCTG GGATGGGTGC	ATACGTGGGG ATATGAGATG	CATCTGGAC	TGTATTTTA	5940
GGTTGGCTAT GTTCCCAGCC	ATATCCCTCC GGGGATTCAT	GTTGTGCAGA	ACCACCAGCA	6000
CAGTGTATCC GGTGCACTTG	GGAAATTGT CATGTAGCTT	AGAAGGAAAT	GCGTGGAAAGA	6060
ACTTGGAGAC GCCCTGTGA	CCTCCAAGAT TTTCCATGCA	TTCGTCCATA	ATGATGGCAA	6120
TGGGCCACG GGCAGCGGCC	TGGCGAAGA TATTTCTGGG	ATCACTAACG	TCATAGTTGT	6180
GTTCCAGGAT GAGATCGTCA	TAGGCCATT TTACAAAGCG	CGGGCGGAGG	GTGCCAGACT	6240
GCGGTATAAT GGTCATCC	GGCCCAGGGG CGTAGITACC	CTCACAGATT	TGCATTTCCC	6300
ACGCTTGAG TTCAGATGGG	GGGATCATGT CTACCTGCGG	GGCGATGAAG	AAAACGGTTT	6360
CCGGGGTAGG GGAGATCAGC	TGGGAAGAAA GCAGGTTCT	GAGCAGCTGC	GACTTACCGC	6420
AGCCGGTGGG CCCGTAATC	ACACCTATTA CCGGGTGCAA	CTGGTAGTTA	AGAGAGCTGC	6480
AGCTGCCGTC ATCCCTGAGC	AGGGGGCCA CTTCGTTAAG	CATGTCCCTG	ACTCGCATGT	6540
TTTCCCTGAC CAAATCCGCC	AGAAGGCGCT CGCCGCCAG	CGATAGCAGT	TCTTGCAAGG	6600
AAGCAAAGTT TTTCAACGGT	TTGAGACCGT CGGCCGTAGG	CATGCTTTG	AGCGTTTGAC	6660
CAAGCAGTTC CAGGCGTCC	CACAGCTCGG TCACCTGCTC	TACGGCATCT	CGATCCAGCA	6720
TATCTCCTCG TTTCGGGGT	TGGGGCGGCT TTCGCTGTAC	GGCAGTAGTC	GGTGCTCGTC	6780
CAGACGGGCC AGGGTCATGT	CTTTCCACGG GCGCAGGGTC	CTCGTCAGCG	TAGTCTGGGT	6840
CACGGTGAAG GGGTGCCTC	CGGGCTGCAGC GCTGGCCAGG	GTGCAGCTGA	GGCTGGTCCT	6900
GCTGGTGCTG AAGCGCTGCC	GGTCTTCGCC CTGGCGCTCG	GCCAGGTAGC	ATTTGACCAT	6960
GGTGTATAG TCCAGCCCT	CCGCGCGTG GCCCTGGCG	CGCAGCTTGC	CCTTGGAGGA	7020
GGCGCCGCAC GAGGGGCAGT	GCAGACTTTT GAGGGCGTAG	AGCTTGGCG	CGAGAAATAC	7080
CGATTCCGGG GAGTAGGCAT	CCGCGCCGCA GGCCCCGCAG	ACGGTCTCGC	ATTCCACGAG	7140
CCAGGTGAGC TCTGGCCGTT	CGGGGTCAA AACCAGGTTT	CCCCCATGCT	TTTGATGCG	7200
TTTCTTACCT CTGGTTCCA	TGAGCCGGTG TCCACGCTCG	GTGACGAAAA	GGCTGTCCGT	7260
GTCCCCGTAT ACAGACTTGA	GAGGCCTGTC CTCGAGCGGT	GTTCCGCGGT	CCTCCTCGTA	7320
TAGAAACTCG GACCACTCTG	AGACAAAGGC TCGCGTCCAG	GCCAGCACGA	AGGAGGCTAA	7380

GTGGGAGGGG TAGCGGTCGT TGTCCACTAG GGGGTCCACT CGCTCCAGGG TGTGAAGACA	7440
CATGTGCCCT CTTTCCGCAT CAAGGAAGGT GATTGGTTG TAGGTGAGG CCACGTGACC	7500
GGGTGTTCCCT GAAGGGGGC TATAAAAGGG GGTGGGGCG CGTCGTCCT CACTCTCTTC	7560
CGCATCGCTG TCTGCGAGGG CCAGCTGTTG GGGTGAGTAC TCCCTCTGAA AAGCGGGCAT	7620
GACTTCTGCG CTAAGATTGT CAGTTCCAA AAACGAGGAG GATTGATAT TCACCTGGCC	7680
CGCGGTGATG CCTTGAGGG TGCCGCATC CATCTGGTCA GAAAAGACAA TCTTTTGTT	7740
GTCAAGCTTG GTGGCAAACG ACCCGTAGAG GGCCTGGAC AGCAACTTGG CGATGGAGCG	7800
CAGGGTTTGG TTTTGTCGC GATCGGCGCG CTCCCTGGCC GCGATGTTA GCTGCACGTA	7860
TTCGCGCGCA ACGCACCGCC ATTGGGAAA GACGGTGGTG CGCTCGTCGG GCACCAGGTG	7920
CACCGGCCAA CCGCGTTGT GCAGGGTGAC AAGGTCAACG CTGGTGGCTA CCTCTCCGCG	7980
TAGGCCTCG TTGGTCCAGC AGAGGCGGCC GCCCTGGCG GAGCAGAATG GCGGTAGGGG	8040
GTCTAGCTGC GTCTCGTCCG GGGGGTCTGC GTCCACGGTA AAGACCCCAG GCAGCAGGCG	8100
CGCGTCGAAG TAGTCTATCT TGCACTCCTTG CAAGTCTAGC GCCTGCTGCC ATGCGCGGGC	8160
GGCAAGCGCG CGCTCGTATG GGTGAGTGG GGGACCCCAT GGCATGGGGT GGGTGAGCGC	8220
GGAGGCGTAC ATGCCGAAA TGTCGTAAAC GTAGAGGGC TCTCTGAGTA TTCCAAGATA	8280
TGTAGGGTAG CATCTTCCAC CGCGGATGCT GGCGCGCACG TAATCGTATA GTTCGTGCGA	8340
GGGAGCGAGG AGGTGGGAC CGAGGTTGCT ACGGGCGGGC TGCTCTGCTC GGAAGACTAT	8400
CTGCCTGAAG ATGGCATGTG AGTTGGATGA TATGGTTGGA CGCTGGAAAGA CGTTGAAGCT	8460
GGCGTCTGTG AGACCTACCG CGTCACGCAC GAAGGAGGCG TAGGAGTCGC GCAGCTTGT	8520
GACCAGCTCG GCGGTGACCT GCACGTCTAG GGCGCAGTAG TCCAGGGTTT CCTTGATGAT	8580
GTCATACTTA TCCTGCCCC TTGAGGACAA ACTCTCGCG	8640
GTCTTTCCAG TACTCTGGA TCGGAAACCC GTCGGCCTCC GAACGGTAAG AGCCTAGCAT	8700
GTAGAACTGG TTGACGGCCT GGTAGGCGCA GCATCCCCTT TCTACGGGTAA GCGCGTATGC	8760
CTGCGCGGCC TTCCGGAGCG AGGTGTGGGT GAGCGAAAG GTGTCCTGA CCATGACTTT	8820
GAGGTACTGG TATTTGAAGT CAGTGTGTC GCATCCGCC TGCTCCAGA GCAAAAGTC	8880
CGTGCCTTT TTGGAACGCG GATTTGGCAG GGCGAAGGTG ACATCGTTGA AGAGTATCTT	8940
TCCCGCGCGA GGCATAAAAGT TGCGTGTGAT GCGGAAGGGT CCCGGCACCT CGGAACGGTT	9000
GTAAAGTTCC AAGAACGCG GGATGCCCTT GATGGAAGGC AATTTTTAA GTTCCCTCGTA	9120
GGTGAGCTCT TCAGGGGAGC TGAGCCCGTG CTCTGAAAGG GCCCAGTCTG CAAGATGAGG	9180
GTTGGAAGCG ACGAATGAGC TCCACAGGTC ACGGGCCATT AGCATTGCA GGTGGTCGCG	9240
AAAGGTCTTA AACTGGCGAC CTATGGCCAT TTTTCTGGG GTGATGCAGT AGAAGGTAAG	9300
CGGGTCTTGT TCCAGCGGT CCCATCCAAG GTTCGCGGCT AGGTCTCGCG CGGCAGTCAC	9360
TAGAGGCTCA TCTCCGCCGA ACTTCATGAC CAGCATGAAG GGCACGAGCT GCTTCCAAA	9420
GGCCCCCATC CAAGTATAGG TCTCTACATC GTAGGTGACA AAGAGACGCT CGGTGCGAGG	9480

WO 98/17783**PCT/US97/19541**

ATGCGAGCCG ATCGGAAAGA ACTGGATCTC CCGCCACCAA TTGGAGGAGT GGCTATTGAT	9540
GTGGTGAAG TAGAAGTCCC TGCACGGGC CGAACACTCG TGCTGGCTTT TGTAAAAACG	9600
TGCGCAGTAC TGGCAGCGGT GCACGGGCTG TACATCCTGC ACGAGGTTGA CCTGACGACC	9660
GCGCACAAAGG AAGCAGAGTG GGAATTGAG CCCCTCGCCT GGCGGGTTG GCTGGTGGTC	9720
TTCTACTTCG GCTGCTTGTC CTTGACCGTC TGGCTGCTCG AGGGGAGTTA CGGTGGATCG	9780
GACCACCACG CCGCGCGAGC CCAAAGTCCA GATGTCCGCG CGCGGCGGTC GGAGCTTGAT	9840
GACAACATCG CGCAGATGGG AGCTGTCCAT GGTCTGGAGC TCCCAGGGCG TCAGGTCAGG	9900
CGGGAGCTCC TGCAGGTTA CCTCGCATAG ACGGGTCAGG GCGCGGGCTA GATCCAGGTG	9960
ATACCTAATT TCCAGGGCT GGTTGGTGGC GGCGTCGATG GCTTGAAGA GGCGCATCC	10020
CCCGCGCGCG ACTACGGTAC CGCGCGCGG GCGGTGGGCC GCGGGGGTGT CCTTGGATGA	10080
TGCATCTAAA AGCGGTGACG CGGGCGAGCC CCCGGAGGTA GGGGGGGCTC CGGACCCGCC	10140
GGGAGAGGGG GCAGGGGCAC GTCGCGCCG CGCGCGGGCA GGAGCTGGTG CTGCGCGCGT	10200
AGGTTGCTGG CGAACCGCAG GACCGCGCGG TTGATCTCCT GAATCTGGCG CCTCTGCGTG	10260
AAGACGACGG GCCCAGGTGAG CTTGAGCCTG AAAGAGAGTT CGACAGAACAT AATTCGGT	10320
TCGTTGACGG CGGCCTGGCG CAAAATCTCC TGACAGTCTC CTGAGTTGTC TTGATAGGCG	10380
ATCTCGGCCA TGAACGTCTC GATCTCTTCC TCCCTGGAGAT CTCCCGCTCC GGCTCGCTCC	10440
ACGGTGGCGG CGAGGTGCTT GGAAATGCGG GCCATGAGCT GCGAGAAGGC GTTGAGGCCT	10500
CCCTCGTTCC AGACCGGGCT GTAGACCACG CCCCCCTTCGG CATCGCGGGC GCGCATGACC	10560
ACCTCGCGA GATTGAGCTC CACGTGCCGG GCGAAGACGG CGTAGTTTCG CAGGCGCTGA	10620
AAGAGGTAGT TGAGGGTGGT GGCGGTGTGT TCTGCCACGA AGAAGTACAT AACCCAGCGT	10680
CGCAACGTGG ATTCTGTTGAT ATCCCCAAG GCCTCAAGGC GCTCCATGGC CTCGTAGAAG	10740
TCCACGGCGA AGTTGAAAAA CTGGGAGTTG CGCGCCGACA CGGTTAACTC CTCCCTCCAGA	10800
AGACGGATGA GCTCGCGAC AGTGTGCGC ACCTCGCGCT CAAAGGCTAC AGGGGCCTCT	10860
TCTTCTTCTT CAATCTCCTC TTCCATAAGG GCCTCCCCCTT CTTCTTCTTC TGCGGGCGGT	10920
GGGGGAGGGG GGACACGGCG GCGACGACGG CGCACCGGGA GGCGGTGAC AAAGCGCTCG	10980
ATCATCTCCC CGCGCGACG GCGCATGGTC TCGGTGACGG CGCGGCCGTT CTCGCGGGGG	11040
CGCAGTTGGA AGACGCCGCC CGTCATGTCC CGGTTATGGG TTGGCGGGGG GCTGCCATGC	11100
GGCAGGGATA CGGCCCTAAC GATGCATCTC AACAAATTGTT GTGTAGGTAC TCCGCCGCCG	11160
AGGGACCTGA GCGAGTCCGC ATCGACCGGA TCGGAAAACC TCTCGAGAAA GGCGTCTAAC	11220
CAGTCACAGT CGCAAGGTAG GCTGAGCACC GTGGCGGGCG GCAGCGGGCG GCGGTGGGG	11280
TTGTTTCTGG CGGAGGTGCT GCTGATGATG TAATTAAGT AGGCGGTCTT GAGACGGCGG	11340
ATGGTCGACA GAACCACCAT GTCTTGGGT CGGGCCTGCT GAATGCGCAG GCGGTGGCC	11400
ATGCCCGAGG CTTGTTTTG ACATCGCGC AGGTCTTGT AGTAGTCTTG CATGAGCCTT	11460
TCTACCGGCA CTTCTTCTTC TCCCTCCTCT TGTCCTGCAT CTCTGCAATC TATCGCTGCG	11520
GCGGCGGGCG AGTTTGGCCG TAGGTGGCGC CCTCTTCCTC CCATGCGTGT GACCCCGAAG	11580

CCCCTCATCG GCTGAAGCAG GGCTAGGTCG GCGACAACGC GCTCGGCTAA TATGGCCTGC 11640
 TGCACCTGCG TGAGGGTAGA CTGGAAAGTCA TCCATGTCCA CAAAGCGGTG GTATGCGCCC 11700
 GTGTTGATGG TGTAAGTGCA GTTGGCCATA ACGGACCAGT TAACGGTCTG GTGACCCGGC 11760
 TGCGAGAGCT CGGTGTACCT GAGACGCGAG TAAGCCCTCG AGTCAAATAC GTAGTCGTTG 11820
 CAAGTCCGCA CCAGGTACTG GTATCCCACC AAAAAGTGC GCGGGCGCTG GCGGTAGAGG 11880
 GGCCAGCGTA GGGTGGCCGG GGCTCCGGGG GCGAGATCTT CCAACATAAG GCGATGATAT 11940
 CCGTAGATGT ACCTGGACAT CCAGGTGATG CCGGCGGCCGG TGGTGGAGGC GCGCGGAAAG 12000
 TCGCGGACGC GGTTCCAGAT GTTGCAGC GGCAGAAAGT GCTCCATGGT CGGGACGCTC 12060
 TGGCCGGTCA GGCAGCGCA ATCGTTGACG CTCTACCGTG CAAAGGAGA GCCTGTAAGC 12120
 GGGCACTCTT CCGTGGTCTG GTGGATAAAAT TCGCAAGGGT ATCATGGCGG ACGACCAGGG 12180
 TTCGAGCCCC GTATCCGGCC GTCCGCCGTG ATCCATGCCG TTACCGCCCG CGTGTGAAAC 12240
 CCAGGTGTGC GACGTCAGAC AACGGGGAG TGCTCCCTTT GGCTCCCTTC CAGGCGCGGC 12300
 GGCTGCTGCG CTAGCTTTT TGGCCACTGG CCGCGCGCAG CGTAAGCGGT TAGGCTGGAA 12360
 AGCGAAAGCA TTAAGTGGCT CGCTCCCTGT AGCCGGAGGG TTATTTCCA AGGGTTGAGT 12420
 CGCGGGACCC CCGGTTGAG TCTCGGACCG GCCGGACTGC GGCGAACGGG GGTTTGCCTC 12480
 CCCGTATGC AAGACCCCGC TTGCAAATTG CTCCGGAAAC AGGGACGAGC CCCTTTTTG 12540
 CTTTTCCAG ATGCATCCGG TGCTGCGCA GATGCGCCCC CCTCCCTCAGC AGCGGCAAGA 12600
 GCAAGAGCAG CGGCAGACAT GCAGGGCACC CTCCCCCTCCT CCTACCGCGT CAGGAGGGGC 12660
 GACATCCGCG GTTGACGCCG CAGCAGATGG TGATTACGAA CCCCCCGCGC GCCGGGGCCCG 12720
 GCACTACCTG GACTTGGAGG AGGGCGAGGG CCTGGCGCGG CTAGGAGCGC CCTCTCCTGA 12780
 GCGGTACCCA AGGGTGCAGC TGAAGCGTGA TACCGGTGAG GCGTACGTGC CGCGGCAGAA 12840
 CCTGTTTCGC GACCGCGAGG GAGAGGAGCC CGAGGAGATG CGGGATCGAA AGTTCCACGC 12900
 AGGGCGCGAG CTGCGGCATG GCCTGAATCG CGACGGTTG CTGCGCGAGG AGGACTTTGA 12960
 GCCCCGACCG CGAACCGGGG TTAGTCCCGC GCGCGCACAC GTGGCGGCCG CGCACCTGGT 13020
 AACCGCATAAC GAGCAGACGG TGAACCAGGA GATTAACCTT CAAAAAAAGCT TTAACAACCA 13080
 CGTGCCTACG CTTGTGGCGC GCGAGGAGGT GGCTATAGGA CTGATGCATC TGTGGGACTT 13140
 TGTAAGCGCG CTGGAGCAAA ACCCAAATAG CAAGCCGCTC ATGGCGCAGC TGTTCCTTAT 13200
 AGTGCAGCAC AGCAGGGACA ACGAGGCATT CAGGGATGCG CTGCTAAACA TAGTAGAGCC 13260
 CGAGGGCCGC TGGCTGCTCG ATTTGATAAA CATCCTGCAG AGCATAGTGG TGCAGGAGCG 13320
 CAGCTTGAGC CTGGCTGACA AGGTGGCCGC CATCAACTAT TCCATGCTTA GCCTGGGCAA 13380
 GTTTTACGCC CGCAAGATAT ACCATAACCC TTACGTTCCC ATAGACAAGG AGGTAAAGAT 13440
 CGAGGGGTTC TACATGCGCA TGGCGCTGAA GGTGCTTACC TTGAGCGACG ACCTGGGCGT 13500
 TTATCGCAAC GAGCGCATCC ACAAGGCCGT GAGCGTGAGC CGGCAGCGCG AGCTCAGCGA 13560
 CCGCGAGCTG ATGCACAGCC TGCAAAGGGC CCTGGCTGGC ACGGGCAGCG GCGATAGAGA 13620
 GGCGGAGTCC TACTTGACG CGGGCGCTGA CCTGCGCTGG GCCCAAGCC GACGCGCCCT 13680

GGAGGCAGCT GGGGCCGGAC CTGGGCTGGC GGTGGCACCC GCGCGCGCTG GCAACGTCGG 13740
 CGGCGTGGAG GAATATGACG AGGACGATGA GTACGAGCCA GAGGACGGCG AGTACTAAGC 13800
 GGTGATGTTT CTGATCAGAT GATGCAAGAC GCAACGGACC CGGCGGTGCG GGC GGCGCTG 13860
 CAGAGCCAGC CGTCCGGCCT TAACTCCACG GACGACTGGC GCCAGGTCA G GACCGCAGTC 13920
 ATGTCGCTGA CTGCGCGAA TCCTGACGCG TTCCGGCAGC AGCCGCAGGC CAACCGGCTC 13980
 TCCGCAATTG TGGAAGCGGT GGTCCCGGCG CGCGCAAACC CCACGCACGA GAAGGTGCTG 14040
 GCGATCGTAA ACGCGCTGGC CGAAAACAGG GCCATCCGGC CCGACGAGGC CGGCCTGGTC 14100
 TACGACGCGC TGCTTCAGCG CGTGGCTCGT TACAACAGCG GCAACGTGCA GACCAACCTG 14160
 GACCGGCTGG TGGGGGATGT GCGCGAGGCC GTGGCGCAGC GTGAGGCCGC GCAGCAGCAG 14220
 GGCAACCTGG GCTCCATGGT TGC ACTAAAC GCCTTCTGA GTACACAGCC CGCCAACGTG 14280
 CCGCGGGGAC AGGAGGACTA CACCAACTTT GTGAGCGCAC TGCGGCTAAT GGTGACTGAG 14340
 ACACCGCAAA GTGAGGTGTA CCAGTCTGGG CCAGACTATT TTTTCCAGAC CAGTAGACAA 14400
 GG CCTGCAGA CCGTAAACCT GAGCCAGGCT TTC AAAACT TGCAGGGCT GTGGGGGGTG 14460
 CGGGCTCCCA CAGGCGACCG CGCGACCGTG TCTAGCTTG TGACGCCAA CTCGCGCTG 14520
 TTGCTGCTGC TAATAGCGCC CTTCACGGAC AGTGGCAGCG TGTCCGGGA CACATACTA 14580
 GGTCACTTGC TGACACTGTA CCGCGAGGCC ATAGGTCAAG CGCATGTGGA CGAGCATACT 14640
 TTCCAGGAGA TTACAAGTGT CAGCCGCGCG CTGGGGCAGG AGGACACGGG CAGCCTGGAG 14700
 GCAACCTAA ACTACCTGCT GACCAACCGG CGGCAGAAGA TCCCCTCGTT GCACAGTTA 14760
 AACAGCGAGG AGGAGCGCAT TTTGCCTAC GTGCAGCAGA GCGTGAGCCT TAACCTGATG 14820
 CGCGACGGGG TAACCCCGAG CGTGGCGCTG GACATGACCG CGCGCAACAT GGAACCGGGC 14880
 ATGTATGCCT CAAACCGGCC GTTATCAAC CGCTTAATGG ACTACTTGCA TCGCGCGGCC 14940
 GCCGTGAACC CCGAGTATTT CACCAATGCC ATCTTGAAACC CGCAGTGGCT ACCGCCCCCT 15000
 GGTTTCTACA CCGGGGGATT CGAGGTGCC GAGGGTAACG ATGGATTCCCT CTGGGACGAC 15060
 ATAGACGACA GCGTGTTC CCGCAACCG CAGACCTGC TAGAGTTGCA ACAGCGCGAG 15120
 CAGGCAGAGG CGGGCTGCG AAAGGAAAGC TTCCGCAAGC CAAGCAGCTT GTCCGATCTA 15180
 GGCCTGCCTT CCCCCGGTC AGATGCTAGT AGCCCATTTC CAAGCTTGAT AGGGTCTCTT 15240
 ACCAGCACTC GCACCACCCG CCCGCGCTG CTGGCGAGG AGGAGTACCT AAACAACCTG 15300
 CTGCTGCAGC CGCAGCGCGA AAAAAACCTG CCTCCGGCAT TTCCCAACAA CGGGATAGAG 15360
 AGCCTAGTGG ACAAGATGAG TAGATGGAAG ACGTACCGC AGGAGCACAG GGACGTGCCA 15420
 GGCCCGCGCC CGCCCACCCG TCGTCAAAGG CACGACCGTC AGCGGGGTCT GGTGTGGGAG 15480
 GACGATGACT CGGCAGACGA CAGCAGCGTC CTGGATTGG GAGGGAGTGG CAACCCGTTT 15540
 GCGCACCTTC GCCCCAGGCT GGGGAGAATG TTTAAAAAA AAAAAAGCAT GATGAAAT 15600
 AAAAAACTCA CCAAGGCCAT GGCACCGAGC GTTGGTTTTC TTGTATTCCC CTTAGTATGC 15660
 GGCGCGCGGC GATGTATGAG GAAGGTCCCTC CTCCCTCCTA CGAGAGTGTG GTGAGCGCGG 15720
 CGCCAGTGGC GGCGCGCTG GTTCTCCCT TCGATGCTCC CCTGGACCCG CCGTTGTGC 15780

CTCCGCGGTA CCTGCGGCCT ACCGGGGGGA GAAACAGCAT CCGTTACTCT GAGTTGGCAC	15840
CCCTATTGCA CACCACCGT GTGTACCTGG TGGACAACAA GTCAAACGGAT GTGGCATCCC	15900
TGAACATCCA GAACGACCAC AGCAACTTC TGACCACGGT CATTAAAAC AATGACTACA	15960
GCCCCGGGGGA GGCAAGCACA CAGACCATCA ATCTTGACGA CCGGTCGCAC TGGGGCGGCG	16020
ACCTGAAAAC CATCCTGCAT ACCAACATGC CAAATGTGAA CGAGTTCATG TTTACCAATA	16080
AGTTTAAGGC GCGGGTGATG GTGTCGCGCT TGCTACTAA GGACAATCAG GTGGAGCTGA	16140
AATACGAGTG GGTGGAGTTC ACGCTGCCG AGGGCAACTA CTCCGAGACC ATGACCATAG	16200
ACCTTATGAA CAACGCGATC GTGGAGCACT ACTTGAAAAGT GGGCAGACAG AACGGGGTTC	16260
TGGAAAGCGA CATCGGGGTA AAGTTTGACA CCCGCAACTT CAGACTGGGG TTTGACCCCG	16320
TCACTGGTCT TGTCAKGCT GGGGTATATA CAAACGAAGC CTTCCATCCA GACATCATT	16380
TGCTGCCAGG ATGCGGGGTG GACTTCACCC ACAGCCGCT GAGCAACTTG TTGGGCATCC	16440
GCAAGCGGCA ACCCTTCCAG GAGGGCTTTA GGATCACCTA CGATGATCTG GAGGGTGGTA	16500
ACATTCCCGC ACTGTTGGAT GTGGACGCCT ACCAGGCGAG CTTGAAAGAT GACACCGAAC	16560
AGGGCGGGGG TGGCGCAGGC GGCAGCAACA GCAGTGGCAG CGGCGCGGAA GAGAACTCCA	16620
ACGCGGCAGC CGCGGCAATG CAGCCGGTGG AGGACATGAA CGATCATGCC ATTGCGGGCG	16680
ACACCTTGC CACACGGCT GAGGAGAACG GCGCTGAGGC CGAAGCAGCG GCCGAAGCTG	16740
CCGCCCCCGC TGCGCAACCC GAGGTCGAGA AGCCTCAGAA GAAACCGGTG ATCAAACCCC	16800
TGACAGAGGA CAGCAAGAAA CGCAGTTACA ACCTAATAAG CAATGACAGC ACCTTCACCC	16860
AGTACCGCAG CTGGTACCTT GCATACAAC ACTGGCGACCC TCAGACCGGA ATCCGCTCAT	16920
GGACCCCTGCT TTGCACTCCT GACGTAACCT GCGGCTCGGA GCAGGTCTAC TGGTCGTTGC	16980
CAGACATGAT GCAAGACCCC GTGACCTTCC GCTCCACGCG CCAGATCAGC AACTTTCCGG	17040
TGGTGGCGC CGAGCTGTTG CCCGTGCACT CCAAGAGCTT CTACAACGAC CAGGCCGTCT	17100
ACTCCCAACT CATCCGCCAG TTTACCTCTC TGACCCACGT GTTCAATCGC TTTCCCGAGA	17160
ACCAGATTTT GGCGCGCCCG CCAGCCCCA CCATCACCAAC CGTCAGTGAA AACGTTCCCTG	17220
CTCTCACAGA TCACGGGACG CTACCGCTGC GCAACAGCAT CGGAGGAGTC CAGCGAGTGA	17280
CCATTACTGA CGCCAGACGC CGCACCTGCC CCTACGTTA CAAGGCCCTG GGCATAGTCT	17340
CGCCGCGCGT CCTATCGAGC CGCACTTTT GAGCAAGCAT GTCCATCCTT ATATCGCCCA	17400
GCAATAACAC AGGCTGGGC CTGCCTTCC CAAGCAAGAT GTTGGCGGG GCCAAGAACG	17460
GCTCCGACCA ACACCCAGTG CGCGTGCACG GGCACCTACCG CGCGCCCTGG GGCACGCGACA	17520
AACGCGGCCG CACTGGGCGC ACCACCGTCG ATGACGCCAT CGACGCGGTG GTGGAGGAGG	17580
CGCGCAACTA CACGCCACG CGGCCACCAAG TGTCCACAGT GGACGCGGCC ATTCAAGACCG	17640
TGGTGCACGG AGCCCGCGC TATGCTAAA TGAAGAGACG GCGGAGGCGC GTAGCACGTC	17700
GCCACCGCCG CGGACCCGGC ACTGCCTGCC AACGCGCGC GGCACCCCTG CTTAACCGCG	17760
CACGTGCAC CGGCCGACGG CGGCCATGC GGGCCGCTCG AAGGCTGGCC GCGGGTATTG	17820
TCACGTGCC CCCCCAGGTCC AGGCGACGAG CGGCCGCCGC AGCAGCCCGC GCCATTAGTG	17880

CTATGACTCA GGGTCGCAGG GGCAACGTGT ATTGGGTGCG CGACTCGGTT AGCGGCCTGC	17940
GCCTGCCCCGT GCGCACCCGC CCCCCCGCGA ACTAGATTGC AAGAAAAAAC TACTTAGACT	18000
CGTACTGTTG TATGTATCCA GCGGCGGCCG CGCGCAACGA AGCTATGTCC AAGCGCAAAA	18060
TCAAAGAAGA GATGCTCCAG GTCATCGCGC CGGAGATCTA TGCCCCCG AAGAAGGAAG	18120
AGCAGGATTA CAAGCCCCGA AAGCTAAAGC GGGTCAAAAA GAAAAAGAAA GATGATGATG	18180
ATGAACCTGA CGACGAGGTG GAACTGCTGC ACGCTACCGC GCCCAGCGA CGGGTACAGT	18240
GGAAAGGTG AC CGCTAAAAA CGTGTGTC GACCCGGCAC CACCGTAGTC TTTACGCCCG	18300
GTGAGCGCTC CACCCGCACC TACAAGCGCG TGTATGATGA GGTGTACGGC GACGAGGACC	18360
TGCTTGAGCA GGCCAACGAG CGCCTCGGGG AGTTTGCTA CGGAAAGCGG CATAAGGACA	18420
TGCTGGCGTT GCCGCTGGAC GAGGGCAACC CAACACCTAG CCTAAAGCCC GTAACACTGC	18480
AGCAGGTGCT GCCCGCGCTT GCACCGTCCG AAGAAAAGCG CGGCCTAAAG CGCGAGTCTG	18540
GTGACTTGGC ACCCACCGTG CAGCTGATGG TACCCAAGCG CCAGCGACTG GAAGATGTCT	18600
TGGAAAAAT GACCGTGGAA CCTGGGCTGG AGCCCGAGGT CGCGTGCAG CCAATCAAGC	18660
AGGTGGGCC GGGACTGGGC GTGCAGACCG TGGACGTTCA GATACCCACT ACCAGTAGCA	18720
CCAGTATTGC CACCGCCACA GAGGGCATGG AGACACAAAC GTCCCCGGTT GCCTCAGCGG	18780
TGGCGGATGC CGCGGTGCAG GCGGTCGCTG CGGCCGCGTC CAAGACCTCT ACGGAGGTG	18840
AAACGGACCC GTGGATGTTT CGCGTTTCAG CCCCCCGCG CCCGCGCGGT TCGAGGAAAGT	18900
ACGGCGCCGC CAGCGCGCTA CTGCCGAAT ATGCCCTACA TCCTTCCATT GCGCCTACCC	18960
CCGGCTATCG TGGCTACACC TACCGCCCCA GAAGACGAGC AACTACCCGA CGCCGAACCA	19020
CCACTGGAAC CCGCCGCCGC CGTCGCGCTC GCCAGCCGT GCTGGCCCG ATTCCGTGC	19080
GCAGGGTGGC TCGCGAAGGA GGCAGGACCC TGGTGTGCC AACAGCGCGC TACCAACCCA	19140
GCATCGTTA AAAGCGGTC TTTGTGGTTC TTGCAGATAT GGCCCTCACC TGCGCCTCC	19200
GTTTCCCGGT GCCGGGATTC CGAGGAAGAA TGCACCGTAG GAGGGGCATG GCCGGCCACG	19260
GCCTGACGGG CGGCATCGT CGTGCACCC ACCGGCGCG GCGCGCGTCG CACCGTCGCA	19320
TGCGCGCGG TATCCTGCC CTCCTTATTG CACTGATCGC CGCGCGATT GGCGCCGTGC	19380
CCGGAATTGC ATCCGTGGCC TTGCAGGCGC AGAGACACTG ATTAAAAACA AGTTGCATGT	19440
GGAAAAATCA AAATAAAAAG TCTGGACTCT CACGCTCGCT TGGCCTGTA ACTATTTGT	19500
AGAATGGAAG ACATCAACTT TGCCTCTCTG GCCCCCGAC ACGGCTCGCG CCCGTTCATG	19560
GGAAACTGGC AAGATATCGG CACCAAGCAAT ATGAGCGGTG GCGCCTTCAG CTGGGGCTCG	19620
CTGTGGAGCG GCATTAAAA TTTCGGTTCC ACCGTTAAGA ACTATGGCAG CAAGGCCTGG	19680
AACAGCAGCA CAGGCCAGAT GCTGAGGGAT AAGTTGAAAG AGCAAAATTT CCAACAAAAG	19740
GTGGTAGATG GCCTGGCTC TGGCATTAGC GGGGTGGTGG ACCTGGCCAA CGAGGCAGTG	19800
CAAATAAGA TTAACAGTAA GCTTGATCCC CGCCCTCCCG TAGAGGAGCC TCCACCGGCC	19860
GTGGAGACAG TGTCTCCAGA GGGGCGTGGC GAAAAGCGTC CGCGCCCCGA CAGGGAAGAA	19920
ACTCTGGTGA CGCAAATAGA CGAGCCTCCC TCGTACGAGG AGGCACTAAA GCAAGGCCTG	19980

CCCACCCACCC	GTCCCATCGC	GCCCCATGGCT	ACCGGAGTGC	TGGGCCAGCA	CACACCCGTA	20040
ACGCTGGACC	TGCCCTCCCC	CGCCGACACC	CAGCAGAAAC	CTGTGCTGCC	AGGCCCGACC	20100
GCGTTGTTG	TAACCCGTCC	TAGCCGCGCG	TCCCTGCGCC	GCGCCGCCAG	CGGTCCGCGA	20160
TCGTTGCGGC	CCGTAGCCAG	TGGCAACTGG	CAAAGCACAC	TGAACAGCAT	CGTGGGTCTG	20220
GGGGTGCAAT	CCCTGAAGCG	CCGACGATGC	TTCTGAATAG	CTAACGTGTC	GTATGTGTGT	20280
CATGTATGCG	TCCATGTCGC	CGCCAGAGGA	GCTGCTGAGC	CGCCGCGCGC	CCGCTTTCCA	20340
AGATGGCTAC	CCCTTCGATG	ATGCCGCACT	GGTCTTACAT	GCACATCTCG	GGCCAGGACG	20400
CCTCGGAGTA	CCTGAGCCCC	GGGCTGGTGC	AGTTTGCCCG	CGCCACCGAG	ACGTACTTCA	20460
GCCTGAATAA	CAAGTTAGA	AACCCCACGG	TGGCGCCTAC	GCACGACGTG	ACCACAGACC	20520
GGTCCCAGCG	TTTGACGCTG	CGGTTCATCC	CTGTGGACCG	TGAGGATACT	GGGTACTCGT	20580
ACAAGGCGCG	GTTCACCCCTA	GCTGTGGGTG	ATAACCGTGT	GCTGGACATG	GCTTCCACGT	20640
ACTTTGACAT	CCGCAGCGTG	CTGGACAGGG	GCCCTACTTT	TAAGCCCTAC	TCTGGCACTG	20700
CCTACAACGC	CCTGGCTCCC	AAGGGTGCCC	CAAATCCTTG	CGAATGGGAT	GAAGCTGCTA	20760
CTGCTCTTGA	AATAAACCTA	GAAGAAGAGG	ACGATGACAA	CGAAGACGAA	GTAGACGAGC	20820
AAGCTGAGCA	GCAAAAAACT	CACGTATTTG	GGCAGGCGCC	TTATTCTGGT	ATAAAATATTA	20880
CAAAGGAGGG	TATTCAAATA	GGTGTGAAAG	GTCAAACACC	TAAATATGCC	GATAAAACAT	20940
TTCAACCTGA	ACCTCAAATA	GGAGAAATCTC	AGTGGTACGA	AACTGAAATT	AATCATGCAG	21000
CTGGGAGAGT	CCTTAAAAG	ACTACCCAA	TGAAACCATG	TTACGGTTCA	TATGCAAAAC	21060
CCACAAATGA	AAATGGAGGG	CAAGGCATTC	TTGTAAAGCA	ACAAAATGGA	AAGCTAGAAA	21120
GTCAAGTGGA	AATGCAATT	TTCTCAACTA	CTGAGGCGAC	CGCAGGCAAT	GGTGATAACT	21180
TGACTCCTAA	AGTGGTATTG	TACAGTGAAG	ATGTAGATAT	AGAAAACCCA	GACACTCATA	21240
TTTCTTACAT	GCCCCACTATT	AAGGAAGGTA	ACTCACGAGA	ACTAATGGGC	CAACAATCTA	21300
TGCCCAACAG	GCCTAAATTAC	ATTGCTTTTA	GGGACAATT	TATTGGTCTA	ATGTATTACA	21360
ACAGCACGGG	TAATATGGGT	GTTCTGGCGG	GCCAAGCATC	GCAGTTGAAT	GCTGTTGTAG	21420
ATTTGCAAGA	CAGAAACACA	GAGCTTCAT	ACCAGCTTT	GCTTGATTCC	ATTGGTGATA	21480
GAACCAGGTA	CTTTCTATG	TGGAATCAGG	CTGTTGACAG	CTATGATCCA	GATGTTAGAA	21540
TTATTGAAAA	TCATGGAACT	GAAGATGAAC	TTCCAAATT	CTGCTTCCA	CTGGGAGGTG	21600
TGATTAATAC	AGAGACTCTT	ACCAAGGTA	AACCTAAAAC	AGGTCAAGGAA	AATGGATGGG	21660
AAAAAGATGC	TACAGAATT	TCAGATAAAA	ATGAAATAAG	AGTTGGAAAT	AATTTTGCCA	21720
TGGAAATCAA	TCTAAATGCC	AACCTGTGGA	GAAATTTCT	GTACTCCAAC	ATAGCGCTGT	21780
ATTTGCCCGA	CAAGCTAAAG	TACAGTCCTT	CCAACGTAAA	AATTCTGAT	AACCCAAACAA	21840
CCTACGACTA	CATGAACAAG	CGAGTGGTGG	CTCCCGGGTT	AGTGGACTGC	TACATTAACC	21900
TTGGAGCAGC	CTGGTCCCTT	GACTATATGG	ACAACGTCAA	CCCATTAAAC	CACCACCGCA	21960
ATGCTGGCCT	GCGCTACCGC	TCAATGTTGC	TGGGCAATGG	TCGCTATGTG	CCCTTCCACA	22020
TCCAGGTGCC	TCAGAAGTTC	TTGCCATT	AAAACCTCCT	TCTCCTGCCG	GGCTCATACA	22080

WO 98/17783**PCT/US97/19541**

CCTACGAGTG GAACTTCAGG AAGGATGTTA ACATGGTTCT GCAGAGCTCC CTAGGAAATG	22140
ACCTAAGGGT TGACGGAGCC AGCATTAAGT TTGATAGCAT TTGCCTTAC GCCACCTTCT	22200
TCCCCATGGC CCACAAACACC GCCTCCACGC TTGAGGCCAT GCTTAGAAC GACACCAACG	22260
ACCAGTCCTT TAACGACTAT CTCTCCGCGC CCAACATGCT CTACCCATA CCCGCCAACG	22320
CTACCAACGT GCCCATATCC ATCCCCTCCC GCAACTGGGC GGCTTCCGC GGCTGGGCCT	22380
TCACGCGCCT TAAGACTAAG GAAACCCAT CACTGGGCTC GGGCTACGAC CCTTATTACA	22440
CCTACTCTGG CTCTATACCC TACCTAGATG GAACCTTTA CCTCAACCAC ACCTTTAAGA	22500
AGGTGGCCAT TACCTTGAC TCTCTGTCA GCTGGCCTGG CAATGACCGC CTGCTTACCC	22560
CCAACGAGTT TGAAATTAAG CGCTCAGTTG ACGGGGAGGG TTACAACTGTT GCCCAGTGT	22620
ACATGACCAA AGACTGGTTC CTGGTACAAA TGCTAGCTAA CTACAAACATT GGCTACCAGG	22680
GCTTCTATAT CCCAGAGAC TACAAGGACC GCATGTACTC CTTCTTAGA AACTTCCAGC	22740
CCATGAGCCG TCAGGTGGTG GATGATACTA AATACAAGGA CTACCAACAG GTGGGCATCC	22800
TACACCAACA CAACAACTCT GGATTTGTTG GCTACCTTGC CCCACCATG CGCGAAGGAC	22860
AGGCCTACCC TGCTAACTTC CCCTATCCGC TTATAGGCAA GACCGCAGTT GACAGCATT	22920
CCCAGAAAAA GTTTCTTGC GATCGCACCC TTTGGCGCAT CCCATTCTCC AGTAACTTA	22980
TGTCCATGGG CGCACTCACA GACCTGGGCC AAAACCTCT CTACGCCAAC TCCGCCAACG	23040
CGCTAGACAT GACTTTGAG GTGGATCCA TGGACGAGCC CACCCCTCTT TATGTTTGT	23100
TTGAAGTCTT TGACGTGGTC CGTGTGCACC GGCGCACC CGCGTCATC GAAACCGTGT	23160
ACCTGCGCAC GCCCTCTCG GCCGGCAACG CCACAAACATA AAGAAGCAAG CAACATCAAC	23220
AACAGCTGCC GCCATGGGCT CCAGTGAGCA GGAACTGAAA GCCATTGTCA AAGATCTTGG	23280
TTGTGGCCA TATTTTTGG GCACCTATGA CAAGCGCTTT CCAGGCTTIG TTTCTCCACA	23340
CAAGCTCGCC TGCGCCATAG TCAATACGGC CGGTCGCGAG ACTGGGGCG TACACTGGAT	23400
GGCCTTGC TGGAAACCGC ACTCAAAAAC ATGCTACCTC TTTGAGCCCT TTGGCTTTTC	23460
TGACCAGCGA CTCAGCAGG TTTACCAGTT TGAGTACGAG TCACCTCTGC GCCGTAGCGC	23520
CATTGCTTCT TCCCCGACC GCTGTATAAC GCTGGAAAAG TCCACCCAAA GCGTACAGGG	23580
GCCCCAACT CGCCCTGTG GACTATTCTG CTGCATGTTT CTCCACGCCT TTGCCAAC	23640
CCCACGGATC ACAACCCAC CATGAACCTT ATTACCGGGG TACCCAACTC	23700
CATGCTAAC AGTCCCCAGG TACAGCCAC CCTGCCTCGC AACCAAGGAAC AGCTCTACAG	23760
CTTCCTGGAG CGCCACTCGC CCTACTTCCG CAGCCACAGT GCGCAGATTA GGAGCGCCAC	23820
TTCTTTTGT CACTGAAAA ACATGAAAA ATAATGTACT AGAGACACTT TCAATAAAGG	23880
CAAATGCTT TATTGTACA CTCTCGGGTG ATTATTTACC CCCACCCCTG CCGTCTGC	23940
CGTTAAAAA TCAAAGGGT TCTGCCGC GCATCGTATGC GCCACTGGCA GGGACACGTT	24000
GCGATACTGG TGTTTAGTGC TCCACTTAA CTCAGGCACA ACCATCCCGC GCAGCTCGGT	24060
GAAGTTTCA CTCCACAGGC TGCGCACCAC CACCAACGCG TTTAGCAGGT CGGGCGCCGA	24120
TATCTGAAG TCGCAGTTGG GGCTCCGCC CTGCGCGC GAGTTGCGAT ACACAGGGTT	24180

WO 98/17783**PCT/US97/19541**

GCAGCACTGG AACACTATCA GCGCCGGGTG GTGCACGCTG GCCAGCACGC TCTTGTCCGA	24240
GATCAGATCC GCGTCAGGT CCTCCCGTT GCTCAGGGCG AACGGAGTCA ACTTTGGTAG	24300
CTGCCTTCCC AAAAAGGGCG CGTGCCCCAGG CTTTGAGTTG CACTCGCACC GTAGTGGCAT	24360
CAAAAGGTGA CCGTGCCCCG TCTGGCGTT AGGATACAGC GCCTGCATAA AAGCCTTGAT	24420
CTGCTTAAAA GCCACCTGAG CCTTTGCGCC TTCAGAGAAG AACATGCCGC AAGACTTGCC	24480
GGAAAAGTGA TTGGCCGGAC AGGCCGCGTC GTGCACGCAG CACCTTGCCT CGGTGTTGGA	24540
GATCTGCACC ACATTTCGGC CCCACCGGTT CTTCACGATC TTGGCCTTGC TAGACTGCTC	24600
CTTCAGCGCG CGCTGCCCGT TTTCGCTCGT CACATCCATT TCAATCACGT GCTCCTTATT	24660
TATCATAATG CTTCCGTGTA GACACTTAAG CTCGCCTTCG ATCTCAGCGC AGCGGTGCAG	24720
CCACAACCGCG CAGCCCGTGG GCTCGTGATG CTTGTAGGTC ACCTCTGCAA ACGACTGCAG	24780
GTACGCCTGC AGGAATCGCC CCATCATCGT CACAAAGGTC TTGTTGCTGG TGAAGGTCAG	24840
CTGCAACCCG CGGTGCTCCT CGTTCAGCCA GGTCTTGCAT ACGGCCGCCA GAGCTTCCAC	24900
TTGGTCAGGC AGTAGTTGA AGTTCGCCTT TAGATCGTTA TCCACGTGGT ACTTGTCCAT	24960
CAGCGCGCG GCAGCCTCCA TGCCCTTCTC CCACGCAGAC ACGATCGGCA CACTCAGCGG	25020
GTTCATCACC GTAATTTCAC TTTCCGCTTC GCTGGGCTCT TCCTCTTCCT CTTGCGTCCG	25080
CATACCACGC GCCACTGGGT CGTCTTCATT CAGCCGCCGC ACTGTGGCCT TACCTCCTTT	25140
GCCATGTTG ATTAGCACCG GTGGGTTGCT GAAACCCACC ATTTGTAGCG CCACATCTTC	25200
TCTTTCTTCC TCGCTGTCCA CGATTACCTC TGGTGATGGC GGGCGCTCGG GCTTGGGAGA	25260
AGGGCGCTTC TTTTTCTTCT TGCCGCAAT GGCCAAATCC GCCGCCGAGG TCGATGGCCG	25320
CGGGCTGGGT GTGCGCGGCA CCAGCGCGTC TTGTGATGAG TCTTCCTCGT CCTCGGACTC	25380
GATAACGCCGC CTCATCCGCT TTTTTGGGGG CGCCCGGGGA GGCGGCGCG ACGGGGACGG	25440
GGACGACACG TCCTCCATGG TTGGGGGACG TCGCGCCGCA CCGCGTCCGC GCTCGGGGGT	25500
GGTTTCGCGC TGCTCCTCTT CCCGACTGGC CATTTCCTTC TCCTATAGGC AGAAAAAGAT	25560
CATGGAGTCA GTCGAGAAGA AGGACAGCCT AACCGCCCCC TCTGAGTTCG CCACCACCGC	25620
CTCCACCGAT GCCGCCAACG CGCCTACAC CTTCCCCGTC GAGGCACCCC CGCTTGAGGA	25680
GGAGGAAGTG ATTATCGAGC AGGACCCAGG TTTTGTAAGC GAAGACGACG AGGACCGCTC	25740
AGTACCAACA GAGGATAAAA AGCAAGACCA GGACAACGCA GAGGCAAACG AGGAACAAGT	25800
CGGGCGGGGG GACGAAAGGC ATGGCGACTA CCTAGATGTG GGAGACGACG TGCTGTTGAA	25860
GCATCTGCAG CGCCAGTGC CGATTATCTG CGACGCGTTG CAAGAGCGCA GCGATGTGCC	25920
CCTCGCCATA GCGGATGTCA GCCTTGCCTA CGAACGCCAC CTATTCTCAC CGCGCGTACC	25980
CCCCAAACGC CAAGAAAACG GCACATGCGA GCCCAACCCG CGCCTCAACT TCTACCCGT	26040
ATTTGCCGTG CCAGAGGTGC TTGCCACCTA TCACATCTTT TTCCAAAAGT GCAAGATACC	26100
CCTATCCTGC CGTGCCAAACC GCAGCCGAGC GGACAAGCAG CTGGCCTTGC GGCAGGGCGC	26160
TGTCATACCT GATATCGCCT CGCTCAACGA AGTGCCAAAATC TTGAGGAGG GTCTTGGACG	26220
CGACGGAGAAG CGCGCGGCAA ACGCTCTGCA ACAGGAAAAC AGCGAAAATG AAAGTCACTC	26280

TGGAGTGTG	GTTGACTCG	AGGGTGACAA	CGCGCGCCTA	GCCGTACTAA	AACGCAGCAT	26340
CGAGGTCA	CCACTTGCCT	ACCCGGCACT	TAACCTACCC	CCCAAGGTCA	TGAGCACAGT	26400
CATGAGTGAG	CTGATCGTGC	GCCGTGCGCA	GCCCCTGGAG	AGGGATGCAA	ATTGCAAGA	26460
ACAAACAGAG	GAGGGCCTAC	CCCGAGTTGG	CGACGAGCAG	CTAGCGCGCT	GGCTTCAAAC	26520
GCGCGAGCCT	GCCGACTTGG	AGGAGCGACG	CAAACTAATG	ATGGCCGCAG	TGCTCGTTAC	26580
CGTGGAGCTT	GAGTGCATGC	AGCGGTTCTT	TGCTGACCCG	GAGATGCAGC	GCAAGCTAGA	26640
GGAAACATTG	CACTACACCT	TTCGACAGGG	CTACGTACGC	CAGGCCCTGCA	AGATCTCAA	26700
CGTGGAGCTC	TGCAACCTGG	TCTCCTACCT	TGGAATTTG	CACGAAAACC	GCCTTGGGCA	26760
AAACGTGCTT	CATTCCACGC	TCAAGGGCGA	GGCGCGCCCG	GAETACGTCC	GCGACTGCGT	26820
TTACTTATTT	CTATGCTACA	CCTGGCAGAC	GGCCATGGGC	GTTCGGCAGC	AGTGCTTGGA	26880
GGAGTGCAAC	CTCAAGGAGC	TGCAGAAACT	GCTAAAGCAA	AACTTGAAGG	ACCTATGGAC	26940
GGCCTTCAAC	GAGCGCTCCG	TGGCCGCGCA	CCTGGCGGAC	ATCATTTC	CCGAACGCCT	27000
GCTTAAAACC	CTGCAACAGG	GTCTGCCAGA	CTTCACCACT	CAAAGCATGT	TGCAGAACTT	27060
TAGGAACCTT	ATCCTAGAGC	GCTCAGGAAT	CTTGCCCCGC	ACCTGCTGTG	CACTTCCTAG	27120
CGACTTTGTG	CCCATTAAGT	ACCGCGAATG	CCCTCCGCCG	CTTTGGGGCC	ACTGCTACCT	27180
TCTGCAGCTA	GCCAAC TACC	TTGCCTACCA	CTCTGACATA	ATGGAAGACG	TGAGCGGTGA	27240
CGGTCTACTG	GAGTGTCACT	GTCGCTGCAA	CCTATGCACC	CCGCACCGCT	CCCTGGTTTG	27300
CAATTGCGAG	CTGCTTAACG	AAAGTCAAAT	TATCGGTACC	TTTGAGCTGC	AGGGTCCCTC	27360
GCCTGACGAA	AAGTCCGCGG	CTCCGGGGTT	GAAACTCACT	CCGGGGCTGT	GGACGTCGGC	27420
TTACCTTCGC	AAATTTGTAC	CTGAGGACTA	CCACGCCAC	GAGATTAGGT	TCTACGAAGA	27480
CCAATCCCGC	CCGCCAAATG	CGGAGCTTAC	CGCCTGGTC	ATTACCCAGG	GCCACATTCT	27540
TGGCCAATTG	CAAGCCATCA	ACAAAGCCCG	CCAAGAGTTT	CTGCTACGAA	AGGGACGGGG	27600
GGTTTACTTG	GACCCCCAGT	CCGGCGAGGA	GCTCAACCCA	ATCCCCCGC	CGCCGCAGCC	27660
CTATCAGCAG	CAGCCGCGGG	CCCTTGCTTC	CCAGGATGGC	ACCCAAAAAG	AAGCTGCAGC	27720
TGCCGCCGCC	ACCCACGGAC	GAGGAGGAAT	ACTGGGACAG	TCAGGCAGAG	GAGGTTTTGG	27780
ACGAGGAGGA	GGAGGACATG	ATGGAAGACT	GGGAGAGCCT	AGACGAGGAA	GCTTCCGAGG	27840
TCGAAGAGGT	GTCAGACGAA	ACACCGTCAC	CCTCGTGC	ATTCCCCCTCG	CCGGCGCCCC	27900
AGAAATCGGC	AACCGGTTCC	AGCATGGCTA	CAACCTCCGC	TCCTCAGGCG	CCGCCGGCAC	27960
TGCCCCTTCG	CCGACCCAAC	CGTAGATGGG	ACACCACTGG	AACCAGGGCC	GGTAAGTCCA	28020
AGCAGCCGCC	GCCGTTAGCC	CAAGAGCAAC	AACAGGCCA	AGGCTACCGC	TCATGGCGCG	28080
GGCACAAAGAA	CGCCATAGTT	GCTTGCTTGC	AAGACTGTGG	GGGCAACATC	TCCTTCGCC	28140
GCCGTTTCT	TCTCTACCAT	CACGGCGTGG	CCTTCCCCCG	TAACATCCTG	CATTACTACC	28200
GTCATCTCTA	CAGCCATAC	TGCACCGGGG	GCAGCGGCAG	CGGCAGCAAC	AGCAGCGGCC	28260
ACACAGAAGC	AAAGGCGACC	GGATAGCAAG	ACTCTGACAA	AGCCCAAGAA	ATCCACAGCG	28320
GCGGCAGCAG	CAGGAGGAGG	AGCGCTGCGT	CTGGCGCCCA	ACGAACCCGT	ATCGACCCGC	28380

GAGCTTAGAA ACAGGATTT TCCCACCTCG TATGCTATAT TTCAACAGAG CAGGGGCCAA 28440
 GAACAAGAGC TGAAAATAAA AAACAGGTCT CTGCGATCCC TCACCCGCAG CTGCCTGTAT 28500
 CACAAAAGCG AAGATCAGCT TCGGCGCACG CTGGAAGACG CGGAGGCTCT CTTCAGTAAA 28560
 TACTGCGCGC TGACTCTTAA GGACTAGTTT CGCGCCCTTT CTCAAATTAA AGCGCGAAAAA 28620
 CTACGTCATC TCCAGGGCC ACACCCGGCG CCAGCACCTG TCGTCAGCGC CATTATGAGC 28680
 AAGGAAATTG CCACGCCCTA CATGTGGAGT TACCAGCCAC AAATGGGACT TGCGGCTGGA 28740
 GCTGCCAAG ACTACTAAC CCGAATAAAC TACATGAGCG CGGGACCCA CATGATATCC 28800
 CGGGTCAACG GAATCCGCGC CCACCGAAAC CGAATTCTCT TGGAACAGGC GGCTATTACC 28860
 ACCACACCTC GTAATAACCT TAATCCCCGT AGTTGGCCCG CTGCCCTGGT GTACCAGGAA 28920
 AGTCCCGCTC CCACCACTGT GGTACTTCCC AGAGACGCCA AGGCCGAAGT TCAGATGACT 28980
 AACTCAGGGG CGCAGCTTGC GGGCGGCTTT CGTCACAGGG TGCGGTCGCC CGGGCAGGGT 29040
 ATAACTCACC TGACAATCAG AGGGCGAGGT ATTCAAGCTCA ACGACGAGTC GGTGAGCTCC 29100
 TCGCTTGGTC TCCGTCCGA CGGGACATTG CAGATCGCG GCGCCGGCCG TCCTTCATTG 29160
 ACGCCTCGTC AGGCAATCCT AACTCTGCAG ACCTCGCCT CTGAGCCGCG CTCTGGAGGC 29220
 ATTGGAACTC TGCAATTAT TGAGGAGTTT GTGCCATCGG TCTACTTTAA CCCCTTCTCG 29280
 GGACCTCCCCG GCCACTATCC GGATCAATTG ATTCCCTAACT TTGACGCGGT AAAGGACTCG 29340
 GCGGACGGCT ACGACTGAAT GTTAATTAAG TTCCTGTCCA TCCGCACCCA CTATCTTCAT 29400
 GTTGTGCAAG ATGAAGCGCG CAAGACCGTC TGAAGATAAC TTCAACCCCG TGTATCCATA 29460
 TGACACGGAA ACCGGTCCCTC CAACTGTGCC TTTTCTTACT CCTCCCTTG TATCCCCAA 29520
 TGGGTTTCAA GAGAGTCCCC CTGGGGTACT CTCTTGTGCG CTATCCGAAC CTCTAGTTAC 29580
 CTCCAATGGC ATGCTTGCAGC TCAAAATGGG CAACGGCCTC TCTCTGGACG AGGCCGGCAA 29640
 CCTTACCTCC CAAAATGTA CCACTGTGAG CCCACCTCTC AAAAAAACCA AGTCAAACAT 29700
 AACACCTGGAA ATATCTGCAC CCCTCACAGT TACCTCAGAA GCCCTAACTG TGGCTGCCGC 29760
 CGCACCTCTA ATGGTCGCGG GCAACACACT CACCATGCAA TCACAGGCC CGCTAACCGT 29820
 GCACGACTCC AAACCTAGCA TTGCCACCCA AGGACCCCTC ACAGTGTCAAG AAGGAAAGCT 29880
 AGCCCTGCAA ACATCAGGCC CCCTCACAC CACCGATAGC AGTACCCCTA CTATCACTGC 29940
 CTCACCCCT CTAACACTG CCACTGGTAG CTTGGGCATT GACTTGAAAG AGCCCATTTA 30000
 TACACAAAAT GGAAAATAG GACTAAAGTA CGGGGCTCCT TTGCAATGAA CAGACGACCT 30060
 AACACCTTG ACCGTAGCAA CTGGTCCAGG TGTGACTATT AATAATACCT CCTTGCAAAC 30120
 TAAAGTTACT GGAGCCTTGG GTTTGATTCA ACAAGGCAAT ATGCAACTTA ATGTAGCAGG 30180
 AGGACTAAGG ATTGATTCTC AAAACAGACG CCTTATACTT GATGTTAGTT ATCCGTTGAA 30240
 TGCTCAAAAC CAACTAAATC TAAGACTAGG ACAGGGCCCT CTTTTATAA ACTCAGCCCA 30300
 CAAACTGGAT ATTAACCTACA ACAAAAGGCCT TTACTTGTCTT ACAGCTTCAA ACAATTCCAA 30360
 AAAGCTTGAG GTTAACCTAA GCACTGCCAA GGGGTTGATG TTTGACGCTA CAGCCATAGC 30420
 CATTAATGCA GGAGATGGGC TTGAATTGGG TTCACCTAAT GCACCAAACAA CAAATCCCC 30480

CAAAACAAAA ATTGGCCATG GCCTAGAACATT TGATTCAAAC AAGGCTATGG TTCCCTAAACT	30540
AGGAACCTGGC CTTAGTTTG ACACGCACAGG TGCCATTACA GTAGGAAACA AAAATAATGA	30600
TAAGCTAACT TTGTGGACCA CACCAGCTCC ATCTCCTAAC TGTAGACTAA ATGCAGAGAA	30660
AGATGCTAAA CTCACTTTGG TCTTAACAAA ATGTGGCAGT CAAATACTTG CTACAGTTTC	30720
AGTTTTGGCT GTTAAAGGCA GTTTGGCTCC AATATCTGGA ACAGTTCAA GTGCTCATCT	30780
TATTATAAGA TTTGACGAAA ATGGAGTGCT ACTAAACAAT TCCTTCCTGG ACCCAGAATA	30840
TTGGAACCTT AGAAATGGAG ATCTTACTGA AGGCACAGCC TATACAAACG CTGTTGGATT	30900
TATGCCTAAC CTATCAGCTT ATCCAAAATC TCACGGTAAA ACTGCCAAAA GTAACATTGT	30960
CAGTCAGTT TACTTAAACG GAGACAAAAC TAAACCTGTA ACACTAACCA TTACACTAAA	31020
CGGTACACAG GAAACAGGGAG ACACAACCTCC AAGTGCATAC TCTATGTCAT TTTCATGGGA	31080
CTGGTCTGGC CACAACATACA TTAATGAAAT ATTTGCCACA TCCTCTTACA CTTTTTCATA	31140
CATTGCCAA GAATAAAAGAA TCGTTTGTGT TATGTTCAA CGTGTATTATT TTTCAATTGC	31200
AGAAAATTTCA AAGTCATTT TCATTCAGTA GTATAGCCCC ACCACCACAT AGCTTATACA	31260
GATCACCGTA CCTTAATCAA ACTCACAGAA CCCTAGTATT CAACCTGCCA CCTCCCTCCC	31320
AACACACAGA GTACACAGTC CTTTCTCCCC GGCTGGCCTT AAAAAGCATH ATATCATGGG	31380
TAACAGACAT ATTCTTAGGT GTTATATTCC ACACGGTTTC CTGTCGAGCC AAACGCTCAT	31440
CAGTGATATT AATAAACTCC CCGGGCAGCT CACTTAAGTT CATGTCGCTG TCCAGCTGCT	31500
GAGCCACAGG CTGCTGTCCA ACTTGCGGTT GCTTAACGGG CGCGAAGGA GAAGTCCACG	31560
CCTACATGGG GGTAGAGTCA TAATCGTCA TCAGGATAGG GCGGTGGTGC TGAGCAGCG	31620
CGCGAATAAA CTGCTGCCGC CGCCGCTCCG TCCTGCAGGA ATACAACATG GCAGTGGTCT	31680
CCTCAGCGAT GATTGGCACC GCCCGCAGCA TAAGGCCT TGCCCTCCGG GCACAGCAGC	31740
GCACCCCTGAT CTCACTTAAAC TCAGCACAGT AACTGCAGCA CAGCACCACA ATATTGTTCA	31800
AAATCCCACA GTGCAAGGCG CTGTATCCAA AGCTCATGGC GGGGACCACA GAACCCACGT	31860
GGCCATCATA CCACAAGCGC AGGTAGATTA AGTGGCGACC CCTCATAAAC ACGCTGGACA	31920
TAAACATTAC CTCTTTGGC ATGTTGTAAT TCACCACCTC CCGGTACCAT ATAAACCTCT	31980
GATTAAACAT GGCGCCATCC ACCACCACCC TAAACCAGCT GGCCAAAACC TGCCCGCCGG	32040
CTATACACTG CAGGGAACCG GGACTGGAAC AATGACAGTG GAGAGCCCAG GACTCGTAAC	32100
CATGGATCAT CATGTCGTC ATGATATCAA TGTTGGCACA ACACAGGCAC ACGTGCATAC	32160
ACTTCCTCAG GATTACAAGC TCCTCCCGCG TTAGAACCAT ATCCCAGGGA ACAACCCATT	32220
CCTGAATCAG CGTAAATCCC ACACTGCAGG GAAGACCTCG CACGTAACTC ACGTTGTGCA	32280
TTGTCAAAGT GTTACATTGCG GGCAGCAGCG GATGATCCTC CAGTATGGTA GCGCGGGTTT	32340
CTGTCTCAAAGT AGGAGGTAGA CGATCCCTAC TGTACGGAGT GCGCCGAGAC AACCGAGATC	32400
GTGTTGGTCG TAGTGTCAAGT CCAAATGGAA CGCCGGACGT AGTCATATTT CCTGAAGCAA	32460
AACCAGGTGC GGGCGTGACA AACAGATCTG CGTCTCCGGT CTCGCCGCTT AGATCGCTCT	32520
GTGTAGTAGT GTAGTATAT CCACTCTCTC AAAGCATCCA GGCGCCCCCT GGCTTCGGGT	32580

TCTATGAAA CTCCTTCATG CGCCGCTGCC CTGATAACAT CCACCACCGC AGAATAAGCC 32640
 ACACCCAGCC AACCTACACA TTGTTCTGC GAGTCACACA CGGGAGGAGC GGGAAAGAGCT 32700
 GGAAGAACCA TGTTTTTTT TTTATTCAA AAGATTATCC AAAACCTCAA AATGAAGATC 32760
 TATTAAGTGA ACGCGCTCCC CTCCGGTGGC GTGGTCAAAC TCTACAGCCA AAGAACAGAT 32820
 AATGGCATTG GTAAGATGTT GCACAATGGC TTCCAAAAGG CAAACGGCCC TCACGTCCAA 32880
 GTGGACGTAA AGGCTAAACC CTTCAGGGTG AATCTCCTCT ATAAACATTC CAGCACCTTC 32940
 AACCATGCC AAATAATTCT CATCTCGCCA CCTTCTCAAT ATATCTCTAA GCAAATCCCG 33000
 AATATTAAGT CCGGCCATTG TAAAAATCTG CTCCAGAGCG CCCTCCACCT TCAGCCTCAA 33060
 GCAGCGAATC ATGATTGCAA AAATTCAAGGT TCCTCACAGA CCTGTATAAG ATTCAAAAGC 33120
 GGAACATTAA CAAAAATACC GCGATCCCGT AGGTCCCTTC GCAGGGCCAG CTGAACATAA 33180
 TCGTGCAGGT CTGCACGGAC CAGCGCGGCC ACTTCCCCGC CAGGAACCTT GACAAAAGAA 33240
 CCCACACTGA TTATGACACG CATACTCGGA GCTATGCTAA CCAGCGTAGC CCCGATGTAA 33300
 GCTTTGTTGC ATGGGCGGCG ATATAAAATG CAAGGTGCTG CTCAAAAAAT CAGGCAAAGC 33360
 CTCGCGAAA AAAGAAAGCA CATCGTAGTC ATGCTCATGC AGATAAAGGC AGGTAAGCTC 33420
 CGGAACCACC ACAGAAAAAG ACACCATTTC TCTCTCAAAC ATGTCTGCGG GTTTCTGCAT 33480
 AACACAAAAA TAAAATAACA AAAAAACATT TAAACATTAG AAGCCTGTCT TACAACAGGA 33540
 AAAACAAACCC TTATAAGCAT AAGACGGACT ACGGCCATGC CGGCGTGACC GTAAAAAAAC 33600
 TGGTCACCGT GATTAAAAG CACCACCGAC AGCTCCTCGG TCATGTCCGG AGTCATAATG 33660
 TAAGACTCGG TAAACACATC AGGTTGATTG ATCGGTCAGT GCTAAAAGC GACCGAAATA 33720
 GCCCGGGGGA ATACATACCC GCAGGCGTAG AGACAACATT ACAGCCCCA TAGGAGGTAT 33780
 AACAAAATTAA ATAGGAGAGA AAAACACATA AACACCTGAA AAACCCCTCT GCCTAGGCAA 33840
 AATAGCACCC TCCCCTCCA GAACAACATA CAGCGCTTCA CAGCGGCAGC CTAACAGTCA 33900
 GCCTTACCAAG TAAAAAAGAA AACCTATTAA AAAACACCA CTCGACACGG CACCAGCTCA 33960
 ATCAGTCACA GTGTAAAAAA GGGCCAAGTG CAGAGCGAGT ATATATAGGA CTAAAAAAATG 34020
 ACGTAACGGT TAAAGTCCAC AAAAAACACC CAGAAAACCG CACGCGAACCC TACGCCCAGA 34080
 AACGAAAGCC AAAAAACCCCA CAACTTCCCTC AAATCGTCAC TTCCGTTTTC CCACGTTACG 34140
 TAACTTCCCA TTTTAAGAAA ACTACAATTG CCAACACATA CAAGTTACTC CGCCCTAAAA 34200
 CCTACGTAC CCGCCCCGTT CCCACGGCCC GCGCCACGTC ACAAAACTCCA CCCCTCATT 34260
 ATCATATTGG CTTCAATCCA AAATAAGGTA TATTATTGAT GAT 34303

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 380 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCAGGCTTA CACTTATGC TTCCGGCTCG TATGTTGTGT GGAATTGTGA GCGGATAACA	60
ATTCACACA GGAAACAGCT ATGACCATGA TTACGCCAAG CGCCCAATTAA ACCCTCACTA	120
AAGGGAACAA AAGCTGGTA CCGGGCCCCC CCTCGAGGTC GACGGTATCG ATAAGCTTAC	180
GCGTGGCCTA GGCGGCCGAA TTCCTGCAGC CCAGGGGATC CACTAGTTCT AGAGCGGCCG	240
CCACCGCGGC GCCTTAATTAA ATACGTAAGC TCCAATTCCG CCTATAGTGA GTCTATTAC	300
GCGCGCTCAC TGGCCGTCGT TTTACAACGT CGTGACTGGG AAAACCTGG CGTTACCAA	360
CTTAATCGCC TTGCAGCACA	380

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TGCCGCAGCA CCGGATGCAT C

21

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCGTCCGGAG GCTGCCATGC GGCAGGG

27

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1481 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGCTGCCATG CGGCAGGGAT ACGGCGCTAA CGATGCATCT CAACAATTGT TGTGTAGGTA	60
CTCCGGCCG GAGGGACCTG AGCGAGTCGG CATCGACCGG ATCGAAAAAC CTCTCGAGAA	120
AGGCGTCTAA CCAGTCACAG TCGCAAGGTA GGCTGAGGCAC CGTGGCGGGC GGCAGCGGGC	180
GGCGGTGGG GTTGTCTG GCGGAGGTGC TGCTGATGAT GTAATTAAAG TAGGCGGTCT	240
TGAGACGGCG GATGGTCGAC AGAACGACCA TGTCTTGGG TCCGGCCTGC TGAATGCGCA	300
GGCGGTGGC CATGCCAG GCTTCGTTTT GACATGGCG CAGGTCTTG TAGTAGTCTT	360
GCATGAGCCT TTCTACCGGC ACTTCTTCTT CTCCTTCCTC TTGTCTGCA TCTCTTGCAT	420

CTATCGCTGC GGCGGCCGCG GAGTTGGCC GTAGGTGGCG CCCTCTCCT CCCATGCGTG	480
TGACCCCGAA GCCCCTCATC GGTGAAGCA GGGCTAGGTC GGCGACAACG CGCTCGGCTA	540
ATATGGCCTG CTGCACCTGC GTGAGGGTAG ACTGGAAGTC ATCCATGTCC ACAAAGCGGT	600
GGTATGCGCC CGTGTGATG GTGTAAGTGC AGTTGGCCAT AACGGACCAG TTAACGGTCT	660
GGTGACCCGG CTGCGAGAGC TCGGTGTACC TGAGACCGA GTAAGCCCTC GAGTCAAATA	720
CGTAGTCGTT GCAAGTCCGC ACCAGGTACT GGTATCCAC CAAAAAGTGC GGCGCGGCT	780
GGCGGTAGAG GGGCCAGCGT AGGGTGGCCG GGGCTCCCCG GGCGAGATCT TCCAACATAA	840
GGCGATGATA TCCGTAGATG TACCTGGACA TCCAGGTGAT GCCGGCGCG GTGGTGGAGG	900
CGCGCGGAAA GTCGCGGACG CGGTTCCAGA TGTTGCCAG CGGAAAAAG TGCTCCATGG	960
TCGGGACGCT CTGGCCGGTC AGGCGCGC GC AATCGTTGAC GCTCTACCGT GC AAAAGGAG	1020
AGCCTGTAAG CGGGCACTCT TCCGTGGTCT GGTGGATAAA TT CGCAAGGG TATCATGGCG	1080
GACGACCGGG GTTCGAGCCC CGTATCCGGC CGTCCGCCGT GATCCATGCG GTTACCGCCC	1140
GCGTGTGAA CCCAGGTGTG CGACGTCAGA CAACGGGGGA GTGCTCCTTT TGGCTTCCTT	1200
CCAGGCGCGG CGGCTGCTGC GCTAGCTTT TTGGCCACTG GCCGCGCGCA GCGTAAGCGG	1260
TTAGGCTGGA AAGCGAAAGC ATTAAGTGGC TCGCTCCCTG TAGCCGGAGG GTTATTTCC	1320
AAGGGTTGAG TCGCGGGACC CCCGGTTCGA GTCTCGGACC GGCGGACTG CGCGAACGG	1380
GGGTTTGCCT CCCC GTCATG CAAGACCCCG CTTGCAAATT CCTCCGGAAA CAGGGACGAG	1440
CCCCTTTTTT GCTTTCCCA GATGCATCCG GTGCTGCCG A	1481

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3364 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAATTCCCCA TCCTGGCTA TAGAGAGAGT TCCAGAACAG CCAGGGCTAC AGATAAACCC	60
ATCTGGAAAA ACAAAAGTTGA ATGACCCAAG AGGGGTTCTC AGAGGGTGGC GTGTGCTCCC	120
TGGCAAGCCT ATGACATGGC CGGGGCCTGC CTCTCTCTGC CTCTGACCCCT CAGTGGCTCC	180
CATGAACCTC TTGCCCAATG GCATCTTTT CCTGCGCTCC TTGGGTTATT CCAGTCTCCC	240
CTCAGCATTG CTTCTCTCAGG GCCTCGCTCT TCTCTCTGCT CCCTCCTTGC ACAGCTGGCT	300
CTGTCCACCT CAGATGTCAC AGTGCTCTCT CAGAGGAGGA AGGCACCATG TACCCCTGT	360
TTCCCAGGTA AGGGTTCAAT TTTAAAAAT GGTTTTTGT TTGTTGTTT GTTTGTTTGT	420
TTGTTTGTGTT TTCAAGACAG GGCTCCTCTG TGTAGTCTTA ACTGTCTGAA AACTCCCTCT	480
GTAGACCAGG TCGACCTCGA ACTCTTGAAA CCTGCCACGG ACCACCCAGT CAGGTATGGA	540
GGTCCCTGGA ATGAGCGTCC TCGAAGCTAG GTGGGTAAGG GTTCGGCGGT GACAAACAGA	600
AACAAACACA GAGGCAGTTT GAATCTGAGT GTATTTGCA GCTCTCAAGC AGGGGATTTT	660

WO 98/17783

PCT/US97/19541

ATACATAAAA	AAAAAAACCA	AAACATTACA	TCTCTTAGAA	ACTATATCCA	720
ATGAAACAT	CACAGATACC	AACCAAACCC	ATTGGGCAGA	GTAAAGCACA	780
AAGCATTACA	ACTCTGAAAC	CATGTATTCA	GTGAATCACA	AACAGAACAG	840
TATTAATATA	AATCACCAAA	ATATAACAAT	TCTAAAAGGA	TGTATCCAGT	900
GTCCAAGGCT	AGTGGCAGAT	TTCCAGGAGC	AGGTTAGTAA	ATCTTAACCA	960
TCTCCAGCCC	CATGGTCAAT	TATTATTTAG	CATCTAGTGC	CTAATTTTTT	1020
TTCACTATGT	AATTAAAAC	TATTTTAATT	CTTCCTAATT	AAGGCTTTCT	1080
CCAAAATTCA	CCTCCAATGA	CACACGCGTA	GCCATATGAA	ATTTTATTGT	1140
TGTACCTATC	ATAATAGTTT	TGTAAATGAT	TTAAAAAGCA	AAGTGTAGC	1200
GGCACACGCC	TTTAATCCCT	GCACCTGGGA	GGCAGGGCA	GGAGGATTTG	1260
GCCAGCCTGG	TCTACAGAGT	GAGTTCCAGG	ACAGCCAGGG	CTACACAGAG	1320
TCGAACCCCC	CACCCCCAA	AAAAAGCAAA	GTGTTGGTTT	CCTTGGGAT	1380
TAGTGGCCA	TCTCTAGGCC	CATCTCACCC	ATTATTCTCG	CTTAAGATCT	1440
TACCAGGAAC	ATGTAAATAA	GAAAAGGAAT	AAGAGAAAAC	AAAACAGAGA	1500
AGAACTACGG	CTCAATATTT	TTTCTCTCCG	GCGAAGAGTT	CCACAACCCT	1560
CCTCCACGTT	TTGAGGTCAA	TGGCCTCAGT	CTGTGGAAC	TGTACACAG	1620
AGGTGGTGTG	GCAGAAACCC	ATTCCCTTTA	GTGTCTGGG	CTAAAAGTAA	1680
GGAGGCCTTT	GCTCATCTGA	CCATGCTGAC	AAGGAACACG	GGTGCCAGGA	1740
ACCCCCAGGAA	CACCTTAAAC	ACTCTTCCC	TTCTCCGCC	CCTAGAGCAG	1800
CCAGCCTGGG	CAGAAATGGG	GGAAGATGGA	GTGAAGCCAT	ACTGGCTACT	1860
CAGAGGGAGC	CGGGGGCAAT	ACTGGAGAAG	CTGGTCTCCC	CCCAGGGCA	1920
CTCCCGAGGCA	GAAGAGGAAA	CTTCCACAGT	GCATCTCACT	TCCATGAATC	1980
ACTCTGAGGT	CCTTGGTCAC	AGCTGAGGTG	CAAAAGGCTC	CTGTCATATT	2040
CTGGTCTGCC	TTCCACAGCT	TGGGGGCCAC	CTAGCCCACC	TCTCCCTAGG	2100
GCCACTACGG	GTCTAGGCTG	CCCATGTAAG	GAGGCAAGGC	CTGGGGACAC	2160
TGGTTATAAT	TAACCCAGAC	ATGTGGCTGC	CCCCCCCCCC	CCAACACCTG	2220
CTCACCCCCA	CCCCGGTGCC	TGGGTCTTAG	GCTCTGTACA	CCATGGAGGA	2280
CTAAAAATAA	CCCTGTCCCT	GGTGGATCCA	GGGTGAGGGG	CAGGCTGAGG	2340
CCCTCAGCCG	CAGGTTTGTT	TTCCCAAGAA	TGGTTTTCT	GCTTCTGTAG	2400
CAATTCTGCC	ATGGTGGAGC	AGCCTGCACT	GGGCTCTGG	GAGAAACCAA	2460
AACCTTTCAG	CTACAGTTAT	TGCCTTCCCT	GTAGATGGGC	GACTACAGCC	2520
CCCCGTCTCC	TGTATCCTTC	CTGGGCCTGG	GGATCCTAGG	CTTTCACTGG	2580
CCAGGTGCTG	TAGGCTAGAG	TCACGGCTCC	CAAGAACAGT	GCTTGCCTGG	2640
TCTGAACCTC	CAACTGCAAA	AAATGACACA	TACCTTGACC	CTTGGAAAGGC	2700
GGATTGCCAT	GAGTGCAAAG	CCAGACTGGG	TGGCATAGTT	AGACCCCTGTC	2760

AAAAACAAATT AAATAACTAA AGTCAGGCAA GTAATCCTAC TCGGGAGACT GAGGCAGAGG	2820
GATTGTTACA TGTCTGAGGC CAGCCTGGAC TACATAGGGT TTCAGGCTAG CCCTGTCTAC	2880
AGAGTAAGGC CCTATTCAA AAACACAAAAC AAAATGGTTC TCCCAGCTGC TAATGCTCAC	2940
CAGGCAATGA AGCCTGGTGA GCATTAGCAA TGAAGGCAAT GAAGGAGGGT GCTGGCTACA	3000
ATCAAGGCTG TGGGGGACTG AGGGCAGGCT GTAACAGGCT TGGGGGCCAG GGCTTATACG	3060
TGCCTGGGAC TCCCCAAGTA TTACTGTTCC ATGTTCCCGG CGAAGGGCCA GCTGTCCCCC	3120
GCCAGCTAGA CTCAGCACTT AGTTTAGGAA CCAGTGAGCA AGTCAGCCCT TGGGGCAGCC	3180
CATACAAGGC CATGGGGCTG GGCAAGCTGC ACGCCTGGGT CCGGGGTGGG CACGGTGCCC	3240
GGGCAACGAG CTGAAAGCTC ATCTGCTCTC AGGGGCCCCCT CCCTGGGAC AGCCCCCTCCT	3300
GGCTAGTCAC ACCCTGTAGG CTCCTCTATA TAACCCAGGG GCACAGGGC TGCCCCCGGG	3360
TCAC	3364

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 174 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGTACCACTA CGGGTCTAGG CTGCCCATGT AAGGAGGCAA GGCCTGGGA CACCCGAGAT	60
GCCTGGTTAT AATTAACCCC AACACCTGCT GCCCCCCCCC CCCAACACCC TGCTGCCTGA	120
GCCTGAGCGG TTACCCCACC CCGGTGCCTG GGTCTTAGGC TCTGTACACC ATGG	174

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 699 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AGATCTTCCT AGAAATTTCGC TGCTCGCGAG GGCGGGCTGT TGGGGTGAGT ACTCCCTCTC	60
AAAAGCGGGC ATGACTTCTG CGCTAAGATT GTCAGTTCC AAAAACGAGG AGGATTTGAT	120
ATTCACCTGG CCCGCGGTGA TGCCTTGAG GGTGGCCGCG TCCATCTGGT CAGAAAAGAC	180
AATCTTTTG TTGTCAAGCT TGAGGTGTGG CAGGCTTGAG ATCGATCTGG CCATACACTT	240
GAGTGACAAT GACATCCACT TTGCCTTCT CTCCACAGGT GTCCACTCCC AGGTCCAACC	300
GCGGATCTCC CGGGACCATG CCCAAGAAGA AGAGGAAGGT GTCCAATTAA CTGACCGTAC	360
ACCAAAATTG GCCTGCATTA CCGGTGATG CAACGAGTGA TGAGGTTCGC AAGAACCTGA	420
TGGACATGTT CAGGGATCGC CAGGCCTTTT CTGAGCATAAC CTGGAAAATG CTTCTGTCCG	480

TTTGCCGGTC GTGGGCGGCA TGGTGCAAGT TGAATAACCG GAAATGGTTT CCCGCAGAAC	540
CTGAAGATGT TCGCGATTAT CTTCTATATC TTCAGGCAG CGGTCTGGCA GTAAAAACTA	600
TCCAGCAACA TTTGGGCCAG CTAAACATGC TTCATCGTCG GTCCGGGCTG CCACGACCAA	660
GTGACAGCAA TGCTGTTCA CTGGTTATGC GGCGGATCC	699

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 68 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GAAGATCTAT AACTTCGTAT AATGTATGCT ATACGAAGTT ATTACCGAAG AAATGGCTCG	60
AGATCTTC	68

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 68 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GAAGATCTCG AGCCATTCTC TCGGTAATAA CTTCGTATAG CATACTATTAC ACGAAGTTAT	60
AGATCTTC	68

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCACATGTAT AACTTCGTAT ASCATACATT ATACGAAGTT ATACATGTGG	50
--	----

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCACATGTAT AACTTCGTAT AATGTATGCT ATACGAAGTT ATACATGTGG	50
--	----

CLAIMS

1. A recombinant plasmid, comprising in operable combination:
 - a) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element;
 - 5 b) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone;
 - c) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs; and
 - 10 d) a first gene of interest operably linked to said promoter element.
2. The recombinant plasmid of Claim 1 wherein the total size of said plasmid is between 27 and 40 kilobase pairs.
3. The recombinant plasmid of Claim 1, wherein said 5' end of said packaging sequence is linked to said 3' end of said left ITR.
- 15 4. The recombinant plasmid of Claim 3, wherein said first gene of interest is linked to said 3' end of said packaging sequence.
5. The recombinant plasmid of Claim 4, wherein said first gene of interest is the dystrophin cDNA gene.
- 20 6. The recombinant plasmid of Claim 4, further comprising a second gene of interest.
7. The recombinant plasmid of Claim 6, wherein said second gene of interest is linked to said 3' end of said right ITR.
- 25 8. The recombinant plasmid of Claim 7, wherein said second gene of interest is a reporter gene.

9. The recombinant plasmid of Claim 8, wherein said reporter gene is selected from the group consisting of the *E. coli* β -galactosidase gene, the human placental alkaline phosphatase gene, the green fluorescent protein gene and the choramphenicol acetyltransferase gene.

5 10. A mammalian cell line containing the recombinant plasmid of
Claim 1.

11. The cell line of Claim 10, wherein said cell line is a 293-derived cell line.

10 12. A helper adenovirus comprising i) first and a second *loxP* sequences, and ii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end.

13. The helper adenovirus of Claim 12, wherein said first *loxP* sequence is linked to the 5' end of said packaging sequence and said second *loxP* sequence is linked to said 3' end of said packaging sequence.

15 14. The helper adenovirus of Claim 12, further comprising at least one adenovirus gene coding region.

15. A mammalian cell line, comprising:
a) a recombinant plasmid, comprising, in operable combination:
20 i) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element,
ii) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone,
iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs, and

- iv) a first gene of interest operably linked to said promoter element; and
- b) a helper adenovirus comprising i) first and a second *loxP* sequences, and ii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end.

5

16. The cell line of Claim 15, wherein said helper adenovirus further comprises at least one adenovirus gene coding region.

17. The cell line of Claim 15, wherein said first gene of interest is the dystrophin cDNA gene

10

18. A method of producing an adenovirus minichromosome, comprising:

15

A) providing a mammalian cell line containing:

- a) a recombinant plasmid, comprising, in operable combination, i) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukarotic promoter element, ii) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone, iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs, and iv) a first gene of interest operably linked to said promoter element; and

20

- b) a helper adenovirus comprising i) first and a second *loxP* sequences, ii) at least one adenovirus gene coding region, and iii) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end; and

25

- B) growing said cell line under conditions such that said adenovirus gene coding region is expressed and said recombinant plasmid directs the production of at least one adenoviral minichromosome.

19. The method of Claim 18, wherein said adenovirus minichromosome is encapsitated.

20. The method of Claim 18, further comprising 3) recovering said encapsidated adenovirus minichromosome.

21. The method of Claim 20, further comprising 4) purifying said recovered encapsidated adenovirus minichromosome.

5 22. The method of Claim 21, further comprising 5) administering said purified encapsidated adenovirus minichromosome to a host.

23. The method of Claim 22, wherein said host is a mammal.

24. The method of Claim 23, wherein said mammal is a human.

10 25. A recombinant adenovirus comprising the adenovirus E2b region having a deletion, said adenovirus capable of self-propagation in a packaging cell line and said E2b region comprising the DNA polymerase gene and the adenovirus preterminal protein gene.

26. The recombinant adenovirus of Claim 25, wherein said deletion is within the adenovirus DNA polymerase gene.

15 27. The recombinant adenovirus of Claim 25, wherein said deletion is within the adenovirus preterminal protein gene.

28. The recombinant adenovirus of Claim 25, wherein said deletion is within the adenovirus DNA polymerase and preterminal protein genes.

20 29. A mammalian cell line stably and constitutively expressing the adenovirus E1 gene products and the adenovirus DNA polymerase.

30. The cell line of Claim 29, wherein said cell line comprises a recombinant adenovirus comprising a deletion within the E2b region, said recombinant adenovirus being capable of self-propagation in said cell line.

31. The cell line of Claim 30, wherein said deletion within said E2b region comprises a deletion within the adenoviral DNA polymerase gene.

5 32. The cell of Claim 29, wherein the genome of said cell line contains a nucleotide sequence encoding adenovirus DNA polymerase operably linked to a heterologous promoter.

33. The cell line of Claim 32, wherein said cell line is selected from the group consisting of the B-6, B-9, C-1, C-4, C-7, C-13, and C-14 cell lines.

10 34. The cell line of Claim 29 further constitutively expressing the adenovirus preterminal protein gene product.

35. The cell line of Claim 34, wherein said cell line comprises a recombinant adenovirus comprising a deletion within the E2b region, said recombinant adenovirus being capable of self-propagation in said cell line.

36. The cell line of Claim 35, wherein said deletion within said E2b region comprises a deletion within the adenoviral preterminal protein gene.

15 37. The cell line of Claim 36, wherein said deletion within said E2b region comprises a deletion within the adenoviral DNA polymerase and preterminal protein genes.

20 38. The cell line of Claim 34, wherein the genome of said cell line contains a nucleotide sequence encoding adenovirus preterminal protein operably linked to a heterologous promoter.

39. The cell line of Claim 38, wherein said cell line is selected from the group consisting of the C-1, C-4, C-7, C-13, and C-14 cell lines.

40. A method of producing infectious recombinant adenovirus particles containing an adenoviral genome containing a deletion within the E2b region, comprising

a) providing:

5 i) a mammalian cell line stably and constitutively expressing the adenovirus E1 gene products and the adenovirus DNA polymerase;

10 ii) a recombinant adenovirus comprising a deletion within the E2b region, said recombinant adenovirus being capable of self-propagation in said cell line;

b) introducing said recombinant adenovirus into said cell line under conditions such that said recombinant adenovirus is propagated to form infectious recombinant adenovirus particles; and

c) recovering said infectious recombinant adenovirus particles.

15 41. The method of Claim 40, further comprising d) purifying said recovered infectious recombinant adenovirus particles.

42. The method of Claim 41, further comprising e) administering said purified recombinant adenovirus particles to a host.

20 43. The method of Claim 40, wherein said mammalian cell line further constitutively expresses the adenovirus preterminal protein.

44. A recombinant plasmid capable of replicating in a bacterial host comprising adenoviral E2b sequences, said E2b sequences containing a deletion within the polymerase gene, said deletion resulting in reduced polymerase activity.

25 45. The recombinant plasmid of Claim 44, wherein said deletion comprises a deletion of nucleotides 8772 to 9385 in SEQ ID NO:4.

46. The recombinant plasmid of Claim 45, wherein said plasmid has the designation pΔpol.

47. The recombinant plasmid of Claim 45, wherein said plasmid has the designation pBHG11 Δ pol.

48. A recombinant plasmid capable of replicating in a bacterial host comprising adenoviral E2b sequences, said E2b sequences containing a deletion 5 within the preterminal protein gene, said deletion resulting in the inability to express functional preterminal protein without disruption of the VA RNA genes.

49. The recombinant plasmid of Claim 48, wherein said deletion within said preterminal protein gene comprises a deletion of nucleotides 10,705 to 11,134 in SEQ ID NO:4.

10 50. The recombinant plasmid of Claim 49, wherein said plasmid has the designation p Δ pTP.

51. The recombinant plasmid of Claim 49, wherein said plasmid has the designation pBHG11 Δ pTP.

15 52. The recombinant plasmid of Claim 48 further comprising a deletion within the polymerase gene, said deletion resulting in reduced polymerase activity.


53. The recombinant plasmid of Claim 52, wherein said deletion within said polymerase and said preterminal protein genes comprises a deletion of nucleotides 8,773 to 9586 and 11,067 to 12,513 in SEQ ID NO:4.

20 54. The recombinant plasmid of Claim 53, wherein said plasmid has the designation pAXB Δ pol Δ pTPVARNA+t13.

55. The recombinant plasmid of Claim 53, wherein said plasmid has the designation pBHG11 Δ pol Δ pTPVARNA+t13.

FIGURE 1

A



B




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18





FIGURE 19



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/19541

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 5/06, 5/10, 7/01, 7/02, 15/86
US CL :435/235.1, 320.1, 369

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/235.1, 320.1, 369

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KUMAR-SINGH et al. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. July 1996, Vol.5, No.7, pages 913-921, see entire document.	1-11
---		---
Y		15-24
X,P	PARKS et al. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA. November 1996, Vol.93, pages 13565-13570, see entire document.	12-14
---		—
Y,P		15-24

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
B earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	"A"	document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 JANUARY 1998

Date of mailing of the international search report

10 FEB 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faxsimile No. (703) 305-3230

Authorized officer:
Robert Schwartzman
ROBERT SCHWARTZMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No. PCT/US97/19541

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MITANI et al. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc. Natl. Acad. Sci USA. April 1995, Vol.92, pages 3854-3858, especially pages 3855-3856.	25, 27
X	AMALFITANO et al. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc. Natl. Acad. Sci. USA. April 1996, Vol.93, pages 3352-3356, see entire document.	29, 32, 33
X	CHAMBERLAIN et al. Packaging cells expressing the adenovirus (Ad) E1, polymerase, and preterminal proteins to allow the growth of a new class of replication defective Ad-vector for use in Duchenne muscular dystrophy (DMD). Am. J. Hum. Genet. 24 SEP 1996, Vol.59, No.4 Suppl., page A377, see entire document.	25-32, 34-38, 40-44, 48, 52
X	AMALFITANO et al. Modification of adenoviral vectors for use in gene therapy of Duchenne muscular dystrophy. Am. J. Hum. Genet. October 1995, Vol.57, No. 4 Suppl., page A234, see entire document.	25, 26, 29-33, 40, 41

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/19541

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN: Medline, Biosis, Embase, CAPIus, WPIDS, JAPIO, PATOSEP, PATOSWO

APS

Search Terms: adenovirus, vector, LTR, inverted, E2B, DNA polymerase, preterminal protein, Cre, loxP

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)